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Introduction 
Cardiovascular disease (CVD) is the leading cause of death in most industrialized 
countries. In the Netherlands, it is responsible for 40% of all deaths.' Major risk 
factors for CVD are identified such as smoking, high cholesterol level and hyperten-
sion. Other important determinants of cardiovascular risk are nutrition, physical activ-
ity and body weight. However, these known risk factors cannot fully explain individual 
differences in cardiovascular risk. An intriguing hypothesis has been postulated in 
which the known beneficial effect of a diet high in flUit and vegetables is combined 
with the known harmful effect of high cholesterol levels or, more specifically, high 
low-density lipoprotein (LDL) cholesterol levels.2 This hypothesis describes a high 
level of LDL cholesterol as a promoting factor in atherosclerosis after LDL has been 
chemically altered by free radical compounds. The uptake of cholesterol in 
macrophages is increased and foam cells are formed. These foam cells can cluster just 
beneath the intima of the vessel wall which is the beginning of the fatty streak and of 
the atherogenic process. Antioxidants can playa role in protecting LDL from oxidation 
by scavenging free radicals. 
Several lines of evidence have indicated that oxidation occurs in vivo and that 
antioxidants may have a preventive effect. Epitopes of oxidized LDL are found in 
atherosclerotic lesions.' Further, supplementation with vitamin E has been reported to 
decrease susceptibility of LDL to oxidation.4.' Evidence for direct relations between 
susceptibility to oxidation and risk of cardiovascular diseases, however, is scarce. To 
investigate susceptibility of LDL to oxidation and the preventive role of antioxidants in 
relation to atherosclerosis, we performed the studies described in this thesis. 
Chapter 1 presents an overview of the current knowledge of the relation between 
antioxidants and CVD, antioxidants and LDL oxidation and the relation between LDL 
oxidation and CVD. 
Chapter 2 describes a small study on seasonal variation in susceptibility of LDL to 
oxidation and in determinants of LDL oxidation. This study was performed to deter-
mine whether the moment of blood sampling should be taken into account in a study 
on LDL oxidation. 
Chapter 3 comprises three studies on the relation between LDL oxidation and risk 
of atherosclerosis. In section 3.1 results of a case-control study on susceptibility of 
LDL to oxidation in relation to risk of coronary atherosclerosis are presented. In 
section 3.2 the association between susceptibility of LDL to oxidation and risk of 
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peripheral atherosclerosis is described. The method of measuring LDL oxidation used 
in these two sections is an ex vivo measure, which may not reflect the processes going 
on ill vivo. Therefore, we investigated the association between an ill vivo measure of 
LDL oxidation, the autoantibody titre against oxidized forms of LDL, and risk of 
coronary atherosclerosis in a small case-control study. This study is described in 
section 3.3. 
An indirect method for investigating the effect of LDL oxidation on the risk of 
atherosclerosis is by measuring antioxidant status (Chapter 4), which may reflect the 
antioxidant defence against oxidation of LDL. The antioxidant status in the LDL 
particle and plasma vitamin C levels were measured and related to risk of coronary 
atherosclerosis (section 4.1). Further the association between plasma levels of the 
antioxidant Coenzyme QIO and coronary atherosclerosis was studied (section 4.2). 
Chapter 5 presents two studies on dietary intake of antioxidants in relation to 
cardiovascular disease. In section 5.1 a study is presented on dietalY intake of vitamin 
C, a-tocopherol and ~-carotene in relation to the risk of having a silent myocardial 
infarction. Data were collected in the Rotterdam Study, a prospective cohort study. 
Section 5.2 describes results on dietary intake of flavonoids in relation to risk of 
coronary atherosclerosis. 
In the epilogue (Chapter 6) a general discussion of the hypothesis, the strength of 
the research performed and some indication for further research are given. 
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ABSTRACT 
This review summarizes the scientific evidence for a possible role of antioxidants in 
the prevention of coronary heart disease (CHD). Dietary antioxidants include vitamin 
E, vitamin C and p-carotene, whereas selenium is an integral part of the antioxidant 
enzyme glutathione peroxidase. Experimental studies suggest that the oxidation of low-
density lipoproteins (LDL) in the vessel wall plays an important role in the develop-
ment of atherosclerotic lesions. The resistance of LDL to oxidation is increased by 
antioxidant supplementation, at least ill vitro. Epidemiological studies have not demon-
strated unequivocally that a high intake of antioxidants leads to a decreased risk of 
CHD. Studies on dietary intake and serum levels of antioxidants do point into the 
direction of a preventive effect of antioxidants, whereas the results of intervention 
studies are less conclusive. p-carotene supplementation is not associated with any 
decrease in CHD; high doses of vitamin E may be beneficial, but results from large 
trials are to be awaited. General preventive measures based on antioxidant supplemen-
tation are not yet justifiable. 
INTRODUCTION 
It has long been hypothesized that free-radical reactions mediate in the development of 
coronary hemt disease (CHD) and that antioxidants playa protective role.' In recent 
years interest in the latter compounds has strongly increased, inspired by experimental 
evidence that the hypothesis regarding the role of blood lipids on the one hand and of 
antioxidants on the other do not contradict but rather may complement one another.' 
Promising epidemiological findings',4 have indicated that a diet adequate in, or 
supplemented with, antioxidants could help prevent CHD. In this review we will 
briefly discuss the possible role of antioxidants in the prevention of CHD. 
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FREE-RADICAL REACTIONS AND LDL OXIDATION 
Free radicals are highly reactive because these molecules contain an unpaired electron. 
They can thus readily oxidize and damage essential biological molecules such as fats, 
proteins and DNA. Polyunsaturated fatty acids are particularly prone to oxidation (lipid 
peroxidation). 
The formation of free radicals is a biological process taking place, for example, 
when oxygen is reduced to water in the respiratory chain of live tissues or during 
enzymatic synthesis of prostaglandins and leukotrienes.'·s Under normal physiological 
conditions, the cell is protected against an overproduction of radicals by the enzymes 
superoxide dismutase, catalase and the selenium-dependent glutathione peroxidase, and 
by various antioxidants such as vitamin E, vitamin C and ~-carotene.5 In case of a 
disturbed balance between formation of free radicals (oxidant stress) and antioxidant 
defence, free radicals can playa role in the development of various diseases including 
CHD. 
Unsaturated fatty acids in low-density lipoproteins (LDL) are sensitive to 
oxidation. The three most important cell types in the vessel wall (endothelial cells, 
smooth muscle cells and macrophages) can release free radicals which affect lipid 
peroxidation. Oxidized LDL can become atherogenic through a number of 
mechanisms. Oxidation can elicit a chemotactic response simulating monocytes and 
T-lymphocytes to be attached to the endothelial monolayer and then migrate into the 
subendothelial space, the intima.""" In the intima the monocytes are transformed to 
macrophages which efficiently absorb oxidatively modified LDL via the 'scavenger 
receptor'. The macro-phages subsequently develop into foam cells and thus give rise to 
'fatty streak', the first stage of the atherosclerotic process. Further, auto-antibodies 
against oxidized LDL are formed;·l0 which form an immune complex with the oxidi-
zed LDL and are recognized by the Fc receptor on the macrophages. This process 
accelerates the uptake of oxidized LDL by macrophages. 
In addition to the formation of foam cells, oxidized LDL stimulate the cells in the 
vessel wall to produce cytokines and growth factors.""· l1 This process leads, among 
other things, to proliferation of smooth muscle cells and production of fibre proteins, 
thus leading to the next stage of the atherosclerotic process, formation of fibrous 
plaque. Moreover, oxidized LDL have an inhibitory effect on the production of endo-
thelium-dependent relaxation factor, thus reducing vasodilatation of the atherosclerotic 
vessel."·8•11 Further, oxidized LDL are cytotoxic and can directly damage endothelial 
6 
______________________________ Review 
cells." In combination with the stimulation of platelet aggregation and of procoagulant 
activity on the surface of endothelial cells and macrophages, the damage to endothelial 
cells will contribute to a further progress of atherosclerosis, leading eventually to 
complex atherosclerotic lesions.~·" 
In addition to this mechanism via oxidized LDL, free radicals and lipid peroxides 
in the cell can have a direct toxic effect on endothelial cells by reacting with proteins 
and lipids in the cell membrane. It has been hypothesized that this process leads to 
changes in the structure of the membranes and thus to changes in membrane permea-
bility or membrane-bound protein activity.12 Among other things, it may change the 
permeability of the endothelial inner lining of the blood vessel. 
Various methods are available to investigate whether oxidative processes in the 
body do occur indeed. Damage to DNA (oxidized DNA bases), proteins (protein 
carbonyls) and lipids can be measured. To study the relation between oxidative stress 
and atherosclerosis, lipid peroxidation and its consequences are of particular interest. 
Two of these methods are the thiobarbituric acid (TBA) test used to measure 
aldehydes, degradation products of lipid peroxides, and the measurement of conjugated 
dienes in LDL. Although both methods have their limitations,!3 they have produced 
indications for oxidative processes to play a role ill vivo in the development of athero-
sclerosis. Stringer et al. 14 have used the TBA test to demonstrate the occutTence of 
elevated levels of lipid peroxides in patients with vascular disorders. Others have 
found an association between sensitivity of LDL to lipid peroxidation (measurement of 
conjugated dienes) and coronmy sclerosis."-17 A new, promising method for the detec-
tion of lipid peroxidation is measurement of 8-isoprostanes, oxidation products of 
arachidonic acid. Plasma levels of 8-isoprostanes have been found to be elevated in 
smokers." 
Subsequent degradation products of lipid peroxidation can form new epitopes in 
LDL, which cml be detected by means of monoclonal antibodies. Immunocytochemical 
techniques have demonstrated the presence of oxidized LDL in atherosclerotic lesions, 
but not in unaffected arteries.'·6 Higher titres of auto-antibodies against modified LDL 
appem' to coincide with an accelerated progression of carotid atherosclerosis;·10 
although they may not be an indicator of the severity of atherosclerosis.'9.20 
If a causal relationship exists between oxidized LDL and atherosclerosis, then it 
would follow that antioxidants may protect against atherosclerosis by preventing or 
retarding the oxidative modification of LDL. In a number of epidemiological and 
clinical studies this possible preventive effect of antioxidants on CHD has been inves-
7 
Chapter 1 _____________________________ _ 
tigated. The concentration of antioxidant micronutrients in tissues depends mainly on 
dietary intake. Antioxidant nutrients for which intake has been studied in relation to 
CVD include vitamins E and C, ~-carotene, and selenium, a co-factor in the enzyme 
glutathion peroxidase. 
OBSERVATIONAL STUDIES 
Vitamin E 
In the WHO/MONICA study, in which various European countries were compared,"·22 
ischaemic heart disease was found to be inversely associated with average plasma 
vitamin E levels. This association has also been found in a survey in 19 European and 
5 non-European countries," but in Finnish men no relationship was found between 
vitamin Elcholestero1 ratio and prevalence of ischaemic heart disease.'4 Riemersma et 
a!." did find lower plasma vitamin E levels in patients with angina pectoris, whereas 
the European multi-centre case-controlled EURAMIC study has not revealed an asso-
ciation between a.-tocopherol in adipose tissue and the risk for myocardial infarction." 
Prospective studies on antioxidant intake or blood levels in relation to CVD risk are 
summarized in Table 1. In three prospective studies,"-29 men who died of ischaemic 
heart disease did not have reduced plasma vitamin E levels standardized for choleste-
rol. However, a higher intake of vitamin E, in particular through supplements, has 
been found to be associated with a lower incidence of CHD both in the prospective 
Nurses' Health Study among women4 and in the Health Professionals Follow-up Study 
among men.' In a large US cohort of post-menopausal women,3D a more than 60% 
reduced risk of CHD mortality was found in the group with the highest intake of 
vitamin E from food, but no association was obselved for higher intakes from 
supplements. In a Finnish COh0l1 with a 14-year follow-up, vitamin E intake tended to 
be related to a reduced risk for CHD mortality both among women and men, but the 
risk in the group with the highest vitamin E intake was significantly lower than in the 
group with the lowest intake for women only." In the ARIC study, too, a significant 
inverse relation between vitamin E intake and thickness of the carotid artery wall was 
found only among women." A recent sub-group analysis of a group treated with niacin 
and colestipol in the Cholesterol Lowering Atherosclerosis Study has demonstrated an 
association between self-chosen vitamin E supplement use and angiographically confir-
med reduction of progression of coronary lesions." 
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Vitamill C 
Vitamin C has also been a subject in the WHO/MONICA study. On a group level, 
lower plasma vitamin C levels appeared to be associated with a higher cardiovascular 
mortality.,!·n In the UK, too, ischaemic heart disease mortality was found to be highest 
in regions with a relatively low vitamin C intake."'" Patients with angina pectoris, 
however, had no reduced plasma vitamin C levels after conection for smoking." 
In the prospective Basel study, lower plasma vitamin C levels preceded a higher 
ischaemic heart disease mortality; however,this conelation was not statistically signi-
ficant. 27 In two large US cohorts.'·'o no relation could be established between vitamin 
C intake and CHD incidence. In a 25-year follow-up of middle-aged men, there was 
no overall association between vitamin C intake and CHD mortality, but men who 
never smoked had a more than 40% decreased risk when they had an intake of more 
than 112 mg vitamin C per day.'" In a prospective study in England, both a high 
vitamin C intake and high plasma vitamin C levels were found to be associated with a 
lower risk for cerebrovascular disorders, but not of coronary disease." In contrast, a 
prospective study in Finland did show a relation with CHD, albeit only for women.'! A 
strong inverse relation between vitamin C intake and risk for CHD has been found in 
NHANES 1.37 Moreover, recent results from the ARIC study reveal a strong inverse 
relation between vitamin C intake and thickness of the carotid artery wall." 
~.carotelle 
In Israel, a strong inverse relation has been found between dietary intake of vitamin A 
from fmit and vegetables and cardiovascular mortality." In a case-control study." the 
incidence of acute myocardial infarction was negatively associated with consumption 
of carrots, green vegetables and fresh fruit. The European EURAMIC study has repor-
ted that patients with acute myocardial infarction had a lower ~-carotene content in 
adipose tissue than had controls" which could be indicative of a lower long-term 
~-carotene intake. However, this relation was found only for smokers and ex-smokers. 
In the prospective Health Professionals Follow-up Study, a high ~-carotene intake was 
found to be associated with a lower risk of CHD, also for smokers only.' In a Finnish 
cohort study, a protective effect of ~-carotene was found neither for women nor for 
men, but ~-carotene did strengthen the favourable effect found for vitamins C and E in 
this study.'! In two subsequently reported cohort studies,30,," no association of ~-caro­
tene with CVD risk was observed. 
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Table 1. Prospective studies on antioxidant intake or blood levels in relation to CVD risk 
Name study Population n follow- Exposure Outcome Results' 
First author (ref) Gender,age up (yr) Contrast in comparison group (nr of cases) RR (95% CI) 
Dietary intake 
NHANES I. d'~ 11.348 10 SMR group ~ 50 mg vit C relative Fatal CVD SMR=0.90 (0.82-0.99) 
Enstrom37 25-74 year to SMR US whites (1809) SMR=0.66 (053-0.82) (inel suppl) 
US health pro- d' health profes- 39.910 4 Vit E: ;:; 6.9 vs. ;, 11.0 IU/d (fond) Fatal CHD. RRn",= 0.79 (0.54-1.15) (fond) 
fessionals, sionals without o vs. ;, 250 IU/d (suppl) non-fatal MI. RRn",= 0.70 (0.55-0.89) (suppl) 
Rimm3 CVD; 40-75 yr Vit C: median 92 vs. 1162 mg/d bypass. PTCA RRn<c= 1.25 (0.91-1.71) 
Carotene: <5030 vs. ;, 14.388 IU/d (667) RRo..,= 0.71 (0.53-0.86) 
RRo..,= 0.30 (0.11-0.82) (smokers) 
US nurses health ~ nurses 87.245 8 Vit E: ;:; 3.5 vs. ;, 21.6 IU/d Non-fatal MI RR."",- 0.66 (0.50-0.87) (inel suppl) 
study. Stampfer' 34-59 year median 2.8 vs. 208 IU/d CHD death RRnr 0.95 (0.72-1.23) (fond) 
;:; 3.1 vs. ;, 6.3 IU/d (fond) (552) 
Finland longitu- d' 2.748 14 Vit E: ;:; 6.8 vs. ;, 8.9 mg; Fatal CHD RRn",= 0.68 (0.42-1.11)ptr=O·01 
dina! population 30-69 year Vit C: ;:; 60 vs. > 85 mg; (186) RRn<c= 1.00 (0.68-1.45) 
study. Knekt" carotenoids: :::; 147 vs. ;::: 258 p.g RRo..,= 1.02 (0.70-1.48) 
retinol equivalents 
Finland longitu- ~ 14 Vit E: :::; 5.3 vs. ;?: 7.1 mg; Fatal CHD RR."",= 0.35 (0.14-0.88) Ptr<O.OI 
dina! population 30-69 year 2.385 Vit C: ;:; 61 vs. > 91 mg; (58) RRn<c= 0.49 (0.24-0.98) 
study. Knekt" carotenoids: :::; 182 vs. ;::: 383 p.g RRo..,- 1.62 (0.30-1.29) 
retinol equivalents 
Western Electric a' employees 1.556 25 Vit C:;:; 82 vs. > 112 mg; Fatal CHD RRn.c= 0.75 (0.52-1.07) 
study. Pandey'" 40-55 year j3-Carotene: ;:; 2.9 vs. > 4.0 mg (231) RRo..,- 0.84 (N.S.) 
Iowa's Womens ~ postmenopau- 34.486 7 Vit E: ;:; 4.9 vs. ;, 9.6 IU/d (fond) Fatal CHD RR."r 0.38 (0.18-0.80) (food) 
Hea!th Study. sal o vs. >250 IU/d (242) RRn",= 1.09 (0.67-1.77) (suppl) 
Kushi30 55-69 year Vit C: ;:; 112.3 vs. ;, 391.3 mg/d RRn<c= 1.49 (0.96-2.30) 
Carotenoids: ;:; 4421 vs. ;, 13465 IU RRo..,= 1.03 (0.63-1.70) 
Name study Population n follow- Exposure Outcome Results! 
First author (ref) Gender,age up (yr) Contrast in comparison group (nr of cases) RR (95% CI) 
Serum levels 
EPOZ-study. d'~ 10.532 6-9' Vit E: < 645 vs. ;, 645 Fatal CVD(84) RRv'<E- 0.7 ( 0.3-1.7) 
Kok" 37-87 year Selenium: <105 vs. ;'105 pgll RRs,- 0.6 (0.3-1.25) 
Basal study. d' working popu- 12 Vit C: <22.7 vs. ;,22.7 prooVl FatalllID RR,;.c"" 0.8 (0.5-1.3) 
Gey" lation; mean age 2.974 Carotene: <0.23 vs. ;,0.23 prooVl (132) RRc.o- 0.7 (0.5-0.9) 
50±9 yr 
MONICA d'~ 5' Vit E: ,; 27.9 VS. > 27.9 prooVl Fatal and non- RR,;r 1.85 (90%CI: 0.7-4.8) 
Augsburg study. 25-64 year 
Hense29 
4.022 fatal MI (46) 
Street4! d'~ 25.802 7-14' Vit E and carotenoids MI(I23) OR".,- 0.45 (0.22-0.90) 
35-65 year lowest vs. highest quintile ORv.c 2.4; OR,,'<FJ_- 0.7 
Morris42 d' 13 Camtenoids: <2.3 vs. >3.2 prooVl Fatal CVD. RR- 0.64 (0.44-0.92) 
40-59 years 1.899 non-fatal MI RR- 0.28 (0.11-0.73) (never smokers) 
(282) 
Skin Cancer d'~ 11.881 8.2 Jl-carotene: <0.21 vs. >0.52 prooVl Fatal CVD RR- 0.57 (0.34-0.95) 
Prevention trial, skin cancer pa-
Greenberg43 tients 
mean age 63.2 yr 
1RR compared to low intakellevel group. ~ested case-control study. 3Prr = P for trend. Abbreviations used: CVD=eardiovascular disease, 
CHD=coronary heart disease, :M1=myocardial infarction, PTCA=percutaneous transluminal coronary angioplasty, S.MR=standardized mortality 
ratio, RR=relative risk. OR=odds ratio. 
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Several studies have looked at blood levels of ~-carotene or carotenoids, as marker of 
dietary intake. In the prospective Basel study, low plasma ~-carotene levels were 
found to be associated with an elevated risk for ischaemic heart disease,'· whereas 
such an elevated risk was found only for smokers in a retrospective study.'! In the 
cohort of the Lipid Research Clinics Coronary Primary Prevention Trial," CHD risk 
for men with the highest serum carotenoid levels was lower than for men with the 
lowest levels (22% and 72% reduction for smokers and non-smokers, respectively). 
Similarly, patients in the Skin Cancer Prevention Study with initial plasma ~-carotene 
levels in the highest quartile were found to have a 43% decreased risk of CVD morta-
lity, compared to patients in the lowest quartile." 
Selellillm 
Selenium is a co-factor of the antioxidant enzyme glutathione peroxidase and has been 
studied extensively in relation to CHD. In Dutch patients with acute myocardial 
infarction, selenium levels measured in erythrocytes, toenails and plasma were lower 
than in healthy controls." Such an unequivocal relation has not been found, however, 
in seven prospective studies varying in follow-up period from 5 to 7 years. Three of 
these studies found low plasma selenium levels to be associated with an elevated risk 
for CHD and death."-47 The other four prospective studies, however, did not find such 
a relation."'" In the European EURAMIC study, a weak but non-significant overall 
inverse association between selenium levels in toenails and risk of non-fatal MI was 
observed.49 Thus, there is not an unequivocal relation between blood selenium levels 
and the incidence of CHD. Two studies that did find an association"'" were conducted 
in Finland, where selenium intake has been very low until recently. Likewise, in the 
EURAMIC study the only country where a significant inverse association was found 
was Germany (Berlin), the center with the lowest selenium levels. It is conceivable 
that CHD risk is, indeed, influenced by extremely low blood selenium levels. 
In interpreting descriptive epidemiological studies, it should be bome in mind that 
comparisons among countries simply show associations and provide no proof for 
causal relations. Moreover, in case-control studies one should always question whether 
a change in antioxidant status is the cause or the consequence of the disease. This 
problem does not exist is prospective studies in which antioxidant status is measured 
some years before the disease is diagnosed. In prospective studies, it is essential that 
the results are corrected for possible confounding factors. For example, smoking is an 
established risk factor, and smokers have usually both lower intakes and lower plasma 
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levels of vitanlin C and l3-carotene. However, even if the results are adequately correc-
ted for known risk factors, it is celtainly conceivable that an elevated plasma concen-
tration of l3-carotene, for example, simply reflects a high consumption level for vege-
tables and that it is not l3-carotene, but another component or combination of compo-
nents of vegetables, that is responsible for the association found. Moreover, a high 
intake of antioxidants could obviously also be correlated with unknown life-style 
factors. 
Studies described above both investigated dietary intake levels and serum or 
plasma levels and their relation to the risk of CVD. Serum and plasma levels have 
been used as a biomarker for dietary intake. However, correlations between dietary and 
plasma levels of antioxidants are low. Kardinaal et al. reported correlations of 0.05 for 
a-tocopherol in non-supplemented subjects. However, significant correlations slightly 
over 0.30 were observed by others (50 and references in 50). For l3-carotene slightly 
higher cOlTelation coefficients have been reported ranging from 0.17 to 0.49.'0 There-
fore it seems more reasonable to use plasma and serum levels as a marker for the 
internal concentration, taking into account the variation in absorbtion and metabolism. 
The epidemiological studies discussed above suggest that there might be an inverse 
association between vitamin E intake and CHD, but that this association may become 
manifest only at high vitanlin E intakes from supplements. For vitanlin C, no consis-
tent inverse relation with CHD has been established. As for l3-carotene, this antioxi-
dant could play a protective role in particular for smokers, which would confirm the 
hypothesis that smoking-induced oxidative stress impairs the body's l3-carotene status. 
The results for selenium do not point consistently to a protective effect of high intakes, 
but an extremely low selenium status could well be a risk factor. The threshold value 
could be relevant in this context. It should be noted, however, that the studies men-
tioned cannot demonstrate a cause-effect relation. The best proof is provided in inter-
vention studies exploring the effects of vitamin supplementation on relative risk, 
morbidity and mortality. 
INTERVENTION STUDIES 
Animal sludies 
Convincing evidence that antioxidants can prevent the progression of atherosclerosis 
has been provided by animal studies. In cholesterol-fed and LDL receptor-deficient 
rabbits and monkeys, the drug probucol, a potent antioxidant, inhibits the progression 
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of atherosclerosis. A similar effect has been found for other synthetic antioxidants in 
some, but not all, other animal studies'!'" and references therein.Probucol also inhibits 
the formation of neo-intima after damage to the vessel wall in pigs." This finding 
suggests that reactive oxygen compounds may play a role in restenosis. Some studies 
have found that supplementation of the diet with vitamin E slows down the develop-
ment of atherosclerosis in rabbits. In other studies, however, such an effect was not 
found." Restenosis is also suppressed by a-tocopherol after balloon dilatation in 
rabbits." 
W6jcicki et al." have reported an additive protective effect of selenium and 
vitamin E on atherosclerosis. Convincing evidence comes from a study" in which 
primates were supplemented with 70 mg vitamin E daily, resulting in prevention of 
experimental atherosclerosis as compared with a control group receiving only the athe-
rogenic diet. In another group, which already had developed atherosclerosis, vitamin E 
supplementation resulted in significant regression. 
Some vitamin C supplementation studies in cholesterol-fed rabbits produced a 
reduction of aortic intimal or more advanced atheromatous lesions, but this effect was 
not uniformly observed." Supplementation with low doses of vitamin E or p-carotene 
resulted in preservation of endothelium-dependent vessel relaxation in rabbits after 
cholesterol feeding," but high doses of vitamin E worsened vasodilative function.'" A 
recent study has demonstrated inhibition of atherosclerosis by all-tralls-p-carotene, but 
not by 9-cis-p-carotene (0.01 % in the chow). This finding suggests the involvement of 
retinoid receptors in the vessel wall in the development of atherosclerosis.6! 
Most of the animal studies report a favourable effect of antioxidant on the deve-
lopment of atherosclerosis, whereas in some studies no clear association was found. 
This can possibly be explained by the fact that both the level of progression of the 
atherosclerotic process and the dose of antioxidants in relation to cholesterol levels are 
important factors. Moreover, some antioxidants have effects other than their 
antioxidant action. 
Human intervention studies 
Human intervention studies with antioxidant vitamins have thus far mainly focused on 
risk factors. None of four well controlled intervention studies conducted in a healthy 
population has shown any effect of vitamin E supplementation on platelet aggregati-
on!' Nor was an effect of vitamin E on symptoms of angina pectoris found in any of 
six intervention studies!' Although five intervention studies have reported a modest 
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favourable effect of vitamin E on symptoms of intermittent claudication, the sample 
sizes were small in each of these studies.63 However, vitamin E supplementation 
ill vivo does lead to an increased resistance of LOL to ex vivo chemical oxidation,"·6 .. 6' 
but the incidence of restenosis after percutaneous trans luminal coronary angioplasty 
was not significantly altered by vitamin E supplementation!9 
Supplementation with 0.5-1.0 g vitamin C was reported to have favourable effects 
on plasma lipids, but these effects were only seen in subjects with marginal plasma 
vitamin C or high selUm cholesterol levels.58•7o 
No favourable effects of ~-carotene on plasma lipids have been reported,n.n and 
reports on effects of ~-carotene on ex vivo LOL oxidation are conflicting.J.64-., More-
over, these results possibly cannot be extrapolated to ill vivo conditions because 
~-carotene is an effective antioxidant in particular under low oxygen tension.74 This 
aspect is suppOlted by a study in which ~-carotene lowered the concentration of 
pentane (an indicator of lipid peroxidation) in exhaled air of smokers, but not of non-
smokers.15 
The only intervention study we know (the Probucol Quantitative Regression 
Swedish Study) in which the effect of probucol on atherosclerosis in the femoral artery 
was studied, did not find any differences between the experimental and the control 
group.76 This could be explained by reduction of high-density lipoprotein (ROL) levels 
and of plasma levels of fat -soluble dietary antioxidants. 
Results of several intervention studies with disease incidence as end-point have 
recently been reported43.77-80 and are summarized in Table 2. The first was a randomi-
zed primary prevention trial with ~-carotene and/or vitamin E among 29,133 male 
Finnish smokers.77 Among men receiving 50 mg a-tocopherol daily for 5-8 years, 
there were not significantly fewer deaths caused by ischaemic heart disease than in the 
control group. Overall mortality did not differ significantly between the a-tocopherol 
and the control group, although more deaths from cerebral haemolThages were seen 
among the tocopherol-supplemented men. For ~-carotene-supplemented subjects 
(20 mg/day), more deaths from ischaemic heart disease were reported after 5-8 years. 
In this same study, the incidence of angina pectoris in the vitamin E and ~-carotene 
intervention groups was not significantly different from the groups using placebo." 
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Table 2. Human intervention studies on antioxidant supplementation in relation to CVD risk 
Name study Population n Intervention Duration Outcome Results I 
(reference) Gender,age mean (range) (number of cases) RR (95% CI) 
ATBC d'smokers; 29.000 fXarotene (20 mg) 6.1 (5-8) yr Death from llID RR,,;<E'" 0.98 (0.89-1.08) 
study-group" 50-69 year andlor vitamin E (50 (1239) RR...,= 1.! I (0.99-1.23) 
mg)! d 
ATBC, Incidence of An- RR,,;<E'" 0.91 (0.83-0.99) 
Rapola8o gina Pectoris RR...,- 1.06 (0.97-1.!6) 
(1983) 
CARET, d'~ smokers + 18.314 30 mg Ikarotene + 4.0 yr Death from CVD RR- 1.26 (0.99-1.61) 
Omenn78 workers exposed 25.000 IU retinol! d 
to asbestos~ 
45-69 year 
PHS, d' physicians; 22.000 50 mg fXarotene ! 2 d 12.0 yr CVD events RR- 1.00 (0.91 -1.09) 
Hennekens 79 40-84 year (1939) 
Linxian d'~ rural subjects 29.584 f\-carotene (IS mg) + 5.25 yr Cerebrovascular RR- 0.90 (0.76-1.07» 
Blot" 40-69 year vitamin E (30 mg) + death (523) 
selenium (50 pg) ! d 
SCPS d'~ skin cancer 1.730 50 mg Ikarotene ! d 8.2' yr CVD (127) RR- 1.!6 (0.82-1.64) 
Greenberg4J patients; 27-84 
year 
CHAOS, d'~ patients with 2.002 800 or 400 IU a-tocop- 510 days CVD, non-fatal MI RR'= 0.53 (0.34-0.83) 
Stephens77 coronary disease herol (3-981 days) (lOS) 
lIntervention compared to placebo. 24.3 years of supplementation. 3a.-tocopherol supplement users (both 400 and 800 IU) vs. placebo. 
Abbreviations used: CVD=eardiovascular disease.llID=ischemic heart disease. :tv1J=myocardial infarction. RR=relative risk. 
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Thus, the results of this Finnish trial provide no evidence for a beneficial effect of 
~-carotene and vitamin E. Major criticism on this study was based on the sample of 
heavy smokers, many of whom had smoked for more than 30 years so that the athero-
sclerotic progress might have progressed too far for a successful intervention, and the 
choice of low doses of vitamin E. However, the lack of a beneficial effect of ~-caro­
tene was reproduced in other large randomized trials.4J·"·'o The relative risk of having a 
major cardiovascular event in the Physicians' Health Study, after a follow-up of 12 
years, was 1.00 for the group receiving 50 mg ~-carotene on altemate days.'o In a ran-
domized trial with a high dose of alpha-tocopherol (25-50 times the usual dietary 
intake) a significant reduction (77%) of the risk of non-fatal MI was observed." 
DISCUSSION 
Experimental data based on ill vitro studies suggest that free-radical reactions play a 
major role in the development of CHD. The results of ill vitro studies and of animal 
models examining the role of antioxidants and oxidative changes are less consistent. 
For example, some antioxidants may exert prooxidant action under specific experimen-
tal conditions. The protective (sparing) effect of vitamin C on vitamin E can be easily 
demonstrated ill vitro, but evidence for a prominent role ill vivo is scarce. III vitro 
studies seem to indicate that vitamin C is very important as an antioxidant, but large 
prospective studies exploring the relation between antioxidant and CHD have revealed 
a prominent role for vitamin E, but not for vitamin C. Although some epidemiological 
studies have produced intriguing results, they have not established unequivocally that 
high intake of antioxidants reduces the risk for CHD. This lack of unanimity may be 
attributed in part to differences in levels of intake, study population or disease outcome 
measure. Also, vitamin E, vitamin C and ~-carotene are not the only antioxidants 
worthy of being considered. For example, flavonoids contained in red wine have been 
proposed as an explanation of the 'French paradox', i.e. the low cardiovascular morta-
lity in France in spite of a high prevalence of known risk factors." Flavonoids are 
found in various products of vegetable origin (grapes, tea, onions, apples). The pros-
pective Zutphen study has shown that a higher intake of flavonoids is associated with a 
lower CHD risk." Similarly, it has been suggested that other carotenoids than 
~-carotene, such as alpha-carotene or lycopene may exert a protective effect. Further, 
the intake of pro-oxidants such as iron, zinc and copper could be relevant" as well as 
the intake of polyunsaturated fatty acids, the most important substrate for oxidative 
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reactions. It has been suggested that substitution of monounsaturated fatty acids for 
polyunsaturated fatty acids may reduce the oxidizability of LDL."·86 The epidemiolo-
gical studies assess intake of antioxidants, through food and supplements, which is 
probably indicative of a long-term exposure. Therefore results from these studies may 
indicate an effect at earlier stages of atherosclerosis. On the other hand, it cannot be 
excluded that persons with a high intake also differ with respect to intake of other 
dietary factors or life-style characteristics related to CVD risk, which may explain the 
inverse associations found. 
The preventive trials do not support a beneficial effect of ~-carotene on CVD risk. 
For vitamin E, we have too little information yet. The dose used in the Finnish trial 
was relatively low and their high risk study population may not have been the most ap-
propriate, if an effect on early stage atherosclerosis is assumed. However, high doses 
have been shown to prevent myocardial infarction in a high risk group." Several 
ongoing trials can hopefully give us some answers in the coming years.87 
In conclusion, general preventive measures based on antioxidant supplementation 
are not justifiable on the basis of current knowledge, although there is certainly support 
for a preventive effect of high doses of vitamin E on cardiovascular disease risk. The 
effect of other compounds from fruit and vegetables may be explored. Fundamental 
research into the pathogenesis of atherosclerosis and the role of lipid peroxidation may 
help to select the most appropriate study designs in terms of type of antioxidant, dose, 
population and duration of the intervention. 
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Seasonal Variation in Low Density Lipoprotein Oxidation 
and Antioxidant Status 
ABSTRACT 
Accumulating evidence indicates that oxidative modification of low-density lipo-
proteins is atherogenic and that antioxidants may play a role in protection of LDL 
against oxidation. Several studies have rep0l1ed a seasonal fluctuation in antioxidant 
levels, but to date nothing is known about seasonal fluctuations in parameters of 
oxidizability. 
We collected blood from 10 volunteers at four different periods over one year 
(Febl1lary, May, September and December), and measured levels of plasma lipids, 
plasma antioxidants, lipid and fatty acid composition of the LDL particle, LDL anti-
oxidant content, LDL particle size and oxidation parameters (resistance time and 
maximum rate of oxidation). 
No seasonal fluctuation for resistance time and maximum rate of oxidation of 
copper ion-induced LDL oxidation was found. Small seasonal fluctuations were obser-
ved for some determinants of LDL oxidation, e.g. plasma and LDL vitamin E and 
LDL particle size, and for plasma lipids, plasma and LDL lutein and LDL ~-carotene. 
Fatty acid composition of LDL did not change during the year. The main determinant 
of oxidation susceptibility was the fatty acid composition of LDL. 
We conclude that LDL oxidation parameters do not change over the year. 
INTRODUCTION 
Oxidative modification of low-density lipoprotein (LDL) by free radicals has been 
implicated as an important determinant in the atherogenic process. By oxidative modi-
fication the uptake of LDL by macrophages is accelerated which is the beginning of 
the fatty streak. J LDL is protected against the free radical attack by antioxidants in 
plasma and in the particle itself. High plasma levels of vitamin E/' vitamin C'·3.5 and 
~-carotene5.6 have been suggested to be associated with a decreased risk of cardiovas-
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cular diseases. 
In the literature seasonal variation in plasma lipid and vitamin levels has been 
reported. Seasonal variation in ~-carotene,'·9 ascorbic acid iO•11 and a-tocopherol'" may 
result either directly or indirectly in seasonal variation in LDL oxidizability through 
variation in plasma or LDL antioxidant activity. Other well-known parameters influen-
cing the oxidizability of LDL are the size and composition of the LDL particleI2•i3 and 
its fatty acid composition.14.15 To our knowledge, no data are available on seasonal 
variation of these parameters. We therefore studied the influence of the time of the 
year on the antioxidant status and parameters of oxidizability of LDL cholesterol in 
healthy subjects. 
METHODS 
Study desigll 
We collected blood of \0 volunteers at four different periods over one year (Feb11lary, 
May, September and December). The six men and four women were apparently 
healthy and had a mean age 39.6 ± 7.4 years. Two of them were current smokers. Two 
persons had only three blood collections. All participants in this study gave their 
informed consent. 
Blood was collected in EDTA-containing Vacutainer tubes (I mg/ml) between 8.30 
and 9.00 am at all four time points. The subjects had consumed a light breakfast. 
Blood was immediately placed on ice and cooled to 4°C. Plasma was prepared, frozen 
in liquid nitrogen in small portions, leaving as little empty space as possible in the 
tubes, and stored at -80°C. This procedure was completed within 1 hour from vena-
puncture. Laboratory analyses were performed at the end of the year of study. 
Preparatioll alld oxidatioll of LDL 
The procedure for preparation and lipid peroxidation of LDL was adapted from the 
method described by Esterbauer and colleaguesl6 with some major modifications as 
described previously in detail. 17•18 Briefly, from each subject 2 ml of frozen plasma, 
stored at -80°C was rapidly thawed and used for isolation of LDL by ultracentrifu-
gation at 4°C in the presence of \0 11M EDTA. To minimize the time between isolati-
on and oxidation and to prevent loss of lipophilic antioxidants,19 the LDL was not 
dialysed. 16 By omitting dialysis a more stable LDL preparation is obtained, which can 
be stored in the dark at 4°C under nitrogen for several days without affecting resistan-
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ce time and maximum rate of oxidation."·I'.'o This improves the precision of the 
method, since each LDL preparation can be oxidized consecutively in triplicate. In a 
representative experiment, resistance time was 90 ± 2 min one hour after LDL isola-
tion in a LDL preparation which had not been dialyzed; 24 hours after LDL isolation 
resistance time was 91 ± 3 min (n = 3). Dialysis under nitrogen for 4 hours (2 chan-
ges) at 4°C against 1000 volumes of an oxygen-free buffer containing 150 mmollL 
NaCl and 10 mmollL sodium phosphate, pH 7.4 resulted in resistance times of 52 ± 5 
min, directly after dialysis and 23 ± 4 min after storage of this LDL under nitrogen for 
24 hours (n = 3). In agreement with these observations, recently, a loss of lipophilic 
antioxidants during dialysis was reported. 19 
LDL oxidation is performed under hypersaline conditions (1.18 mollL NaC!) and 
in the presence of 10 pmollL EDTA. Oxidation of LDL under hypersaline conditions 
results in a higher resistance time compared with oxidation in physiological saline 
(0.15 mollL)." In a test we found a resistance time of 90 ± 2 min in 1.18 mollL NaCI 
and 58 ± 5 min in 0.15 mollL NaCI both with 10 pmollL EDTA and 40 pmollL 
CuSO, (n = 3 independent oxidations with a reference LDL on different days). Ten 
pmollL EDT A is added during ultracentrifugation to protect the LDL against oxidation 
and in the oxidation assay to have equal EDT A concentrations in all assays. To over-
come the 10 pmollL and because of the hypersaline conditions, 40 pmollL CuSO, is 
added to initiate lipid peroxidation. 17.I' Under these conditions (high salt and 40 
pmollL CuSO,) the presence of EDTA does not affect kinetics of LDL oxidation. 
The kinetics of the LDL oxidation was followed by continuously monitoring the 
change of absorbance at 234 nm.I<;'I' All samples from one person were analysed in 
parallel in the same oxidation run. Each LDL preparation was oxidized in three con-
secutive oxidation runs on the same day. Means were calculated based upon these 
three observations. The intra-assay coefficients of variation for resistance time and 
maximum rate of oxidation calculated from measurements obtained at one day were 
2.6% and 3.1%, respectively. The inter-assay coefficients of measurements performed 
on different days were 4.9% and 7.4%, respectively.18 In every oxidation run one 
reference LDL, prepared from a reference plasma stored at -80°C, was used as a 
control. Oxidation mns with a higher than 10% deviation from the mean values of 
former reference measurements were omitted."·I' By using this highly standardized 
method, resistance time and maximum rate of oxidation do not differ between LDL 
prepared from plasma frozen in liquid nitrogen and that from freshly collected plasma 
from the same subject. In addition, no differences in these parameters were found upon 
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storage of plasma at -80°C up to 18 months. 17·18 
Analytical measurements 
Cholesterol and triglyceride concentrations were determined enzymatically using 
commercially available reagents (CHOD-PAP kit nr. 236.691 and Triglyceride kit nr. 
701.904, Boehringer-Mannheim, Mannheim, Germany). Phospholipid concentrations 
were determined using a commercially available colour reagent (Wako Chemicals 
GmbH, Neuss, Germany). 100 pi of LDL (0.25 mg protein/ml) sample and 750 pi 
colour reagent were mixed for 10 minutes at 37°C and the concentration was measured 
at a wavelength of 500 nm. 
High density lipoprotein (HDL)-cholesterol was measured after precipitation of 
very low density lipoprotein (VLDL), intermediate density lipoprotein (IDL) and low 
density lipoprotein (LDL) using the precipitation method with sodium phosphotung-
state-Mg'+.21 LDL-cholesterol concentrations were calculated by the Friedewald formu-
la." LDL size was determined by analysis of 7.5-10 pi plasma using 2-16% nondena-
turing polyacrylamide gradient gel electrophoresis (Pharmacia LKB, Uppsala, Swe-
den)." High molecular weight standards (Pharmacia, Piscataway, N.J., U.S.A.) were 
used, together with a reference selUm obtained from a pool of normolipidemic sera. In 
our institution the reference value for LDL particle size is 25.8 nm. After staining with 
Sudan Black B gels were scanned with an LKB 2202 Uitrascan laser densitometer 
(LKB, Paramus, N.J., U.S.A.). 
Fatty acid composition of LDL was determined by gas-liquid chromatography 
using a Chrompack gas chromatograph (model 438S) equipped with a CP-Sil88 co-
lumn (50 m x 0.25 mm i.d.) and a flame ionisation detector, as described previously.17 
We calculated the amount of poly-unsaturated fatty acids (PUFAs = C18:2 + C20:3 + 
C20:4 + C22:6), mono-unsaturated fatty acids (MUFAs = C16:1 + CI8:1), and satura-
ted fatty acids (SFAs = C14:0 + C16:0 + CI8:0). 
Alpha-tocopherol and carotenoids in plasma and LDL (stored at -80°C) were 
quantified by reverse-phase HPLC with spectrophotometric detection." 
Statistical analysis 
Data analysis was conducted using the statistical package BMDP." First, means and 
standard deviations for the four time periods were calculated for plasma and LDL lipid 
levels, antioxidant levels in plasma and in LDL, LDL particle size and fatty acid 
composition and oxidation parameters. Within-person seasonal fluctuation for these 
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parameters was assessed by analysis of variance (5V module). For those parameters. 
which showed a significant seasonal fluctuation paired t-tests were performed to detect 
which periods differed signicantly from each other (p<O.05). Further, partial correla-
tions were calculated between the oxidation parameters and the determinants of oxida-
tion, e.g. antioxidant vitamins, fatty acid composition and particle size. Adjustment 
was made for person number, to adjust for dependency of the measures of one subject 
over the four moments. 
RESULTS 
Table 1. Seasonal variation ill lipids alld vitamins (mean + SD) 
February May 
(n ~ 10) (n = 9) 
Plasma: 
Cholesterol, mmollL *" 5.65 ± 0.95 5.36 ± 0.94' 
Triglycerides. mmollL* 1.49 ± 0.63' 1.12 ± 0.45" 
HDL, mmol/L * 1.19 ± 0.22 1.32 ± 0.16 
LDL. mmollL * 3.78 ± 0.78 3.53 ± 0.83' 
Vitamin E, llmoIlL * 33.08 ± 6.54 33.53 ± 6.80 
Lycopene, pmollL 0.31 ± 0.20 0.30 ± 0.16 
~·Carotene. pmollL 0.38 ± 0.16 0.34 ± 0.11 
Lutein, llmol/L * 0.25 ± 0,07' 0.28 ± 0.08' 
<x-Carotene, pmollL 0.07 ± 0.03 0.06 ± 0,03 
LDL: 
September 
(n ~ 10) 
5.63 ± 1.04' 
1.44 ± 0.64' 
1.16 ± 0.27 
3.82 ± 0.78' 
33.62 ± 5.39 
0.41 ± 0.30 
0.38 ± 0.15 
0.20 ± 0.05'" 
0,07 ± 0,03 
Vitamin E, nmol/mg protein * 22.18 ± 2.37' 24.10 ± 2.66'·4 19.73 ± 3.64' 
December 
(n - 9) 
5.38 ± 0.94 
1.31 ± 0.55 
1.32 ± 0.45 
3.46 ± 0.90 
29.55 ± 5.60 
0.25 ± 0.11 
0.32 ± 0.08 
0.23 ± 0.09 
0.05 ± 0,03 
18.91 ± 1.83" 
Lycopene, nmol/mg protein 0.25 ± 0.14 0.25 ± 0.16 0.23 ± 0.16 0.21 ± 0.08 
~-Carotene, nmol/mg protein * 0.22 ± 0.12 0.23 ± 0.12 0.29 ± 0.16 0.23 ± 0.11 
Lutein, nmol/mg protein * 0.06 ± 0.02 0.08 + 0,033.4 0.05 + 0.02' 0.05 ± 0.02' 
*significant overall seasonal fluctuation (p<O.05). lsignificantly different from levels in Pebnmry 
(p<O.05). 2significantly different from levels in May (p<O.05). 3significantly different from levels in 
September (p<0.05). 'significantly different from levels in December (p<0.05). 
Table I shows the mean and standard deviation for the plasma lipids, the plasma 
antioxidant vitamins, and the vitamin status of the LDL particle for the four time 
periods. Seasonal fluctuation was found for plasma lipids, plasma vitamin E and 
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plasma lutein. Plasma total-cholesterol aud LDL-cholesterol levels were significantly 
lower in May compared to September aud triglyceride levels were lower in May 
compared to both September aud February. Plasma lutein was significautly lower in 
September compared to Febluary and May. Fm1her seasonal fluctuation was found for 
the vitamin E, p-carotene aud lutein content of the LDL particle. Both LDL vitamin E 
aud lutein had higher values in May compared to September aud December, whereas 
for vitamin E the values in December were also lower thau those in February. 
Table 2. Seasonal variation ill parameters of LDL oxidation, LDL size alld LDL fatty acid compo-
sition 
February May September December 
(n - 10) (n - 9) (n - 10) (n - 9) 
Resistance time, min 100 ± 6 99 ± 5 101 ± 8 97 ± 7 
Maximum rate of oxidation, 9.0 ± 0.8 9.0 ± 0.7 9.1 ± 0.6 9.2 ± 0.9 
nmol dienes/minlmg protein 
LDL particle size, nm* 26.6 ± 0.5'" 27.1 ± 0.4' 27.0 ± 0.5'" 26.0 ± 0.31)" 
LDL fatty acid composition: 4,2 ± 0.4 4,7 ± 0.5 4.5 ± 0.5 4.5 ± 0.4 
Total fatty acids, pmolf 
mg protein 
saturated fatty acids, % 28,2 ± 3,2 28.3 ± 4.0 28,0 ± 2,8 29,5 ± 3,2 
mono-unsaturated fatty acids, % 20.0 ± 2,6 20,9 ± 3.7 21.4 ± 3.1 20,6 ± 2,5 
poly-unsaturated fatty acids, % 51.8 ± 4.1 50,8 ± 3.6 50.6 ± 4.5 50,0 ± 3,0 
*significant overall seasonal fluctuation (p<O.05). isignificantly different from levels in February 
(p<O.05). 2significantIy different from levels in May (p<O.05). 3significanlly different from levels in 
September (p<O.05). 4significantly different from levels in December (p<O.05). 
Seasonal variation in oxidation parameters, LDL particle size aud LDL fatty acid 
composition are presented in Table 2. No significant seasonal variation for resistauce 
time aud maximum rate of oxidation was found, LDL particle size did show seasonal 
fluctuation, with the lowest particle size in December, There were no differences in 
fatty acid composition of the LDL over the four periods. 
The oxidation parameters were not significautly conelated to LDL particle size 
as assessed by partial correlation (r - -0,08 and I' - 0.30 for maximum rate of oxida-
tion aud resistauce time, respectively). A positive correlation was found between the 
amount of poly-unsaturated fatty acids in LDL aud maximum rate of oxidation (Pear-
son's l' - 0.65, p<O.OI) (Figure 1). The partial correlation for the association between 
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poly-unsaturated fatty acids and maximum rate of oxidation was slightly higher 
(r ~ 0.73, p<O.OI). FUither, maximum rate of oxidation was negatively correlated with 
LDL mono-unsaturated fatty acids (r ~ -0.56, p<0.05) and saturated fatty acids 
(r ~ -0.51, p<0.05). No significant correlation was found between fatty acid compo-
sition and resistance time. 
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Figure 1. Plot showing the correlation between maximum rate of oxidation of LDL oxidation and the 
percentage LDL poly-unsaturated fatty acids per moment; February (.). May (.). September (-) and 
December ce). The Pearson correlation is calculated over the total of 38 measures. 
DISCUSSION 
The purpose of this study was to assess the influence of the time of the year on the 
antioxidant status and parameters of LDL oxidizability. Parameters of oxidation re-
mained stable throughout the year. However, small fluctuations in plasma lipid levels, 
plasma and LDL vitamin E and lutein levels, LDL p-carotene levels and particle size 
over the seasons were found. 
33 
Chapter2 _____________________________ _ 
Our study sample comprised only a small number of subjects. Of the 10 participants 
two subjects had no blood sample taking at one moment. To optimize the use of all 
available data we used the repeated measures module, which adequately handles 
missing data. To ensure that the difference in means in the periods could not be 
ascribed to the different number of subjects, we calculated the means in the subset of 
subjects with complete data. Only marginal differences were detected and resulted in 
similar patterns as those presented in the tables (results not shown). 
Weare aware that the differences over the seasons found in some parameters are 
only small. Though statistically significant, this does not imply that these differences 
are also of physiological relevance. 
In our study significant differences in plasma lipids over the seasons were found. 
The fluctuation pattern for total cholesterol, LDL and triglycerides were comparable, 
high in February and September, low in May and December. The HDL levels showed 
the opposite pattern. Several groups described seasonal fluctuation in cholesterol 
Ievels,26-29 but from these and our studies it is still inconclusive in which months the 
peaks and throughs occur. 
For vitamins we found a seasonal fluctuation in plasma vitamin E and lutein levels 
and LDL vitamin E, ~-carotene and lutein levels. A seasonal variation in serum vita-
min E levels, however, was not shown in other studies.'" Several studies considering 
carotenoids found seasonal variations for ~-carotene,'·9 a-carotene, ~-cryptoxanthin and 
lutein.' However, Cantilena and colleagues did not find a seasonal within-person 
fluctuation for a- and ~-carotene and cryptoxanthin'o and no seasonal fluctuations have 
been found for lycopene and zeaxanthin.'·'o To our knowledge no data are available on 
fluctuations of vitamin concentrations in LDL. 
Seasonal fluctuations in vitamin levels in plasma and LDL may be ascribed to 
seasonal fluctuations in intake of these vitamins. Dietary variation of antioxidant intake 
over the year has been described by several groupS.9.3J As a result of better preserva-
tion techniques and marketing facilities seasonal variation in food intake gets less 
pronounced, but may still be important. In present study no dietary data were assessed, 
so we can only speculate on influences of intake on plasma and LDL levels measured 
over different seasons. There is no variation in LDL fatty acid composition over the 
year, which suggests that qualitative intake of oils and fats (with respect to composi-
tion) remained stable over the year. 
To our knowledge this is the first time that seasonal influence on oxidation para-
meters has been assessed. We did not find a difference in parameters of oxidation, e.g. 
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resistance time and maximum rate of oxidation, over the four time periods. Oxidiza-
bility of LDL is influenced by fatty acid composition,14.I5.20.32 LDL triglycerides,32 LDL 
particle size,12.I3 LDL vitamin EI7.I8.33 and plasma vitamin E levels,17.I8 but not by 
carotenoids. I8.34 From the above mentioned parameters a significant seasonal fluctu-
ation was found for LDL particle size and LDL vitamin E. For vitamin E cOITelations 
with parameters of oxidation have been reported only after vitamin E suppletion.I7.I8.33 
The same holds for fatty acids in most studies.I4.I5.20.32 Therefore an intervention seems 
necessary to find a sufficiently large contrast. Nevertheless, we found a possitive 
correlation between the total amount of poly-unsaturated fatty acids in LDL and 
maximum rate of oxidation in this study. Similar associations have been reported in 
other studies in UIlsupplemented normal and hypertriglyceridemic subjects,20.35 indica-
ting that fatty acid composition of the LDL particle is an important parameter deter-
mining LDL oxidizability in an unsupplemented (group of the) population. The LDL 
particle size in our study was not correlated to resistance time or maximum rate of 
LDL oxidation. This could be due to the small sample size of this study, or to the 
small diversity in particle sizes. Following the classification of LDL particles by 
Musliner and Krauss," the predominant LDL type measured in our study is the large 
LDL type I. Other studies in which a relationship between particle size and oxidation 
parameters is reported, showed a greater diversity in particle sizes with separation of 
the various density classes by ultracentrifugation. I2.I3 In our study one LDL preparation 
has been isolated and particle size of the most abundant LDL particles has been deter-
mined. 
In spite of small fluctuations in determinants of LDL oxidtion, no seasonal fluctua-
tion in LDL oxidation was found. Therefore it appears unnecessary to consider seaso-
nality in a study on LDL oxidation. 
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Chapter 3 
Susceptibility of LDL to oxidation 
and atherosclerosis 

3.1 
LDL oxidation and risk of coronary atherosclerosis 
ABSTRACT 
Evidence has accumulated for oxidative modification of low-density lipoproteins 
(LDL) to play an important role in the atherogenic process. Therefore, we investigated 
the relation between coronary atherosclerosis and susceptibility of LDL to oxidation in 
a case-control study in which men between 45 and 80 years of age participated. Cases 
and hospital controls were selected from subjects undergoing a first coromuy angio-
graphy. Subjects with severe coronary stenosis (2 85 % stenosis in one and 2 50% 
stenosis in a second major coronary vessel) were classified as cases (n ~ 91). Hospital 
controls with no or minor stenosis (~ 50% stenosis in no more than 2 of the three 
major coronary vessels (n ~ 94)) and population controls free of plaques in the carotid 
artery (n ~ 85) were pooled for the statistical analysis into one control categOlY. 
Emolment procedures allowed for similar distributions in age and smoking habits. 
Cases had higher levels of total and LDL cholesterol and triglycerides and lower 
levels of HDL cholesterol. Resistance time and maximum rate of oxidation were 
measured ex vivo using copper-induced LDL oxidation. A borderline significant inver-
se trend was observed for coronary atherosclerosis risk at increasing resistance time. 
Odds ratios (95% confidence interval) for the successive quartiles were 1.0 (reference), 
0.77 (0.39-1.53), 0.67 (0.33-1.34) and 0.55 (0.27-1.15) (P"',d ~ 0.07). No relationship 
with maximum rate of oxidation was found. The main determinant of oxidation was 
the fatty acid composition of LDL. 
We conclude that although LDL resistance to oxidation may be a factor in athero-
genesis, the ex vivo measure is not a strong predictor of severity of coromuy atheros-
clerosis. 
INTRODUCTION 
Oxidative modification of low-density lipoprotein (LDL) by free radicals has been 
implicated as an important determinant in the development of atherosclerosis. Oxida-
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tive modification accelerates the uptake of LDL by macrophages which is the begin-
ning of formation of a fatty streakY LDL is thought to be protected against attacks of 
free radicals by antioxidants in plasma and in the pruticle itself.' 
Circumstantial evidence indicates that oxidation occurs in vivo in humans. Epitopes 
of oxidized LDL have been found in plasma'·s and atherosclerotic lesions of experi-
mental animals and human6 and autoantibodies against these epitopes have been 
detected in human plasma.'·7.10 Furthermore, an increased susceptibility of LDL to 
oxidation has been described in patients with coronary heart disease."-l3 The suscepti-
bility of LDL to oxidation is decreased by vitamin E supplementation l 4-17 ruld increased 
by adding unsaturated fatty acids to the diet. 18-2o A reduction in risk of cru·diovascular 
disease (CVD) at higher plasma antioxidant levels21 has been reported and higher 
dietary antioxidant levels have been proposed to be associatied with a reduced risk of 
CVD."-'4 
To determine the relation between oxidative stress and atherosclerosis, lipid pe-
roxidation and its consequences is of pruticular interest. Ex vivo, the peroxidation pro-
cess can be mimicked by incubating isolated LDL with the pro-oxidant Cu'+ and by 
following the production of conjugated dienes from polyunsaturated fatty acids. The 
time elapsing until the onset of diene production, the resistance time, depends on the 
strength of the rultioxidant defence in the LDL particle," and may, therefore, reflect 
the resistance to oxidation in vivo. I By using the copper-induced oxidation method, 
several studies have described individual variation in susceptibility to LDL oxidation. I I-
'0.'6 In previous studies we have detected subtle changes in susceptibility of LDL to 
oxidation after supplementation of only 25 mg/day vitamin EI7 and by adding 5 g fish 
oil to the diet,'O using this oxidation method. 
To address the question whether LDL oxidation is related to the severity of coro-
nary herut disease we compared the susceptibility of isolated LDL to copper-induced 
oxidation in a large group of patients with angiographically determined coronruy 
atherosclerosis and a control group. 
METHODS 
Study populatioll 
The study was conducted in several hospitals and clinical centres in Rotterdam and 
Dordrecht, The Netherlands, in the period 1993-1995. The study was approved by an 
ethical committee on human research and all pruticipants gave their informed consent. 
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We selected a group of coronary atherosclerosis patients, a group of hospital controls 
and a group of population controls. The groups consisted of men between 45 and 80 
years of age. Enrolment procedures allowed for similar distributions of age (in 5-year 
categories) and smoking habits (smoking, non-smoking). 
Selection of the two hospital groups was based on angiographic reports. To reduce 
the impact of the disease on dietary and life-style patterns we selected only those 
patients who undenvent their first angiography and who had not experienced a myo-
cardial infarction (MI) in the year prior to the study. For the same reason, blood was 
collected within 2 months after angiography. Subjects using HMG-CoA reductase 
inhibitors were excluded, because of a possible influence of this medicine on LDL 
oxidation. 
In the study period 2830 patients underwent coronary angiography for suspected 
coronary atherosclerosis, which included 1966 male subjects. Subjects were ineligible 
if they met one of the following exclusion criteria: under 45 or over 80 years of age 
(n = 144), not the first coronary angiography (n = 289), MI in the 12 months prior to 
the study (n = 180), diabetes mellitus (n = 84), liver, kidney or thyroid disease 
(n = 15), alcohol or drug abuse (n = 4), use of HMG-CoA reductase inhibitors 
(n = 82), vegetarian diet (n = 3), psychiatric complaints (n = 2). For 88 subjects more 
than 2 months had elapsed between angiography and case selection and 12 patients 
had died in the meantime, leaving a population of 1063 eligible subjects. Of this group 
124 refused to participate and 50 could not be contacted or were otherwise indisposed. 
From the remaining 889 men, 92 cases were selected who had at least 85% stenosis in 
one and at least 50% stenosis in a second of the three major coronary vessels. Ninety-
five hospital controls were selected with less than 50% stenosis in no more than two 
of the three major coronary vessels. The percentage of stenosis was scored by the 
cardiologist performing the angiography. 
Population controls were selected from participants in the Rotterdam Study. The 
rationale and design of this population-based prospective cohort study have been 
described previously." No angiography data were available, but subjects were selected 
without any plaques in the carotid artery as assessed by ultrasound echography. Also 
these subjects had no history of cardiac disease or treatment, had no diabetes mellitus 
or liver, kidney or thyroid disease, did not use HMG-CoA reductase inhibitors nor 
were vegetarian. As the participants in the Rotterdam Study were all 55 years and over 
at baseline we additionally recruited men between 45 and 55 years of age through an 
advertisement in a local newspaper. Recruitment took place in the area the other 
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population controls originated from. A questionnaire was used to obtain information on 
medical history; when candidates fulfilled the inclusion criteria they were invited to 
the research centre. Enrolment in the study took place after it had been echographically 
ascertained that the carotid artery was free of plaques. 
No oxidation parameters were measured in one case, and two control subjects (one 
population and one hospital control) had invalid resistance time measurements, and 
were hence excluded from the statistical analysis. The final study population consisted 
of 91 cases with severe coronary atherosclerosis, 94 hospital based controls with no or 
minor coronary atherosclerosis and 85 popUlation based controls. 
Data Collection 
For the hospital groups information on medical history was obtained from the medical 
file and through a questionnaire within 2 months after angiography. Information on 
dietary, smoking, and drinking patterns, dlUg use, use of vitamin supplements, occupa-
tion and family history of CVD was obtained. Weight, height and blood pressure were 
measured. A fasting venous blood sample was collected in EDT A Vacutainer tubes 
and immediately placed on ice and cooled to 4'C. Plasma was prepared within 1 h 
after blood collection by centrifugation at 1750 x g for 15 min, frozen in methanol of 
-80'C or liquid nitrogen, and stored at -80'C, 
Preparation and oxidation of LDL 
The procedure for preparation and lipid peroxidation of LDL was adapted from Ester-
bauer et al.25 with some major modifications as described previously in detaiI. 15.17 
Briefly, for each subject, 2 ml of frozen plasma stored at -80'C was rapidly thawed 
and used for isolation of LDL by ultracentrifugation at 4°C in the presence of 10 JlM 
EDTA. To minimize the time between isolation and oxidation and to prevent loss of 
lipophilic antioxidants," the LDL was not dialysed.15.17.20 By omitting dialysis a more 
stable LDL preparation is obtained, which can be stored in the dark at 4°C under 
nitrogen for several days without affecting resistance time and maximum rate of 
oxidation. 15.17.,o This improves the precision of the method since each LDL preparation 
can be oxidized consecutively in triplicate. In a representative experiment, resistance 
time was 90 ± 2 min one hour after LDL isolation in a LDL preparation which had 
not been dialysed; 24 h after LDL isolation resistance time was 91 ± 3 min (n = 3). 
Dialysis under nitrogen for 4 h (2 changes) at 4°C against 1000 volumes of an 
oxygen-free buffer containing 150 mmolll NaCl and 10 mmolll sodium phosphate, pH 
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7.4, resulted in resistance times of 52 ± 5 min directly after dialysis and 23 ± 4 min 
after storage of LDL under nitrogen for 24 h (n = 3). In agreement with these obser-
vations a loss of lipophilic antioxidants during dialysis was recently repOlled." 
The kinetics of LDL oxidation was followed by continuously monitoring the 
change of absorbance at 234 nm. IS•17." Absorbance curves of LDL preparations obtai-
ned from an equal number (3) of subjects from each study group were determined in 
parallel. Each LDL preparation was oxidized in three consecutive oxidation luns on the 
same day. Means were calculated on the basis of these three observations. The intra-
assay coefficients of variation for resistance time and maximum rate of oxidation 
calculated from measurements obtained at one day were 2.6% and 3.1%, respectively. 
The inter-assay coefficients of measurements performed on different days were 4.9% 
and 7.4%, respectively.ls.17 In evelY oxidation nm one reference LDL, prepared from a 
reference plasma stored at -80°C, was used as a control. Oxidation runs with a devia-
tion higher than 10% from the mean values of former reference measurements were 
omittedY·17 By using this highly standardized method, resistance time and maximum 
rate of oxidation do not differ between LDL prepared from plasma frozen in liquid 
nitrogen and that from freshly collected plasma from the same subject. In addition, no 
differences in these parameters were found upon storage of plasma at -80°C up to 18 
months. 
Analytical measurements 
Cholesterol and triglyceride concentrations were determined enzymatically using 
commercially available reagents (CHOD-PAP kit 236.691 and Triglyceride kit 
701.904, Boehringer-Mannheim, Mannheim, Germany). Phospholipid concentrations in 
LDL were determined using a commercially available colour reagent (Wako Chemi-
cals, Neuss, Germany). 100 pI of LDL (0.25 mg protein/ml) sample and 750 pI colour 
reagent were mixed for 10 min at 37°C and the concentration was measured at a 
wavelength of 500 nm. The protein content of the LDL preparations was measured 
according to Lowry et al.29 
High-density lipoprotein (HDL)-cholesterol was measured after precipitation of 
very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL 
using the precipitation method with sodium phosphotungstate-Mg'+:l0 LDL-cholesterol 
concentrations were calculated by the formula of Friedewald et al:'1 
Fatty acid composition of LDL was determined in duplicate by gas liquid chroma-
tography as previously described.17 Heptadonoic acid (C 17:0) was added as an intemal 
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standard. We calculated the amount of polyunsaturated fatty acids (C18:2 + C18:3 + 
C20:2 + C20:3 + C20:4 + C20:5 + C22:6), monounsaturated fatty acids (CI4: I + 
C16:1 + C18:1 + C20:1 + C22:I), and saturated fatty acids (CI2:0 + C14:0 + C15:0 + 
C16:0 + C18:0 + C20:0 + C22:0). 
Concentrations of LDL antioxidants were determined by reversed-phase HPLC and 
spectrophotometric detection." LDL antioxidant concentrations were standardized by 
calculating antioxidant concentrations per mg of LDL protein. 
Statistical analysis 
Characteristics of the case group and the control groups were compared with Student's 
t-test for unpaired samples. Because the two control groups were comparable regarding 
the lipid levels, age and smoking status and to increase statistical power data analyses 
was performed with the two control groups pooled. Age-adjusted means were compa-
red by analysis of covariance. Odds ratios (ORs) were calculated to quantify the 
association between parameters of oxidation and coronary stenosis. Quartile distributi-
ons for calculation of ORs were based on distributions of oxidation parameters in the 
control group. The trend analysis was performed over the oxidation parameters as a 
continuous variable in the logistic model. To determine which variables are important 
in predicting resistance time and maximum rate of oxidation we used univariate ana-
lysis. These analyses were performed in the control group. Variables found to be 
significant contributors in univariate analysis were examined in multiple linear regres-
sion to assess which variable was the most important predictor. Data analysis was 
conducted using the statistical package BMDP.33 
RESULTS 
Table I lists characteristics of cases and controls. Groups were comparable regarding 
the prestratification factors age and smoking status. Total cholesterol, LDL cholesterol 
and triglyceride levels were significantly lower in the control group, whereas HDL 
cholesterol was higher in controls. No differences were seen in blood pressure, body 
mass index, diet use and family history of CVD. Cases reported more often a history 
of MI, use of antihypertensive and lipid-lowering medication other than HMG-CoA 
reductase inhibitors and use of aspirins and coumarin derivatives. 
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Table 1. Characteristics of the study population (Mean ± SD) 
Cases Controls 
(n = 91) (n= 179) 
Age (years) 6l.6 ± 9.2 60.0 ± 8.4 
Smokers (%)' 3l.9 3l.3 
Ex-smokers (%)1 54.9 50.8 
Number of cigarettes (smokers only)2 ILl ± 8.4 12.4 ± 6.7 
Body mass index (kg/m') 26.4 ± 2.5 26.1 ± 3.2 
Total cholesterol (mmoVl) 6.1 ± l.2 5.6 ± l.O' 
Triglycerides (mmoVl) 2.1 ± 0.9 l.7 ± 0.9' 
HOL cholesterol (mmoVI) 0.9 ± 0.2 l.0 ± 0.3' 
LOL cholesterol (mmoVI) 4.3 ± Ll 3.8 ± 0.9' 
Systolic blood pressure (mmHg) 133.3 ± 17.6 135.2 ± 17.2 
Diastolic blood pressure (mmHg) 8l.6 ± 8.1 83.7 ± 8.8 
Under treatment by a cardiologist (years) 3.5 ± 5.0 2.4 ± 4.7 
Oiet use (%) 13.6 8.4 
-Cholesterol-restricted (% in diet users) 58.3 20.0 
-Fat-restricted (% in diet users) 36.4 46.7 
Antioxidant supplementation (%)3 5.5 3.4 
Medication (%) 
-Antihypertensive medication (%) 94.5 43.6' 
-Lipid-lowering medication (%)4 6.6 0.6' 
-Aspirin + coumarin derivatives 93.4 20.7' 
Family history of CVO 27.5 20.6 
History of MI 37.8 4.3' 
lex-smokers stopped smoking more than one year ago; otherwise they are categorized as current 
smokers. 2number of smokers among cases (n = 14) and controls (n = 37). Juse of vitamin A, vitamin 
C or vitamin E supplements. 4lipid-lowering medication other than HMG CoA reductase inhibitors. 
Ssignificant difference (p<O.05) in age-adjusted differences (analysis of covariance). 
LDL composition is given in Table 2. No differences in a-tocopherol level and fatty 
acid composition were seen. Comparison of the LDL composition revealed higher 
percentages of total cholesterol, esterified cholesterol and phospholipids in the controls, 
whereas the percentage of triglycerides was lower in the control group. When expres-
sed as absolute amounts of lipids per mg LDL protein only triglycerides were signifi-
cantly lower in the control group (results not shown). 
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Table 2. LDL vitamin E, LDLfalfy acids content and LDL compositioll (mean ± SE) 
a-Tocopherol (nglmg protein) 
Total fatty acids in LDL (pg per mg protein) 
Polyunsaturated fatty acids(%) 
Monounsaturated fatty acids (%) 
Saturated fatty acids (%) 
Total cholesterol (%) 
Free cholesterol (%) 
Cholesterol ester (%) 
Triglycerides (%) 
Phospholipids (%) 
Protein (%) 
Ip<0.05. 'p<O.Ol. 
Parameters of LDL oxidation 
Cases 
(n = 91) 
5156.0 ± 118.1 
1372.3 ± 18.6 
58.0 ± 0.8 
18.9 ± 0.6 
22.5 ± 0.2 
40.7 ± 0.2 
8.5 ± 0.2 
32.2 ± 0.3 
6.6 ± 0.2 
25.1 ± 0.2 
27.5 ± 0.2 
Controls 
(n = 179) 
4908.0 ± 88.3 
1406.1 ± 14.8 
57.6 ± 0.4 
19.8 ± 0.4 
22.2 ± 0.1 
41.2 ± 0.1 1 
8.0 ± 0.2 
33.3 ± 0.21 
5.8±0.I' 
25.6 ± 0.1 1 
27.3 ± 0.2 
Table 3 lists parameters of LDL oxidation with age-adjusted differences. Resistance 
time and maximum rate of oxidation were not significantly different. However, a 
borderline significant lower resistance time was seen in the cases (p ~ 0.07). 
Surprisingly, a significant difference in oxidation maximum, i.e. maximum diene 
production, was found with a higher maximum production being found in the control 
group. 
Table 3. Parameters of LDL oxidation (mean ± SE) and age-adjusted differences 
Resistance time (min) 
Maximum rate of oxidation 
(nmol diene/min per rug protein) 
Maximum diene production (nmol/mg) 
lease minus control. 2p<O.Ol. 
Cases 
(n = 91) 
87 ± 1 
10.3 ± 0.1 
406 ± 2 
Controls 
(n = 179) 
89 ± 1 
10.1 ± 0.1 
420 ± 3 
Adjusted diffe-
rencel ± SE 
-2 ± 1 
0.1 ± 0.15 
-14 ± 4' 
Odds ratios (ORs) and 95% confidence intervals were calculated for the risk of coro-
nary atherosclerosis per quartile of resistance time and maximum rate of oxidation. For 
resistance time a slightly (non-significant) decreased risk for coronary atherosclerosis 
was found. For maximum rate of oxidation no associations were found (Table 4). 
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Table 4. Odds ratios for the risk of corollary atherosclerosis per quartile of resistance time and 
maximum rate of oxidation 
Quartile II III IV Trend! 
(reference) 
Resistance time <85 85-89 89-94 >94 
number of cases 30 23 21 17 
OR (95% CI) 1.0 0.77 (0.39-1.53) 0.67 (0.33-1.34) 0.55 (0.27-1.15) p=0.07 
Max. rate of oxidation <9.4 9.4-10.3 10.3-11.0 >11.0 
number of cases 20 26 19 26 
OR (95% Cl) 1.0 1.27 (0.62-2.61) 0.91 (0.43-1.93) 1.30 (0.63-2.67) p=0.43 
[the trend is calculated over the oxidation parameters as a continuous variable. 
The ORs calculated for the oxidation parameters as continuous variables in the model 
resulted in an OR of 0.97 (0.94-1.00) per minute increase of resistance time and 1.09 
(0.87-1.37) per unit of maximum rate of oxidation. The difference between the lowest 
10% point of distribution and the 90% point produced an OR of 0.58 (0.32-1.03) for 
resistance time and 1.31 (0.67-2.57) for maximum rate of oxidation. The same ORs as 
found for the pooled control group were observed after calculation of ORs for the 
control groups separately. 
As more subjects in the case group had a histOlY of MI and a histOlY of MI could 
have had impact on dietalY pattems, we repeated the analyses with MI survivors 
excluded. No relevant differences in ORs were detected. 
Stratified analyses for smokers (n ~ 85) and non- and ex-smokers (n ~ 185) were 
pelformed. ORs were 0.97 (0.91-1.03) and 0.97 (0.93-1.01) per unit of resistance time 
and l.l1 (0.78-1.59) and 1.08 (0.81-1.45) per unit of maximum rate of oxidation in 
smokers and non-smokers plus ex-smokers, respectively. 
Determinants of oxidatioll parameters 
We investigated which variables were determinants of the oxidation parameters in the 
control group. For this analysis age, BMI, smoking status, plasma lipids, a-tocopherol 
and fatty acid content of the LDL particle and LDL composition were considered. By 
univariate analysis determinants which were significantly con-elated to the oxidation 
parameters were detected and included in multiple linear regression analysis to identify 
those determinants which give the highest contribution in explaining the outcome. The 
only significant association with resistance time was found in the percentage of satUl'a-
ted fatty acids in the LDL particle (r ~ 0.18). Maximum rate of oxidation was positi-
vely related to percentage of polyunsaturated fatty acids (r ~ 0.55) and inversely to the 
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percentage of monounsaturated (r - -0.36) and saturated fatty acids (I' - -0.53). In 
addition, an association was found between maximum rate of oxidation and body mass 
index (r - -0.18) and percentage total cholesterol (r - 0.24) and triglycerides 
(r - -0.23) in the LDL particle. Multiple linear regression ascribed the most relevant 
contributions to the maximum rate of oxidation to the percentages saturated and 
monounsaturated fatty acids in the LDL particle (R2 - 0.53). 
DISCUSSION 
We investigated the relationship between parameters of LDL oxidation and severity of 
coronary atherosclerosis in a case-control study. Resistance time, as a reflection of 
resistance to oxidation ill vivo, was expected to be lowest in subjects with coronary 
atherosclerosis. We indeed found a slight, but not significant, decreased risk of coro-
nary atherosclerosis with increasing resistance time. Propensity to oxidation may also 
be reflected in a higher maximum rate of oxidation. However, this could not be confir-
med in our study. 
In this study selection of both case and hospital control groups was based on 
angiography. The mean percentage of stenosis in the case group was 75% and 55% of 
the cases had narrowing of at least 50% in all three coronary vessels, whereas the 
hospital controls had a mean of 4% stenosis and 76% of these controls had no substan-
tial narrowing in the 3 major coronary vessels. The contrast between cases and con-
trols was thus sufficient with virtual exclusion of misclassification of disease. More-
over, we included a group of population controls of whom we had a measure of CVD, 
Le, echography of the carotid arteries. 
In this study a positive correlation between the percentage of polyunsaturated fatty 
acids and maximum rate of oxidation was found. The percentages of monounsaturated 
and saturated fatty acids were inversely related to the maximum rate of oxidation, 
whereas resistance time was positively cotTelated with percentage of saturated fatty 
acids. Assessment of determinants important in predicting susceptibility to oxidation 
demonstrated that fatty acid composition of LDL may be most important. These results 
coincide with other studies reporting increased susceptibility to oxidation with the 
degree of unsaturation of fatty acids, which leads to °a decreased resistance time and an 
increased maximum rate of oxidation and maximum diene production. 18-2o In our study 
the mean level of fatty acids, however, did not differ between the groups. Despite 
equal amounts of polyunsatured fatty acids in the LDL particle, we did find a signifi-
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cant higher maximum diene production in controls, most pronounced in the population 
control group. We do not know yet how to interprete this result, but diene production 
seems to be an unsuitable parameter to study LDL oxidation as risk factor for coronruy 
atherosclerosis. 
In our study we found small but significant differences in LDL lipid composition 
between the case group and the control group, with higher total cholesterol and phos-
pholipid levels in the LDL particle and lower LDL triglyceride levels in the control 
group. These differences, however, were not reflected in a significant difference in 
resistance time and maximum rate of oxidation between the groupS.26 The reason for 
this may be the small diversity of LDL particles, despite significrult differences be-
tween cases and controls. 
No difference in fatty acid composition of the LDL particle between cases and 
controls was observed, indicating that dietruy intake of fatty acids was similar in the 
groups. The use of a prescribed diet was not different between groups, and to further 
exclude dietruy changes as a result of angiography blood samples were taken within 
two months after catheterization. ORs for coronruy atherosclerosis risk for the two 
sepru'ate control groups did not differ. Therefore, it seems unlikely that the hospital 
groups have been more prone to dietru'y changes. Another reason for changed dietruy 
patterns could have been the experience of MI, which was more common in the case 
group. Analyses with MI survivors excluded, however, yielded essentially similru' 
results. 
Supplementation with vitamin E has been reported to increase resistance time and 
decrease maximum rate of oxidation. I4-17 About 5% of our study population reported 
the use of rultioxidant supplements. Most common was the use of vitamin C which 
does not have an effect on LDL oxidizability.16 Only one control subject reported the 
use of vitamin E ruld one case used vitamin A. One case and eight controls reported 
the use of multivitamins. As in multivitamins the concentration of antioxidants ru'e 
usually low in the Netherlrulds, subjects who used multivitamins were not categorized 
as being supplement user. Analyses with supplement users excluded did not change the 
results. 
Only three previous studies reported on the relation between oxidation parameters 
and coronary heart disease. De Rijke et a!. found a higher susceptibility of LDL to 
oxidation in coronary bypass patients who had shown progression compru'ed to those 
without progression after seven yeru's of follow Up.13 Regnstrom et a!. described an 
inverse association between resistance phase ruld severity of coronru'y stenosis in young 
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MI survivors. II Cominacini et al. I2 observed a lower lag phase in coronary artery 
patients than in hyperlipidaemic patients or valvular heart disease patients. In our study 
we also found a lower (though not significantly lower) risk of coronary atherosclerosis 
with increasing resistance time. As in the study of de Rijke et aI., no significant diffe-
rence in maximum rate of oxidation was found. The association of resistance time and 
risk of coronary heart disease was weaker in our study than in the other studies, even 
though the sample sizes in the other studies were relatively small and the difference 
between coronary atherosclerosis patients and controls is less discriminative in 
Cominacini's study compared to ours. Similar to Regnstriim et aL" and Cominacini et 
al.t', we had only one measure of CVD and we had no data on progression of athero-
sclerosis. The progression of atherosclerosis may differ between persons and those in 
the most active stage of atherogenesis may be most susceptible to oxidation. 
Intervention studies have shown a clear relationship between vitamin E!4-17 and 
unsaturated fatty acid supplementation!'·2o and LDL susceptibility to oxidation. From 
this it has been concluded that the ex vivo oxidation can mimick the oxidative process 
ill vivo. In this study we found borderline significant associations between risk of 
coronary atherosclerosis and reduced resistance time, indicating that coronary heart 
disease does not lead to a significant contrast in oxidation parameters as was found 
after vitamin E intake or intake of specific fatty acids.!4-20 In addition it is likely that 
this method of assessing oxidizability will not really reflect the oxidative process 
active in development of atherosclerosis ill vivo. The oxidative process is influenced 
not only by antioxidants and fatty acids in the LDL particles themselves, but is part of 
a larger mechanism, in which also plasma antioxidants and cell constituents play a 
role. Direct methods for measuring oxidation ill vivo may therefore be more successful! 
as predictive parameters. Measurement of autoantibodies against oxidized LDL"lO or 
epitopes of oxidized LDL 4.' appears to be promising, but so far results are contradic-
ting. Possibly autoantibodies are not an indicator of severity of atherosclerosis, i.e. the 
extent of thickening of the vessel wall, but can be used as an indicator of the active 
atherogenic process.lO The same may hold true for LDL oxidation and thickening of 
the vessel wall. 
In conclusion, our data do not support the presence of an association between risk 
of coronary atherosclerosis and LDL oxidation in patients with severe coronary heart 
disease. This may be due to the phase of the atherosclerotic process, or failure of the 
method used to measure LDL oxidation to sufficiently reflect ill vivo oxidation. 
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Oxidation of LDL and risk of peripheral atherosclerosis 
ABSTRACT 
Evidence has accumulated for oxidative modification of low-density lipoproteins 
(LDL) to play an important role in the atherogenic process. Therefore, we investigated 
the relation between susceptibility of LDL to oxidation and risk of peripheral athero-
sclerosis among 249 men between 45 and 80 years of age. Participants initially selec-
ted to study the relation between coronary atherosclerosis and LDL oxidation were 
recategorized according to their ankle-arm blood pressure index. The ankle-arm index 
was calculated for both legs as the ratio of systolic blood pressure in the leg divided 
by the arm systolic blood pressure. The lowest of both ankle-arm indices was used to 
categorize subjects into groups with and without peripheral atherosclerosis. Thirty-nine 
men had an ankle-arm index < 1.00 (16% of the study population). 
Subjects with peripheral atherosclerosis reported more often the use of a special 
diet and the use of antihypertensive medication, aspirin and coumarin derivatives. No 
significant differences in total, LDL and HDL cholesterol and triglycerides were 
present between groups. Resistance time and maximum rate of oxidation were measu-
red ex vivo using copper-induced LDL oxidation. Subjects with peripheral atheroscle-
rosis had a significantly lower resistance time, whereas the maximum rate of oxidation 
tended to be increased in subjects with Peripheral atherosclerosis. Odds ratios (ORs, 
and 95% confidence interval) for the successive tertiles of resistance time were 1.00 
(reference), 0.37 (0.15-0.89) and 0.37 (0.16-0.86) (p",",<O.OI). ORs for the successive 
tertiles of maximum rate of oxidation were 1.00 (reference), 1.34 (0.47-3.82) and 1.50 
(0.55-4.15). This inverse association was borderline significant (p"",=0.07). 
These results SUppOlt a role for LDL oxidation in the development of peripheral 
atherosclerosis. 
INTRODUCTION 
Oxidative modification of low-density lipoprotein (LDL) by free radicals has been 
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implicated as an important determinant in the development of atherosclerosis. By 
oxidative modification the uptake of LDL by macrophages is accelerated which is the 
beginning of formation of fatty streak.'" Antioxidants in plasma and in the LDL 
particle itself are thought to protect LDL against attacks of free radicals.' 
Circumstantial evidence indicates that oxidation occurs ill vivo in humans. Epitopes 
of oxidized LDL have been found in plasma'" and atherosclerotic lesions of experi-
mental animals and humans' and autoantibodies against these epitopes have been 
detected in human plasma.'·8 The susceptibility of LDL to oxidation is decreased by 
vitamin E supplementation"" and increased by adding unsaturated fatty acids to the 
diet,"·14 A reduction in risk of cardiovascular disease (CVD) at higher plasma antioxi-
dant levels 15 has been reported and higher antioxidant levels have been proposed to be 
associated with a reduced risk of CVD.'6-18 
Susceptibility of LDL to oxidative stress is measured ex vivo by determining the 
production of conjugated dienes from polyunsaturated fatty acids after incubating 
isolated LDL with the pro· oxidant Cu". The time elapsing until onset of diene produc-
tion, the resistance time, depends on the strength of antioxidant defence in the LDL 
particle" and may, therefore, reflect the resistance to oxidation ill vivo.' 
A few studies have investigated the relationship between oxidation of LDL and 
risk of CHD.'o,,, Thus far, no studies investigated whether LDL oxidation plays a role 
in development of peripheral atherosclerosis. Higher levels of lipid peroxides']·24 and 
autoantibodies against oxidized LDL" were found in patients with peripheral vascular 
disease. In the present study, initially designed to study the relationship between 
coronary atherosclerosis and susceptibility to oxidation, we investigated the association 
between susceptibility to oxidation and peripheral atherosclerosis by measuring resis-
tance time, maximum oxidation rate and determinants of oxidation in subjects with and 
without peripheral atherosclerosis. 
METHODS 
Study populatioll 
The study was conducted in several hospitals and clinical centres in Rotterdam and 
Dordrecht, the Netherlands (1993-1995), initially to study the relationship between 
angiographically documented coronmy atherosclerosis and LDL oxidation. The study 
was approved by an ethical committee on human research and all participants gave 
their informed consent, Subjects with a history of cm"diovasculm" disease (CVD) were 
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selected out of patients undergoing their first coronary angiography. Excluded were 
subjects who had experienced a myocardial infarction in the year prior to the study. 
FUl1her, subjects without a history of CVD were selected from participants in the 
Rotterdam Study, a population-based prospective cohort study" and through advertise-
ment in a local newspaper." Of this latter group, only those subjects without any pla-
ques in the carotid artery as assessed by echography participated. 
All subjects were men between 45 and 80 years of age. Exclusion criteria were; 
use of HMG-CoA reductase inhibitors because of a possible influence of this medicine 
on LDL oxidation; diabetes mellitus; liver, kidney or thyroid disease; alcohol- or dlUg 
abuse; vegetarian diet and psychiatric complaints. Of the 273 participants in the initial 
study, ankle-arm index as a measure of peripheral artery disease was measured in 252 
subjects. We classified patients with peripheral atherosclerosis as those subjects with 
an ankle-arm ratio lower than the 20% cut-off point of distribution. This cut-off point 
was situated at 1.00. As an ankle-arm ratio of 1.00 was found in 33 subjects, we 
decided to categorize as patients with peripheral atherosclerosis only those with an 
ankle-arm ratio lower than 1.00 (16% of the subjects). No oxidation parameters were 
measured in one subject without peripheral atherosclerosis and two subjects without 
peripheral atherosclerosis were excluded from the statistical analysis because of invalid 
resistance time values. This resulted in a study popUlation of 39 patients with and 210 
subjects without peripheral atherosclerosis. 
Data Collectioll 
For the participants with a CVD history information on medical history was obtained 
from the medical file and through a questionnaire within 2 months after angiography. 
For the others information on medical histOlY was obtained from baseline data of the 
Rotterdam Study and via questionnaires. For all subjects information 011 dietary, 
smoking, and drinking habits, dl1lg use, use of vitamin supplements, occupation and 
family history of CVD was obtained and weight and height were measured. 
Systolic and diastolic blood pressure in the right upper arm were measured in 
duplicate with the subject in sitting position. To evaluate the presence of atherosclero-
sis in the lower arteries systolic blood pressure of the posterior tibial artelY at both left 
and right mude was determined using an 8 MHz continuous wave doppler probe CImex 
Pocketdop-II) and a random-zero sphygmomanometer with the subject in supine 
**for detailed information see chapter 3.1 
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position. Ankle-arm index was calculated as the ratio of the systolic blood pressure in 
the ankle to the systolic blood pressure in the arm. The lowest ankle-arm index in 
either leg was used in the analysis. 
Finally, a fasting venous blood sample was collected in EDT A Vacutainer tubes 
and immediately placed on ice and cooled to 4°C. Plasma was prepared within I h 
after blood collection by centrifugation at 3000 rpm for IS min, frozen in methanol of 
-80°C or liquid nitrogen, and stored at -80°C, 
Preparation and oxidation of LDL 
The procedure for preparation and lipid peroxidation of LDL was adapted from Ester-
bauer et al.27 with some major modifications as described previously in detail.'·11 
Briefly, for each subject, 2 ml of frozen plasma stored at -80°C was rapidly thawed 
and used for isolation of LDL by ultracentrifugation at 4°C in the presence of 10 11M 
EDT A. To minimize the time between isolation and oxidation and to prevent loss of 
lipophilic antioxidants," the LDL was not dialysed.29 By omitting dialysis a more 
stable LDL preparation is obtained, which can be stored in the dark at 4°C under 
nitrogen for several days without affecting resistance time and maximum rate of 
oxidation.,·11.14 This improves the precision of the method, since each LDL preparation 
can be oxidized consecutively in triplicate. In a representative experiment, resistance 
time was 90 ± 2 min one hour after LDL isolation in a LDL preparation which had 
not been dialysed; 24 h after LDL isolation resistance time was 91 ± 3 min (n = 3). 
Dialysis under nitrogen for 4 h (2 changes) at 4°C against 1000 volumes of an oxygen-
free buffer containing ISO mmollL NaCl and 10 mmollL sodium phosphate, pH 7.4, 
resulted in resistance times of 52 ± 5 min directly after dialysis and 23 ± 4 min after 
storage of this LDL under nitrogen for 24 h (n = 3). In agreement with these observa-
tions, recently, a loss of lipophilic antioxidants during dialysis was reported." The 
kinetics of the LDL oxidation was followed by continuously monitoring the change of 
absorbance at 234 nm.'·II.27 Absorbance curves of LDL preparations obtained from an 
equal number of subjects from each study group were determined in parallel. Each 
LDL preparation was oxidized in three consecutive oxidation runs on the same day. 
Means were calculated on the basis of these three observations. The intra-assay coeffi-
cients of variation for resistance time and maximum rate of oxidation calculated from 
measurements obtained at one day were 2.6% and 3.1 %, respectively. The inter-assay 
coefficients of measurements performed on different days were 4.9% and 7.4%, res-
pectively.' In every oxidation run one reference LDL, prepared from a reference 
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plasma stored at -80°C, was used as a control. Oxidation runs with a higher than 10% 
deviation from the mean values of former reference measurements were omitted.'·l1 By 
using this highly standardized method, resistance time and maximum rate of oxidation 
do not differ between LDL prepared from plasma frozen in liquid nitrogen and that 
from freshly collected plasma from the same subject. In addition, no differences in 
these parameters were found upon storage of plasma at -80"C up to 18 months." 
Analytica[measureme/lts 
Cholesterol and triglyceride concentrations were determined enzymatically using 
commercially available reagents (CHaD-PAP) kit and Triglyceride kit, Boehringer-
Mannheim, Mannheim, Germany). Phospholipid concentrations were determined using 
a commercially available colour reagent (Wako Chemicals, Neuss, Germany). 100 III 
of LDL (0.25 mg/ml protein) sample and 750 III colour reagent were mixed for 10 min 
at 37"C and the concentration was measured at a wavelength of 500 nm. The protein 
content of the LDL preparations was measured according to Lowry et al.30 
High-density lipoprotein (HDL)-cholesterol was measured after precipitation of 
very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and low-
density lipoprotein (LDL) using the precipitation method with sodium phospho tung-
state-Mg2+. 31 LDL-cholesterol concentrations were calculated by the formula of Friede-
wald et al. 32 
Fatty acid composition of LDL was determined in duplicate by gas-liquid chroma-
tography as previously described. 11 Heptadonoic acid (CI7:0) was added as intemal 
standard. We calculated the amount of polyunsaturated fatty acids (CI8:2 + C18:3 + 
C20:2 + C20:3 + C20:4 + C20:5 + C22:6), monounsaturated fatty acids (CI4: I + 
C16:1 + C18:1 + C20:1 + C22:1), and saturated fatty acids (CI2:0 + C14:0 + C15:0 + 
C16:0 + C18:0 + C20:0 + C22:0). 
Concentrations of LDL antioxidants were determined by reversed-phase HPLC" 
and spectrophotometric detection. LDL-antioxidant concentrations were standardized 
by calculating antioxidant concentrations per mg LDL protein. 
Statistical allalysis 
Characteristics of the subjects with and without peripheral atherosclerosis were com-
pared with Student's t-test for unpaired samples. Age-adjusted means were compared 
by covariance analysis. For comparison of LDL antioxidant concentrations log-trans-
formed data were used. Odds ratios (ORs) were calculated to quantify the association 
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between parameters of oxidation and peripheral atherosclerosis. Classification in 
tertiles for calculation of ORs was based on distributions of oxidation parameters in 
the group without peripheral atherosclerosis. The p for trend was assessed by calcula-
ting the ORs per unit of resistance time or maximum rate of oxidation. Data analysis 
was conducted using the statistical package BMDP.34 
RESULTS 
Table 1 lists characteristics of subjects with and without peripheral atherosclerosis. 
Patients with peripheral atherosclerosis were significantly older. No differences were 
seen in body mass index (BMI), plasma lipid levels, smoking status, systolic and 
diastolic blood pressure and family history of CVD. Patients with peripheral athero-
sclerosis reported more frequently use of a special diet (20.5% in patients with vs. 
8.2% in subjects without peripheral atherosclerosis), use of antihypertensive medication 
(76.9% vs. 55.2%) and use of aspirins and coumarin derivatives (61.5% vs. 40.0%). 
No significant differences in family history of CVD (23.1 % vs. 23.8%) and history of 
MI (33.3% vs. 18.0%) were reported. 
Table 1. Char~cteristics of the study population (Mean ± SD) 
Age (years) 
Smokers (9W 
Ex-smokers (%)1 
Body mass index (kg/m') 
Total cholesterol (mmoVI) 
Triglycerides (mmolfl) 
HDL (mmolfl) 
LDL (mmolfl) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Under treatment by a cardiologist (%) 
Years under treatment (years) 
Subjects with peripheral 
atherosclerosis (n=39) 
64.1 ± 8.1 
33.3 
53.8 
25.6 ± 3.1 
5.7 ± 0.9 
1.8 ± 0.6 
0.9 ± 0.2 
4.0 ± 0.9 
137.7 ± 20.7 
82.6 ± 9.4 
79.5 
2.6 ± 4.1 
Subjects without peripheral 
atherosclerosis (n=210) 
59.9 ± 8.7 * 
28.6 
52.9 
26.1 ± 3.0 
5.7 ± 1.0 
1.8 ± 0.9 
1.0 ± 0.3 
3.9 ± 1.0 
133.6 ± 17.0 
83.0 ± 8.8 
63.3 
3.1 ± 5.1 
lex-smokers quit smoking more than one year ago, otherwise current smoker. *significant difference 
p<0.05. 
Table 2 lists potential determinants of LDL oxidation, i.e. LDL antioxidant concentra-
tions, fatty acid content and LDL composition. Subjects with peripheral atherosclerosis 
had significantly lower lutein/zeaxanthin levels, while the other antioxidants did not 
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differ. No significant differences were seen in fatty acid composition and LDL compo-
sition. However, differences in proportions of poly-unsaturated and mono-unsaturated 
fatty acids were borderline significant. 
Table 2. COllcellfrations of LDL antioxidants, LDL fatty acid content and LDL composition ill subjects 
with and without peripheral atherosclerosis (mean ± SE) 
Subjects with peripheral Subjects without p-
atherosclerosis peripheral athero- value2 
(n=39) sclerosis (n=21O) 
y-Tocopherol (nglmg protein)' 572.2 ± 97.4 640.1 ± 105.6 0.65 
a-Tocopherol (ng/rug protein)1 5149.6 ± 191.8 4994.1 ± 80.0 0.43 
Lutein/Zeaxanthin (ng/rug protein)l 50.0 ± 3.7 60.2 ± 2.1 0.03 
~-Cryptoxanthin (nglmg protein)' 58.8 ± 8.0 54.4 ± 3.0 0.67 
Lycopene (nglmg protein)' 86.2 ± 10.3 117.6 ± 7.1 0.46 
a-Carotene (ng/mg protein)l 17.4±2.8 21.4 ± 1.3 0.12 
~-Carotene (ng/mg protein)l 124.6 ± 9.9 136.0 ± 5.9 0.66 
Total fatty acids in LDL (mg per mg 1364.8 ± 24.0 1406.7 ± 13.8 0.37 
protein) 
Polyunsaturated fatty acids (0/0) 60.1 ± 0.8 58.2 ± 0.3 0.05 
Monounsaturated fatty acids (%) 17.6 ± 0.8 19.4 ± 0.4 0.07 
Saturated fatty acids (%) 22.1 ± 0.2 22.1 ± 0.1 0.76 
Total cholesterol (%)' 41.3 ± 0.3 41.1 ± 0.1 0.42 
Free cholesterol (%)' 8.4 ± 0.4 8.0 ± 0.2 0.49 
Cholesterol ester (% t 32.9 ± 0.5 33.1 ± 0.2 0.93 
Triglycerides (%)' 6.3 ± 0.3 6.0 ± 0.1 0.73 
Phospholipids (%)' 25.1 ± 0.3 25.6 ± 0.1 0.24 
Protein (%)' 27.4 ± 0.3 27.3 ± 0.1 0.96 
ltest of significance on log transfonned data. 2p-value for age-adjusted difference. 3nurnber of cases 
(n=38) and controls (uc 205). 'number of cases (u=31) and controls (n=174). 
Parameters of LDL oxidation are listed in Table 3. Resistance time was lower in the 
group with peripheral atherosclerosis, whereas a borderline significant difference was 
seen for the maximum rate of oxidation. 
Table 3. Oxidation characteristics of subjects with and without peripheral atherosclerosis 
(mean ± SE) 
Resistance time (min) 
Maximum rate of oxidation 
(nmol diene/min per rug protein) 
Subjects with peripheral 
atherosclerosis 
(n=39) 
85 ± 2 
10.5 ± 0.2 
61 
Subjects without p-
peripheral atherosclerosis value3 
(n=21O) 
89 ± I 
10.1 ± 0.1 
<0.01 
0.07 
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ORs were calculated per teltile of resistance time and maximum rate of oxidation 
(Table 4). The risk of peripheral atherosclerosis was significantly decreased in the two 
hlghest tertiles compared to the lowest teltile of resistance time. In the higher tertiles 
of maximum rate of oxidation risk of peripheral atherosclerosis was increased, though 
not significantly. The ORs (95% confidence interval) calculated for the oxidation 
parameters as a continuous variable in the model resulted in an OR of 0.94 (0.90·0.98) 
per minute increase in resistance time and 1.34 (0.97-1.85) per unit increase in maxi-
mum rate of oxidation. The difference between the lowest 10% point of distribution 
and the 90% point produced an OR of 0.34 (0.15-0.75) for resistance time and 2.21 
(0.93-5.23) for maximum rate of oxidation. 
Table 4. Odds ratios per tertile of resistance time alld maximum rate of oxidation 
Tertiles I (reference) II III p~value 
Resistance time (min) <86 86·92 >92 0.008 
Number of cases 22 8 9 
OR 1.0 0.37 (0.15·0.89) 0.37 (0.16·0.86) 
Max. rate of oxidation <9.7 9.7-10.6 >10.6 0.07 
Number of cases 8 12 19 
OR 1.0 1.34 (0.47·3.82) !.SO (0.55·4.15) 
More subjects in the case group reported the use of a prescribed diet or had a history 
of myocardial infarction (MI). This latter also could have had impact on dietary pat-
terns. ORs calculated with diet users or MI survivors excluded, yielded no relevant 
differences in ORs (results not shown). 
We performed analysis with exclusion of subjects (10 subjects without peripheral 
atherosclerosis) who had an ankle-arm index larger than 1.5, as these unusually high 
values may reflect a high degree of arterial calcification." Exclusion, however, resulted 
in similar ORs (results not shown). 
We performed stratified analysis for smoking habits. ORs for smokers (n = 73) 
and non- and ex-smokers (n = 176) were 0.90 (0.82-0.98) and 0.95 (0.90-1.00) per 
minute increase in resistance time and 1.42 (0.85-2.36) and 1.27 (0.84-1.91) per unit 
increase of maximum rate of oxidation, respectively. 
DISCUSSION 
We investigated the relationship between parameters of LOL oxidation ffild peripheral 
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atherosclerosis. Resistance time was used as a measure of resistance to oxidation 
ill vivo, which was expected to be lower in subjects with peripheral atherosclerosis. 
Further, a decline in resistance to oxidation may be reflected in an increased maximum 
rate of oxidation. In this study resistance time was reduced in subjects with peripheral 
atherosclerosis, whereas the maximum rate of oxidation was borderline significantly 
increased. 
This study was initially pelfOimed to study the association between oxidation 
parameters and risk of coronary atherosclerosis. For the initial study three groups were 
selected: subjects with angiographically assessed severe coronary atherosclerosis, 
subjects with angiographically assessed no or minor coronary atherosclerosis and 
healthy population controls with no history of CVD. In the present study, we recate-
gorized subjects according to their lowest ankle-arm index. In both groups patients 
with known CVD were included. As adjustment for severity of coronary atherosclero-
sis yielded similar ORs (results not shown), we feel that the association between 
oxidation parameters and peripheral atherosclerosis is independent of coronary athero-
sclerosis. Because two-thirds of our study population underwent angiography for sus-
pected CVD, changes in dietruy and life-style habits as a result of their disease status 
may have occurred. To minimize dietary changes as a result of the angiography blood 
samples were taken within 2 months after catheterisation. Subjects who had undergone 
angiography did not differ in fatty acid composition of the LDL from those subjects 
without a CVD history, which indicates that dietruy intake of fatty acids did not differ 
between these groups. Another reason for changing dietruy patterns could be the 
experience of MI, which was more commonly reported in the case group. Exclusion of 
MI survivors did not change the results. 
This study did not intend to produce a representative sample of men aged 45-80. 
One third of all participants was free of plaques in the carotid ru1ery. As peripheral 
atherosclerosis is related to presence of carotid artelY disease," the chance of finding 
peripheral atherosclerosis patients in this group was reduced. The same holds for those 
patients who were selected because of no or minor stenosis in the coronruy arteries. 
Therefore, the arbitrru'Y cut-off point 0.90 for ankle-arm index used commonly in 
studies on peripheral atherosclerosis"'" was not appropriate in this study as only 19 
subjects had an index lower than 0.90. As the objective of our study was to disclose 
the presence of susceptibility to LDL oxidation in peripheral artery disease rather than 
to describe those phenomena in the population at lru'ge, we feel that the cut-off point 
chosen does not import our findings. 
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Categorization of subjects was based on a blood pressure measurement at one 
point in time. As blood pressure can fluctuate over time, misclassification could have 
occurred. The ankle-arm index, however, is a ratio between two systolic blood pres-
sures at one specific time point, which is more stable than blood pressure itself. 
The difference in susceptibility of LDL to oxidation between subjects with and 
without peripheral atherosclerosis could not be explained by differences in known 
determinants of LDL oxidation. Other studies have described an increased susceptibil-
ity to oxidation with increasing degree of unsaturation of fatty acids,12-14 with decreas-
ing LDL vitamin E concentration'-II and with decreasing LDL pm1icle size.39•40 No 
correlations were found between fatty acid composition and resistance time, but the 
fatty acid composition was con'elated with maximum rate of oxidation. The same holds 
for antioxidant concentrations. No correlations were found between antioxidants and 
resistance time and only y-tocopherol was inversely cOlTelated with maximum rate of 
oxidation. In this study LDL paJ1icle size was not measured but the LDL composition 
can reflect this; small LDL particles are lower in cholesteryl esters and phospholipids 
and relatively higher in triglycerides and protein than large pmticles. However, we did 
not find differences in LDL composition between the groups. In short, none of the 
known determinants could explain the difference in resistance time between the 
groups. 
Few previous studies have investigated the relation between oxidation pm'ameters 
and CHD. Coronmy bypass patients with progression after 7 years showed a higher 
susceptibility to oxidation than those without progression," an inverse association 
between resistance time and severity of coronary stenosis was described in young MI 
survivors,'o and resistance time was found to be lower in coronary artelY patients thml 
in hyperlipidaemic patients or valvular hemt disease patients.'1 Further, higher 
TBARS-MDA concentrations were described in coronm'Y artelY patients41 and in 
peripheral vascular disease patients"·24 than in controls. Also elevated levels of autoan-
tibodies against oxidized LDL have been reported in young patients with peripheral 
vascular disease." Although our results agree with these findings, it should be noted 
that in the initial study only a borderline significant association between the oxidation 
parameters and risk of coronmy atherosclerosis was found. LDL oxidation seems to 
play a more prominent role in the pathogenesis of peripheral atherosclerosis than in 
coronary atherosclerosis. Other studies have indicated that peripheral atherosclerosis is 
a strong independent predictor of mortality even in patients with known CHD.42 
Further, the susceptibility to atherogenic risk factors appem's to vm-y across vasculm' 
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areas,42 which indicates that the pathogenesis of peripheral atherosclerosis may be 
different from that of coronary atherosclerosis and that oxidative modification of LDL 
is a more imp0l1ant risk factor in peripheral atherosclerosis. 
To our knowledge, this is the first study in which oxidation of LDL has been 
investigated as a potential risk factor of peripheral atherosclerosis. We conclude that 
the susceptibility of LDL to oxidation measured as resistance time is associated with 
peripheral atherosclerosis, with a decreased resistance time seen in cases with periphe-
ral atherosclerosis. 
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3.3 
Autoantibodies against MDA-LDL in subjects with severe and 
minor atherosclerosis and healthy population controls 
ABSTRACT 
Autoantibodies against oxidized low-density lipoprotein (LDL) have been reported to 
be associated with atherosclerosis. However, data are not consistent. 
We compared the titres of autoantibodies to malondialdehyde-modified LOL in 
three groups, a case group with angiographically documented severe coronary stenosis 
(>80% stenosis in at least 1 vessel, n ~ 47), a hospital control group with minor 
stenosis on the coronary angiography «50% stenosis in all three major vessels, 
n ~ 47) and a healthy population control group with no history of coronary heart 
disease (n ~ 49). Age ranged from 26 to 68 years. Subjects were frequency-matched 
for gender distribution and storage time of the blood samples. No relevant differences 
in autoantibody titre between case and control groups were found. The mean autoanti-
body titres (± SO) were 1.44 ± 1.82, 1.46 ± 1.40 and 1.62 ± 1.95 for cases, hospital 
controls and population controls respectively. No correlations were found between 
autoantibody titre and age, number of cigarettes smoked and LDL or total cholesterol. 
Autoantibody titres were con'elated with body mass index (r ~ 0.2) and high-density 
lipoprotein (HOL) (r ~ -0.2). Odds ratios (OR) were calculated by tertiles of autoanti-
body titres for the hospital control group and the population control group, respect-
ively. Age-adjusted OR (95% confidence interval) for medium and high compared to 
low autoantibody titre were 0.76 (0.27-2.14) and 1.09 (0.39-2.95) for the comparison 
between cases and hospital controls and 1.09 (0.39-3.07), 0.90 (0.32-2.56) for the 
comparison between cases and popUlation controls. Adjustment for gender, body mass 
index, smoking habits and HDL yielded essentially the same results. 
This study does not support an association between autoantibody titres to oxidized 
LDL and the extent of coronary stenosis. 
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INTRODUCTION 
Studies implying that oxidative modification of low-density lipoprotein (LDL) takes 
place in vivo and may play an important role in atherogenesis have accumulated over 
recent years. '-4 Oxidized LDL can activate endothelial cells and induce endothelial 
damage, thereby allowing blood elements and monocytes to enter the sub-endothelial 
space, which is the beginning of the atherogenic process. As a consequence of oxida-
tion, the uptake of LDL by macrophages is accelerated and foam cells are formed. 
Furthermore, modified LDL is immunogenic and has the ability to induce the formati-
on of autoantibodies.4•5 Autoantibodies against epitopes of oxidized LDL have been 
found in several studies in both human6-15 and rabbit6•15-16 plasma and atherosclerotic 
lesions. However, data on the relation between autoantibody titres and coronary athe-
rosclerosis are not consistent:-I0.I2.I3.11-19 Though the LDL-oxidation hypothesis is 
attractive in explaining the mechanism of development of atherosclerosis, direct evi-
dence from human studies is still scarce. 
To investigate the association between autoantibody titres and atherosclerosis, we 
studied autoantibody titres of three groups differing in levels of coronmy artelY disea-
se, namely a group of patients with mlgiographically documented severe atherosclero-
sis, a group with angiographically documented minor or non-atherosclerosis and a 
population based group with no history of cardiovascular disease (CVO). 
SUBJECTS AND METHODS 
SWdy population 
Groups of patients and hospital controls were selected from participants in a previous 
hospital-based case-control study on angiographically documented CVD and plasma 
levels of cholesterol oxidation products. A group of popUlation controls consisted of 
participants in the Dutch National Cardiovascular Disease Risk Factor Monitoring 
Project.'o The hospital groups consisted of patients who had undergone a coronary 
angiography for suspected CVD in the period 1991 and 1992 in Rotterdam. Ineligible 
were those patients: over 68 years of age; with a previous bypass surgery; with a 
myocardial infarction (MI) in the 12 months prior to the study period; under cardiac 
care for more then 2.5 years; in whom more then 2 months elapsed between angio-
graphy and case selection; who had diabetes mellitus, liver, kidney or thyroid disease, 
or showed evidence of alcohol or drug abuse. Of the 387 patients eligible for this 
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study, 51 refused to participate, 22 could not be contacted or were otherwise indispo-
sed and 7 had died. From the remaining 307 patients, cases were selected on the basis 
of having more then 80% stenosis in at least one of the three major coronary vessels, 
and controls having less then 50% stenosis in all three major coronary vessels. This 
left 159 patients (80 cases and 79 controls) for the original study. For the study repor-
ted here, 50 cases and 48 controls were randomly selected for determination of plasma 
autoantibodies. 
The population control group is a sample out of 36.000 participants in the Cardio-
vascular Disease Risk Factor Monitoring Project (1987-1991).20 For the original study 
a random sample of men and women aged 20-59 were selected from the civil registry 
of three cities in the Netherlands. The study was performed at the basic health service 
in each city. For the study reported here, the following selection criteria were used: 
domiciled in Amsterdam, the Netherlands, without use of hypercholesterolaemic drugs, 
not under cardiac care, no heart surgery (such as bypass surgery), without a myocar-
dial infarction. The 51 persons selected were frequency-matched for gender distribution 
and storage time of the blood samples to subjects of the hospital study. 
Data collection 
For all three groups, information on medical history, use of medication, dietary, smo-
king and drinking habits, occupation and family history of CVD was obtained through 
a questionnaire. Further, data on height, weight and blood pressure were gathered. The 
hospital cases and controls were seen within 2 months after angiography. Fasting 
venous blood samples were collected into a 10 ml EDT A vacutainer tube and the 
isolated plasma was stored at -80°C. For the population control group non-fasting 
venous blood samples were collected in 10 ml EDT A vacutainer tubes and after 
centrifugation plasma was stored at -20°C. The mean storage period of blood samples 
was 31 ± 3 months (mean ± SD). Storage periods for cases and control groups were 
similar. 
Measurement of allti-MDA-modijied LDL autoalltibodies 
Autoantibody titres were measured by bi-site sandwich ELISA using polystyrene 
microtitre plates (Greiner, number 655001, Alphen aid Rijn, the Netherlands). The 
microtitre plates were coated with MDA-LDL (malondialdehyde-modified LDL) as 
antigen (10 IIg/ml, 100 Ill/well) in phosphate-buffered saline (PBS) for 16 h at 4°C. 
Plates were washed 4 times with PBS and the residual binding sites were blocked with 
71 
Chapter3.3 ___________________________ _ 
1 % CW/,) casein (Merck) in PBS (200 pI/well) for 2 h at room temperature. Plates were 
washed 4 times with PBS, 100 pI/well of diluted samples for autoantibody determina-
tion was added, and the plates were incubated for 16 h at 4°c' Five dilutions, 1:8, 
1:16, 1:24, 1:32, 1:64 (,/,), in blocking buffer containing 0.05% C/v) Tween 20 
(Merck) were applied. After washing 5 times with PBS containing 0.05% (WI,) Tween 
20, 100 pI/well goat-anti-human IgG-Fc fragment conjugated to horseradish peroxidase 
(Nordic, Tilburg, the Netherlands), diluted 1: 11000 in blocking buffer containing 0.1 % 
(W/v) casein and 0.05% CW/) Tween 20, was added and the plates were incubated for 2 
h at 37°C. Plates were washed 4 times and the peroxidase-labelled conjugate was 
visualized using 3,3',5,5'-tetramethylbenzidine and H,O, as substrate mixture" (Orga-
non Technika BV, Boxtel, the Netherlands). Each microtitre plate contained equal 
numbers of samples from the three study groups. 
Extensively modified MDA-LDL was used and prepared essentially as described 
by Palinski et al.6 by incubating I mglml LDL (prepared from pooled plasma from 5 
male and 7 female healthy volunteers aged 21-35) in PBS, pH 7.4 for 4 hours at 37°C 
with 0.1 M MDA, freshly prepared from malonaldehyde-bis-dimethylacetal (Kodak 
Eastman Co.). After conjugation, MDA-LDL was extensively dialysed against PBS and 
stored in the presence of 10% sucrose at -80°C, As additional antigen, native LDL 
(prepared from the above mentioned pool) was used in the assay. This LDL was 
protected from oxidation by addition of 10 pM EDTA and 20 pM butylated hydroxy-
toluene (Sigma) to PBS and stored in the presence of 10% sucrose at -80°C, 
Each microtitre plate contained a dilution series (1:8, 1:16, 1:24, 1:32, 1:64 VI) of 
the above-mentioned pool plasma in triplicate, which was used as a reference standard. 
From the response of these dilution series, a reference line for autoantibody response 
was constructed. Intra- en inter-assay coefficients of variation were 6.0% and 8.3%, 
respectively, for the reference curves. The autoantibody titre is defined as the ratio 
between the dilution on the reference line belonging to the autoantibody response in 
the sample and the original dilution of the sample and is in general the mean of the 
four autoantibody titres obtained at dilutions 1:8, 1:16, 1:24 and 1:32 ('/v)' In most 
cases the optical density (OD) at the 1:64 (,/,) dilution was near the background and 
deviated from the . linear curve. This dilution was then omitted from the calculation. 
The slopes of the calibration curve constructed with reference standard and of the 
curves of the individual samples from the patient group and the control groups were 
not identical. About 15% of the sample curves deviated from the reference curve, 
indicating that the values calculated for the human samples can only be considered as 
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indicators of autoantibody concentrations. This allows comparisons between different 
samples but cannot be considered as an accurate measure of the absolute autoantibody 
mass in each sample. 
Alternatively, data are expressed as the absolute value for the ratio of autoantibody 
binding to MDA-LDLInative LDL (both as OD), as applied by Salonen et a!.' The 
presented value is the mean of the ratios obtained at dilutions 1:8 and 1:32, as the 
response to native LDL was only measured at these dilutions. Binding to native LDL, 
considered as a non-specific control, is defined as the ratio between the autoantibody 
response in the sample to native LDL (as OD) and the autoantibody response in the 
reference standard to native LDL (as OD). 
Allalytical measuremellts 
HDL-cholesterol and triglycerides were determined as described by Sullivan et a!." 
and Warnick et a!." Total-cholesterol was determined with a spectrum analyser (Ab-
bott Laboratories, USA) with CHOD-PAP reagent (cat.no. 236691, Boehringer 
Mannheim). LDL-cholesterol was calculated with the Friedewald formula.'· With this 
formula triglyceride concentrations must not exceed 4.52 mmolJl." Subjects who had a 
triglyceride level above 4.52 were excluded from further analysis (3 cases, 1 hospital 
control and 2 population controls). 
Data allalysis 
Data analysis was conducted using the BMDP statistical package.26 Basic characteris-
tics for the three groups were compared by Student's t-test for unpaired samples 
(p < 0.05) and by the Mann-Whitney test for non-normal distributions. Pearson X' 
analysis was applied for class variables. By means of the Pearson correlation coeffi-
cient the associations between autoantibody titres and continuous variables in the total 
group were quantified. 
To adjust differences between cases and controls for possible confounders, mul-
tiple linear regression was used. Stratified analysis was performed to identify confoun-
ders or effect modifiers. Odds ratios were calculated to quantify the association 
between autoantibody titre and coronary stenosis, the patients were divided into tertiles 
based on autoantibody titres in the hospital or popUlation control group. Multiple 
logistic regression adjusted the odds ratio for potential confounders. 
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RESULTS 
In Table I the baseline characteristics of the three study groups are presented. The 
population control group was slightly, though significantly, younger than the two 
hospital groups. No differences were seen for body mass iudex (BMI). The hospital 
control group had higher HDL (high-density lipoproteiu) and lower LDL and triglyce-
rides than the cases. The population controls had lower total cholesterol, HDL, LDL 
and systolic and diastolic blood pressure than the cases. After adjustment for age and 
smoking habits the significant difference iu HDL disappeared. 
Table 1. Baseline characteristics (mean ±SD) 
Age (years) 
Body mass index (kg/m') 
Plasma cholesterol (mmolll) 
HDL-cholesterol (mmoVl) 
LDL-cholesterol (mmoVl) 
Plasma cholesterollHDL 
Plasma triglycerides (mmoVl) 
Systolic pressure (mmHg) 
Diastolic pressure (mmHg) 
% Male 
% Smokers 
Cases 
(n a 47) 
54.2 ± 8.9 
26.2 ± 3.3 
6.3 ± 0.9 
l.l ± 0.3 
4.4 ± 0.8 
6.0 ± 1.6 
1.8 ± 0.8 
135.0 ± 9.4 
84.8 ± 0.6 
68.1 
25.5 
Hospital controls 
(n - 47) 
53.5 ± 9.2 
25.4 ± 2.8 
5.9 ± l.l 
1.3 ± 0.4' 
4.0 ± 1.0' 
4.9 ± 1.7' 
1.5 ± 0.8' 
134.0 ± 15.1 
83.4 ± 10.9 
68.1 
27.7 
Population controls 
(n - 49) 
49.6 ± 7.8" 
25.9 ± 3.4 
5.6 ± 1.0' 
1.0 ± 0.3'" 
3.9 ± 0.9' 
6.3 ± 1.9' 
1.7 ± 0.9 
127.0 ± 16.5') 
79.3 ± 10.3' 
67.3 
38.8 
[significant difference (p<O.05) with cases. 2significant difference (p<O.05) with hospital controls. 
Autoantibody titres between cases (1.44 ± 1.82 (mean ± SD», hospital controls 
(1.46 ± 1.40) and popUlation controls (1.62 ± 1.95) were not significantly different. 
Figure I shows frequency histograms of the autoantibody titres of the three study 
groups. At the 1:8 and 1:32 dilutions the autoantibody response to native LDL was 
measured. In 42 out of 143 persons a response higher than 0.2 OD in both dilutions 
was found. These higher responses to native LDL were equally distributed over the 
three groups as determined with frequency calculations. Titres to native LDL (mean 
(± SD» were similar for the three groups. The OD assessed at dilution 1:8 were 
0.34 ± 0.35, 0.37 ± 0.36 and 0.32 ± 0.35 and at the 1 :32 dilution 0.23 ± 0.31, 
0.22 ± 0.22 and 0.21 ± 0.20 for cases, hospital controls and population controls, 
respectively. None of the differences reached significancy. 
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Figure 1: Distribution of autoantibody levels against MDA-LDL among cases, hospital controls and 
population controls. 
Table 2 presents correlation coefficients for the total population between risk factors 
for CVD and autoantibody titres. Only BMI and HDL showed a significant relation-
ship with autoantibodies. When LDL is being oxidized, a series of oxidative products 
of cholesterol are produced."·28 We, therefore, also assessed the relationship between 
cholesterol oxidation products (total oxysterols, 7u-OH cholesterol (the main oxysterol, 
but also an important intermediate in the bile acid synthetic pathway) and total 
oxysterols without 7u-OH cholesterol) and autoantibody titres in the case and the 
hospital control group. Correlations were -0.05, -0.02 and -0.07 for total oxysterols, 
7u-OH cholesterol and total minus 7u-OH cholesterol, respectively. None of these 
correlations reached significance. 
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Table 2. Correlations for all data between autoamibody ti/res and risk factors for CVD 
Total (n = 143) Autoantibody titre Ratio titre l 
Age -0.01 -0.14 
Number of cigarettes/day 0.06 -0.08 
Body mass index 0.20' 0.09 
HDL -0.19' -0.15 
Total cholesterol -0.08 -0.13 
Triglycerides 0.03 0.02 
LDL -0.03 -0.10 
Systolic pressure 0.05 0.04 
Diastolic pressure 0.00 0.02 
(autoantibody titres were calculated acording to the method proposed by Salonen et a1.9 . 2p<O.05. 
Odds ratios for the risk of CVD and autoantibody titre were calculated with logistic 
regression analyses for tertiles of autoantibody titre for cases and hospital controls and 
for cases and population controls. Results are shown in Table 3a. No significant asso-
ciations were observed for autoantibody titres and CVD. 
Table 3. Odds ratios and 95% confidence intervals (CI) for the risk of CVD in (erliles of autoantibody 
lUres ill the cOlltrolgroup, for case and hospital control groups and cases alld population controls 
3 •. 
Autoantibody titre Age·adjusted Multivariate adjusted l 
cases/hospital controls 
<0.76 1.0' 1.0' 
0.76-1.17 0.76 (0.27-2.14) 0.63 (0.21-1.93) 
>1.17 1.09 (0.40-2.95) 0.77 (0.26-2.27) 
cases/population controls 
<0.75 1.0' 1.0' 
0.75-1.42 1.09 (0.39-3.07) 1.32 (0.45-3.89) 
>1.42 0.90 (0.32-2.56) 1.08 (0.36-3.25) 
3b. 
Ratio titre3 Age-adjusted Multivariate adjusled l 
cases/hospital controls 
<2.2 1.0' 1.0' 
2.2-4.9 2.22 (0.75-6.58) 1.51 (0.46-4.95) 
>4.9 2.04 (0.67-6.21) 1.60 (0.49-5.23) 
cases/population controls 
<3.0 1.0' 1.0' 
3.0-5.9 0.98 (0.36-2.68) 0.93 (0.32-2.76) 
>5.9 0.71 (0.25-2.06) 0.74 (0.25-2.22) 
ladjusted for gender, age, smoking habits, HDL, body mass index. 2reference. 3autoantibody titres were 
calculated according 10 the method proposed by Salonen et a1.9 
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Additionally, we performed the analysis on data obtained by using the calculation 
method proposed by Salonen et al.,' in which autoantibody titres are expressed as the 
ratio titre (binding to MDA-LDL divided by binding to native LDL, both as OD). The 
mean (± SD) ratio titres for cases, hospital controls and popUlation controls were 
4.54 ± 2.96, 4.26 ± 2.72 and 4.90 ± 3.06, respectively. Comparable to the above 
mentioned approach, no relevant differences among the groups were found. 
When assessing the conelation coefficients between the ratio titre and risk factors 
for CVD, none of the variables age, number of cigarettes, BMI, systolic and diastolic 
blood pressure, total cholesterol, HDL, LDL and triglycerides showed a significant 
association (Table 2). 
Odds ratios calculated for tertiles of the ratio titre in the control group are pre-
sented in Table 3b. No significant association was found between cases and hospital 
controls and between cases and popUlation controls. Adjustment for gender, age, 
smoking habits, HDL and BMI had no impact on the results. 
DISCUSSION 
In this study no association between coronary heart disease and autoantibody titres was 
found. 
It is unlikely that the absence of differences in autoantibody titres is due to flaws 
in the study design. Blood samples were stored at -80°C or -20°C degrees. There is no 
reason to assume that differences in storage tempe'rature have affected the association, 
as autoantibody titres in plasma at the different storage temperatures were within the 
same range. Storage time for the three groups was comparable. 
As it is conceivable that dietary or life-style changes may affect LDL oxidation in 
vivo"-32 and thus may alter autoantibody production, the cases and hospital controls 
were examined within 2 months after the angiography. Thus, dietary and life-style 
changes as a response to the cardiology report are restricted. 
The two hospital groups were slightly older than the population group (mean age 
of 54 and 50 for hospital and population groups, respectively). This could have intro-
duced bias, but no association between autoantibody titres and age was found. Further, 
the result could have been biased by smoking habits, since there were more smokers in 
the popUlation control group. Smoking might be related to oxidative stress.'J--" and thus 
could increase oxidation of LDL. Yet, no difference in autoantibody titres between 
smokers and non-smokers was found and calculation of correlations between autoanti-
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body titres and number of cigarettes smoked did not produce a relevant association. In 
addition, in a previous report we did not observe an effect of smoking on susceptibility 
of LDL to oxidation." 
We compared the autoantibody titres of the cases to both a hospital and a popula-
tion control group. An objective discrimination between cases and hospital controls is 
possibly based on the angiographical data, implying as a control group a group with 
documented minor stenosis. However, in the control group 64% were scored as having 
no stenosis, 23% had less than 10% stenosis in the 3 vessels and the mean percentage 
stenosis over the 3 vessels did not exceed 30%. The population control group was a 
selection of healthy men and women without self-reported history of CVD. However, 
we cannot rule out the possibility of people with unknown, clinically non- manifested 
CVD entering the control group. 
In this study, we defined autoantibody tilres in two different ways: one related to a 
reference line constructed from the response to a reference plasma and the other being 
the ratio between the response to MDA-LDL and that to native LDL. The advantage of 
the first method is the use of several dilutions. The autoantibody titres presented are 
generally the mean of the autoantibody titres obtained at four dilutions. We believe to 
have thus reduced the approximation elTor. When plotting the OD against the concen-
tration, individual curves do not parallel each other. As pointed out by Virella et al.," 
we therefore should not use these autoantibody titres as an absolute measure, but rather 
as an indicator of autoantibody c.oncentrations. The second method for expressing 
autoantibody titres was calculated at the 1:8 and 1:32 dilutions. Both methods were 
significantly cOlTelated (r = 0.34, p<O.OO 1). As both ways of expressing the data 
generate the same result, it is justified to conclude that there is no reason to assume 
that our result can be ascribed to our definition of autoantibody titres. 
The results of our study are consistent with reports from several groups, in which 
no difference in levels of antibodies were found!·I7-" but are inconsistent with ot-
hers.'-'·1O·12-14 In most studies, elevated levels of autoantibodies against epitopes of 
oxidized LDL are reported both in subjects with coronary heart disease and in healthy 
controls. Findings of Maggi et al.,10 Salonen et al.; Puunmen et al.,13 as well as the 
results of Virella et al. I ' who described higher (though not significantly higher) auto-
antibody titres in hyperlipidaemic persons and in subjects with minor atherosclerosis in 
comparison to persons with known CVD, support the idea that antibodies are not an 
indicator of the severity of atherosclerosis, i.e. the extent of thickening of the vessel 
wall, but can be used as an indicator for an active atherogenic process. In our study no 
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data on the change in extent of stenosis in recent years were available. We, therefore, 
can not exclude the possibility that subjects were in a stable state of atherogenesis. 
This may provide an explanation for the lack of difference in our study. Another 
explanation for not finding a relation with the extent of CVD is pointed out by Virella 
et al.,19 who suggest that different persons may have different populations of antibodies 
with a different affinity to antigens. 
We conclude that this study does not support an association between autoantibody 
titres to oxidized LDL and thickening of the vessel wall. We suggest that clinical 
studies focus on assessment of the relationship between autoantibody levels and deve-
lopment of new lesions e.g. by measurement of intima-media thickening by ultrasound. 
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Chapter 4 
LDL and Plasma antioxidant levels 
and atherosclerosis 

4.1 
Plasma vitamin C, LDL antioxidants and risk of coronary 
atherosclerosis 
ABSTRACT 
Antioxidants have been implicated to play a protective role in the atherosclerotic 
process, possibly through inhibition of low-density lipoprotein (LDL) oxidation. We 
studied plasma vitamin C, LDL tocopherols and LDL carotenoids and risk of coronary 
atherosclerosis in a case-control study among men aged 45-80 year. Subjects with 
severe coronary atherosclerosis were classified as cases (n ~ 92). Hospital controls 
with no or minor atherosclerosis (n ~ 95) and population controls free of plaques in 
the carotid artery (n ~ 86) were combined into one control category. 
No difference in mean plasma vitamin C levels between cases and controls was 
found. LDL y-tocopherol levels were higher and LDL lutein/zeaxanthin and LDL 
a-carotene levels were significantly lower in cases. Unexpectedly, a positive associa-
tion between LDL tocopherol levels and risk of coronary atherosclerosis was seen. 
Odds ratios calculated for the successive quartiles of LDL a-tocopherol were l.00 
(reference), l.34 (0.55-3.30), 2.61 (1.l5-5.90) and 2.26 (0.97-5.26) (PO"d ~ 0.02). LDL 
carotenoids, especially a-carotene and lutein/zeaxanthin, showed slightly decreased 
risks of coronary atherosclerosis at higher levels, which however disappeared after 
con'ection for blood cholesterol level. No intermediate effect of LDL oxidation in the 
association between antioxidants and the risk of coronary atherosclerosis could be 
detected. 
We conclude that in this study only high circulating levels of a-carotene showed a 
slight preventive effect against coronary atherosclerosis. For the antioxidants in general 
no protective effect was seen on coronary atherosclerosis as measured by LDL anti-
oxidants. The association between antioxidants and coronroy atherosclerosis can not be 
ascribed to their inhibition of LDL oxidation. 
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INTRODUCTION 
Antioxidants have been implicated to playa protective role in the atherogenic process. 
In several epidemiological and clinical studies the preventive potential of antioxidants 
on coronary heart disease (CHD) has been investigated. A preventive effect of dietary 
and supplementary vitamin E against CHD has been described in prospective studies,I-' 
whereas prospective studies on plasma vitamin E did not reveal clear associations with 
CHD.'-6 Further, the risk of angina pectoris was significantly decreased at high plasma 
vitamin E levels,' but no reduction in risk of myocardial infarction was found at high 
vitamin E levels in adipose tissue.' Dietary vitamin C was strongly inversely related to 
risk of CHD' and thickness of the carotid artelY wall, JO but such a reduced risk of 
CHD at higher levels of vitamin C intake was not observed in the studies by Rimm 
and colleaguesl and Stampfer and colleagues.' For dietary intake of ~-carotene lower 
risk of CHD at high intake levels has been observed in a prospective study,l but no 
association was found in a Finnish cohort study. I I Low plasma levels of ~-carotene, 
however, were associated with an increased risk of CHD' and myocardial infarction 
(MI),I' and high levels of adipose ~-carotene were related to decreased risk of MI.' 
Results from trials on antioxidant supplementation do not SUppOit a beneficial effect of 
~-carotene.I'-15 For vitamin E data is scanty, no effect has been observed for CHD 
mortality,l'·16 whereas it may have a preventive effect on CHD morbidity, e.g. high 
doses were found to prevent non-fatal MI in coronary atherosclerosis patients l6 and the 
incidence of angina pectoris. 17 
One mechanism by which antioxidants are thought to have a protective effect is 
through inhibition of low-density lipoprotein (LDL) oxidation. Oxidative modification 
of LDL by free radicals has been implicated as an important step in the development 
of atherosclerosis. Oxidative modification accelerates the uptake of LDL by macrop-
hages which is the beginning of the fatty streak.I'.I' LDL is thought to be protected 
against free radicals by antioxidants in plasma and in the particle itself. Antioxidants 
incorporated in the LDL particle may therefore be relevant. From supplementation 
studies evidence arose that increased LDL vitamin E, the most prominent lipid soluble 
antioxidant, lowers the susceptibility of LDL to oxidation,'O-" and an inverse associ-
ation has been reported recently between LDL vitamin E concentrations and coronary 
artelY disease." Not much is known about other LDL antioxidants such as carotenoids 
and their relation to atherosclerosis. 
Many studies have examined the role of antioxidants in the development of CHD 
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in subjects with MI. 111e pathogenesis of MI comprises both atherogenic aud thrombo-
tic processes. To gain more insight into the mechauism by which autioxidauts cau play 
a role in the atherogenic process we performed a case-control study in which the 
relationship between plasma vitamin C aud LDL concentrations of various lipid solu-
ble autioxidauts aud risk of augiographically determined coronary atherosclerosis was 
investigated. Also the susceptibility to LDL oxidation was measured in order to ad-
dress the question whether antioxidaut concentrations are related to LDL oxidation aud 
whether LDL oxidation plays au intermediate role in the relation between autioxidauts 
aud atherosclerosis. 
METHODS 
Study population 
The study was conducted in several hospitals aud clinical centres in Rotterdam aud 
Dordrecht, the Netherlands, in the period 1993-1995. The study was approved by au 
ethical committee on humau research aud all participauts gave their informed consent. 
We selected a group of CHD patients, a group of hospital controls and a group of 
population controls. The groups consisted of men between 45 aud 80 years of age. 
Emolment procedures allowed for similar distributions of age (in 5-year categories) 
aud smoking status (smoking, non-smoking). 
Selection of the two hospital groups was based on augiographic reports. To reduce 
the impact of disease on dietary aud life-style patterns we selected only those patients 
who underwent their first angiography aud who had not experienced a MI in the year 
prior to the study. For the same reason, blood was collected within 2 months after 
augiography. Subjects using HMG-CoA reductase inhibitors were excluded because of 
a possible influence of this medicine on LDL oxidation. 
In the study period 2830 patients underwent coronary augiography for suspected 
CHD, which included 1966 male subjects. Subjects were ineligible if they met one of 
the following exclusion criteria: under 45 or over 80 years of age (n ~ 144), not the 
first coronary augiography (n ~ 289), MI in the 12 months prior to the study 
(n ~ 180), diabetes mellitus (n ~ 84), liver, kidney or thyroid disease (n ~ 15), alcohol 
or drug abuse (n ~ 4), use of HMG-CoA reductase inhibitors (n ~ 82), vegetarian diet 
(n ~ 3), psychiatric complaints (n ~ 2). For 88 subjects more thau 2 months elapsed 
between angiography aud case selection aud 12 patients had died in the meantime, 
leaving a population of 1063 eligible subjects. Of this group 124 refused to participate 
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and 50 could not be contacted or were otherwise indisposed. From the remainiug 889 
men, 92 cases were selected who had at least 85% stenosis iu one and at least 50% 
stenosis iu a second of the three major coronary vessels. Further, 95 hospital controls 
were selected with less then 50% stenosis in no more than two of the three major 
coronary vessels. The percentage of stenosis was scored by the cardiologist performiug 
the angiography. 
Population controls were selected from participants iu the Rotterdam Study. The 
rationale and design of this population-based prospective cohort study have been 
described previously." We selected subjects without any plaques iu the carotid at1ery 
as assessed by ultrasound. Fm1her, these subjects reported not to have a history of 
cardiac treatment, not to have diabetes mellitus, or liver, kidney or thyroid disease, not 
to use HMG-CoA reductase inhibitors nor to be vegetariatl. As the pat1icipants iu the 
Rotterdam Study were all 55 years and over at baseline, we additionally rec11lited men 
between 45 and 55 years of age through an advel1isement in a local newspaper. Re-
c11litment took place iu the area the other popUlation controls originated from. A 
questioll1laire was used to obtaiu information on medical history; when candidates 
fulfilled the iuclusion criteria they were invited to the reseat'ch centre. Enrolment in the 
study took place after it had been echographically ascertained that their carotid at'tery 
was free of plaques. Eighty six population-based male controls were included, which 
led to a study population consisting of 92 patients with severe coronary atherosclerosis, 
95 hospital-based controls with no or minor coronmy atherosclerosis and 86 popula-
tion-based controls. 
Data Collection 
For the hospital groups information on medical history was obtained from medical 
status records and through a questionnaire within 2 months after angiography. Infor-
mation on dietmy, smoking and drinking pattems, medicine use, use of vitamin sup-
plements, occupation and family history of CVD was obtained. Weight, height and 
blood pressure on ankle and mm were measured. A fasting venous blood sample was 
collected in EDT A Vacutainer tubes and immediately placed on ice mId cooled to 4'C. 
Plasma was prepared withiu 1 h after blood collection by centrifugation at 1750 x g 
for 15 min, frozen in methanol of -80'C or liquid nitrogen, mId stored at -80'C. 
Preparation and oxidation of LDL 
The procedure for preparation and lipid peroxidation of LDL was adapted from Ester-
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bauer et al.26 with some major modifications as described previously in detail."'" The 
kinetics of LDL oxidation was followed by continuously monitoring the change of 
absorbance at 234 nm.21 ,23,,. Absorbance curves of LDL preparations obtained from an 
equal number (3) of subjects from each study group were determined in parallel. Each 
LDL preparation was oxidized in three consecutive oxidation runs on the same day. 
Means were calculated on the basis of these three observations, 
Allalyticalmeasllremellts 
Cholesterol and triglyceride concentrations were determined enzymatically using 
commercially available reagents (CHOD-P AP kit 236.691 and Triglyceride kit 
701.904, Boehringer-Mannheim, Mannheim, Germany), 
High-density lipoprotein (HDL)-cholesterol was measured after precipitation of 
very-low-density lipoprotein (VLDL), intermediate-density lipoprotein (IDL) and LDL 
using the precipitation method with sodium phosphotungstate-Mg2+.27 LDL-cholesterol 
concentrations were calculated by the formula of Friedewald et al.28 
Plasma vitamin C concentrations were assessed within 1 month after blood sampl-
ing with HPLC and fluorometric determination." Concentrations of LDL antioxidants 
were determined by reversed-phase HPLC and spectrophotometric detection.'o Lutein 
and zeaxanthin were combined. LDL antioxidant concentrations were standardized by 
calculating antioxidant concentrations per mg LDL protein. 
Statistical analysis 
Characteristics of the case group and the control groups were compm'ed with Student's 
t-test for unpaired samples. Because the two control groups were comparable regarding 
lipid levels, age and smoking status, further data analysis was performed with the two 
control groups pooled. Age-adjusted means were compared by analysis of covm·iance. 
Log transformations were performed to compare non-normal distributed variables. 
Odds ratios (OR) were calculated to quantify the association between antioxidant 
concentrations and coronm'y atherosclerosis. Quartile distributions for calculation of 
ORs were based on distributions in the control group, Trend analysis was performed 
over the antioxidants as a continuous vm'iable in the logistic model. Confounding 
factors taken into account were; body mass index (BMI), total, HDL- and LDL-choles-
terol and diastolic and systolic blood pressure. Data were analyzed with the statistical 
package BMDP." 
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RESULTS 
Characteristics of the study groups are described in Table I. No differences were 
present in age, smoking habits, BMI and blood pressure. Total cholesterol, LDL-
cholesterol and triglycerides were significantly higher in the case group, whereas HDL-
cholesterol was significantly lower in the cases. Cases more frequently reported the use 
of antihypertensive medication, lipid-lowering medication other than HMG-CoA 
reductase inhibitors and aspirin or coumarin derivatives. A history of MI was more 
common in the case group. 
Table 1. Characteristics of the study population (Mean ± SD) 
Age (years) 
Smokers (%)1 
Ex-smokers (9W 
Body mass index (kg/m') 
Total cholesterol (mmoYI) 
Triglycerides (mmoYl) 
HDL (mmoYl) 
LDL (mmoYI) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Under treatment by a cardiologist (years) 
Diet use (%) 
-Cholesterol-restricted (% in diet users) 
-Fat-restricted (% in diet users) 
Antioxidant supplementation use (%i 
Medication use 
-Antihypertensive medication (%) 
-Lipid-lowering medication (%)3 
-Aspirin + coumarin derivatives (0/0) 
Family history of CVD 
History of MI 
Cases (n - 92) 
61.8 ± 9.2 
31.5 
54.3 
26.4 ± 2.5 
6.0 ± 1.2 
2.1 ± 0.9 
0.9 ± 0.2 
4.3 ± l.l 
133.4 ± 17.6 
81.7 ± 8.1 
3.4 ± 5.0 
13.5 
58.3 
36.4 
5.4 
93.5 
6.5 
93.5 
27.2 
37.4 
Controls (n - 181) 
60.1 ± 8.4 
31.5 
50.3 
26.1 ± 3.2 
5.6 ± 1.0 * 
1.7±0.9* 
1.0 ± 0.3 * 
3.8 ± 0.9 * 
135.3 ± 17.1 
83.7 ± 8.8 
2.4 ± 4.7 
8.3 
20.0 
46.7 
3.3 
43.1 * 
0.6 * 
20.4 * 
21.0 
4.2 * 
lex-smokers stopped smoking more then one year ago, othenvise current smoker. 2use of vitamin A. 
vitamin C or vitamin E supplements. 30ther than HMO CoA reductase inhibitors. *significant age-
adjusted difference (analysis of covariance), p<O.OI. 
Table 2 lists plasma vitamin C and LDL antioxidant levels. Cases had a higher 
y-tocophel'Ol level, but lower levels of a-carotene and lutein/zeaxanthin. One case had 
an extremely high y-tocophel'Ol value (21,099 ng/mg protein), but analysis after ex-
clusion of this subject still resulted in a significantly higher y-tocopherol level in the 
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cases (adjusted mean ± SE 777.7 ± 61.2). Expressing tocopherol as tocopherol to 
LDL-cholesterol ratio instead of tocopherol to LDL-protein ratio resulted in significant 
higher "1- and a.-tocopherol levels in the cases. Mean a.-tocopherol levels (±SE) were 
1338.1 ± 29.8 vs. 1250.7 ± 21.9 (p ~ 0.02) and mean "I-tocopherol levels were 
257.43 ± 57.9 vs. 123.1 ± 11.7 for cases vs. controls. 
Table 2. Antioxidant concentrations (mean ± SEM) alld age-adjusted differences between cases and 
cOllfrols 
Cases (n - 92) Controls p-valuel 
(n - 181) 
plasma vitamin C (lImoV1)2 47.1 ± 2.1 50.6 ± 1.7 0.21 
LDL antioxidants: 3 
y·Tocopherol (ng/mg protein) 997.3 ± 231.1 474.9 ± 40.2 <0.01 
a·Tocopherol (ng/mg protein) 5157.8 ± 116.8 4906.3 ± 87.4 0.08 
Lutein/Zeaxanthin (nglmg proteint 52.8 ± 2.4 60.1 ± 2.3 0.04 
B·Cryptoxanthin (ng/mg protein)' 54.8 ± 5.2 53.1 ± 3.1 0.92 
Lycopene (ng/mg protein)' 99.5 ± 11.0 113.7 ± 6.8 0.08 
«-Carotene (ng/mg protein)4 16.3 ± 1.4 21.9 ± 1.5 om 
B·Carotene (ng/mg protein)' 117.9 ± 8.1 136.1 ± 6.0 0.06 
ltest of significance for age-adjusted difference. 2 no data for 2 cases and 6 controls. 3test of signifi-
cance on log transfonned data. 4no data for 1 case. 
Antioxidants and risk of coronary atherosclerosis 
We calculated the ORs for risk of coronary atherosclerosis per quartile of antioxidant 
level. ClUde ORs and ORs adjusted for age and smoking status were only marginally 
different; therefore only the ORs adjusted for age and smoking status are presented in 
Table 3. A significantly elevated risk of coronary atherosclerosis was seen in the 
highest compared to the lowest quartile of "I-tocopherol. Significant trends were found 
for "I-tocopherol, lutein/zeaxanthin and a.-carotene. We expanded the logistic model, 
which resulted in a model with fm1her adjustment for total cholesterol, HDL-choles-
terol and diastolic blood pressure. The positive association for "I-tocopherol remained, 
whereas for a.-tocopherol the positive association with risk of coronmy atherosclerosis 
now reached significance. The inverse association of lutein/zeaxanthin and a.-carotene 
no longer reached significance. For "I-tocopherol the continuous OR (95% CI-interval) 
per ng/mg LDL protein increase was calculated which resulted in an OR for a 100 ng 
increase of 1.08 (1.02-1.14) mId an OR for the contrast between the lowest 10% point 
of distribution compared to the 90% point of dislribution of 1.70 (1.16-2.48). For 
a.-tocopherol Ihe OR calculated per ng/mg LDL protein increase resulted in an 1.03 
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(1.01-1.06) for a 100 nglmg increase with the 10-90% point contrast of 2.26 (1.16-
4.46). 
Cases more frequently reported a history of MI, which could have influenced dietary 
patterns and consequently could have resulted in a changed antioxidant pattern in the 
LDL. Exclusion of MI survivors, however, had only marginal effects on the ORs 
(results not shown). 
Stratified analyses for smoking status were performed. The mean levels of vitamin 
C and the LDL antioxidants were lower in smokers compared to never/ex-smokers. For 
smokers vs. never/ex-smokers mean levels ± SE were 41.1 ± 2.5 vs. 53.3 ± 1.5 pmolll 
(p < 0.01) for vitamin C, 4779.5 ± 130.4 vs. 5093.6 ± 82.4 nglmg protein (p ~ 0.04) 
for a-tocopherol and 112.2 ± 8.6 vs. 138.4 ± 5.8 nglmg protein (p ~ 0.01) for 
~-carotene. ORs calculated for smokers and never/ex-smokers separately showed an 
inverse association between plasma vitamin C and LDL ~-carotene and risk of 
coronary atherosclerosis for never/ex-smokers only. We, however, could not disclose a 
significant interaction between smoking status and antioxidant levels, and no signifi-
cant correlations were found between antioxidant levels and number of cigarettes 
smoked by current smokers. This may be due to the small number of smokers and the 
inaccuracy of measuring number of cigarettes. 
In the results in Table 1-3, the two control groups were pooled for the statistical 
analyses, as the groups were comparable according to the plasma lipid levels, BMI and 
blood pressure. We also calculated the ORs for the control groups separately. The 
same associations were found as in the pooled analysis, with exception of 'V-tocophe-
rol. The positive trend for 'V-tocopherol was seen only when comparing cases with 
popUlation controls (p<O.O I). 
Associatiolls with oxidatioll parameters 
A possible mechanism by which antioxidants may play a role in the atherogenic 
process is by inhibition of LDL oxidation. Resistance time, as a measure of LDL 
resistance to oxidation, however, was not related to antioxidant levels, and only 
'V-tocopherol was weakly inversely correlated to maximum rate of oxidation (I' ~ -0.15, 
p<0.04). Adjustment of the ORs for risk of coronary atherosclerosis pel' quartile of 
antioxidant concentration for the parameters of LDL oxidation, such as resistance time 
and maximum rate of oxidation, resulted in marginal differences (results not shown). 
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Table 3. Odds ratios for the risk of corollary atherosclerosis per quartile of antioxidant concentralioll 
in LDL 
Quartile II! III! IV! trend 
plasma vitamin C (pmolll) 34.1-50.2 50.2-69.0 ;'69.0 
number of cases 23 29 13 
OR model I' 0.88 (0.43-1.80) 1.03 (0.51-2.08) 0.48 (0.21-1.08) p=O.17 
OR model 2' 1.17 (0.52-2.63) 1.19 (0.55-2.59) 0.57 (0.23-1.38) p=0.37 
LDL antioxidants:4 
y-Tocopherol (ng/mg) 207.7-380.3 380.3-558.0 ;'558.0 
number of cases 20 14 46 
OR model I 1.57 (0.67-3.63) 1.21 (0.49-2.95) 3.82 (1.77-8.24) p<O.OI 
OR model 2 1.52 (0.62-3.76) 1.23 (0.47-3.17) 3.65 (1.58-8.43) p<O.OI 
a-Tocopherol (ng/mg) 403.8·493.1 493.1-568.7 ;'568.7 
number of cases 16 33 26 
OR model I 0.95 (0.42-2.15) 1.83 (0.89-3.79) 1.50 (0.70-3.20) p=0.08 
OR model 2 1.34 (0.55-3.30) 2.61 (1.15-5.90) 2.26 (0.97-5.26) p=0.02 
LuteinlZeaxanthin (ng/mg) 38.4-55.3 55.3-74.8 ;'74.8 
number of cases 29 24 15 
OR model I 1.18 (0.59-2.36) 0.96 (0.47-1.97) 0.58 (0.26-1.28) p=0.04 
OR model 2 1.21 (0.56-2.60) 1.41 (0.63-3.15) 0.70 (0.29-1.66) p=0.23 
p·Cryptoxanthin (ng/mg) 24.0-41.1 41.1-69.1 ;'69.1 
number of cases 20 30 19 
OR model I 0.74 (0.35-1.60) 1.29 (0.64-2.62) 0.75 (0.35-1.60) p=0.74 
OR model 2 0.94 (0.40·2.18) 1.50 (0.68·3.33) 1.01 (0.43·2.37) p=0.47 
Lycopene (ng/mg) 49.1-84.5 84.5-167.5 ;'167.5 
number of cases 16 23 16 
OR model I 0.45 (0.22-0.93) 0.64 (0.32-1.27) 0.49 (0.23-1.08) p=0.50 
OR model 2 0.50 (0.23-1.09) 0.71 (0.33-1.53) 0.74 (0.31-1.78) p=0.28 
a·Carotene (ng/mg) 8.6-15.6 15.6-27.6 ;'27.6 
number of cases 26 18 17 
OR model I 0.78 (0.39-1.55) 0.47 (0.22-1.00) 0.49 (0.23-1.05) p=0.02 
OR model 2 0.88 (0.41-1.89) 0.73 (0.32-1.67) 0.61 (0.27-1.41) p=0.06 
p-Carotene (ng/mg) 77.4-115.3 115.3-172.3 ;'172.3 
number of cases 26 21 15 
OR model I 0.47 (0.22· 1.03) 0.63 (0.30· 1.30) 0.47 (0.22-1.03) p=O.1O 
OR model 2 0.76 (0.36·1.63) 0.71 (0.32-1.60) 0.63 (0.27-1.48) p=O.77 
'compared to the first quartile. 2adjusted for age and smoking status. 3model 1 + adjustment for total 
cholesterol, HDL cholesterol and diastolic blood pressure. 4calculated per mg protein. 
DISCUSSION 
We investigated the relationship between LDL antioxidant and plasma vitamin C 
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concentrations and risk of coronary atherosclerosis. High antioxidant concentrations 
have been hypothesized to play a protective role against atherogenesis. Luteinize-
axanthin and a-carotene levels were indeed inversely related to the risk of coronary 
atherosclerosis, however, these associations disappeared after adjustment for blood 
cholesterol and blood pressure. On the other hand, 'Y-and a-tocopherol levels were 
positively related to risk of coronary atherosclerosis. We did not find indications that 
these relations may be ascribed to an intermediate role of LDL oxidation. 
In this study both cases and hospital controls were selected on the basis of angio-
graphical reports. The mean percentage of stenosis in the case group was 75% of 
whom 55% had narrowing of at least 50% in all three coronary vessels, whereas the 
hospital controls had a mean of 4.3% stenosis of whom 76% had no substantial nar-
rowing in the 3 coronary vessels. The contrast between cases and controls was thus 
sufficiently high to avoid misclassification of the disease. In addition, we included a 
group of popUlation controls for whom a measure of CVD was available, namely an 
ultrasound of the carotid artery. 
LDL antioxidant levels and plasma vitamin C levels are a reflection of dietary 
intake of antioxidants. The use of a biomarker for dietary intake may be more relevant 
to study the association between antioxidants and diseases, because individual variation 
in absorption and metabolism of dietary antioxidants is taken into account. Moreover, 
the chance of under- or overrepOiting dietaty antioxidant intake is excluded. However, 
in a case-control study the possibility remains that disease status influences dietat'y and 
life-style patterns, and thus the antioxidant level in plasma or LDL. Therefore we took 
blood samples within 2 months after catheterization to minimize dietary changes as a 
result of the angiography. In addition, we included a control group consisting of both 
hospital-based and population-based controls. Hospital controls were expected to be 
equally prone to dietaty and life-style changes because of awareness of the disease, 
whereas population controls without cat'diovascular complaints are not likely to have 
Chatlged their diet. In this study no differences in the use of a prescribed diet between 
cases and controls were found. Also, no marked differences in associations between 
antioxidants and risk of coronaty atherosclerosis were found between the two control 
groups. Therefore, dietaty changes in this study at'e not likely to have influenced the 
results. 
Use of antioxidant supplements was reported by 5% of our study population. One 
control subject reported the use of vitamin E supplements and one case used vitamin A 
supplements. Most prominent was the use of vitamin C supplements. Analysis with 
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supplement users excluded did not change the results. 
In our study a significant positive association between both 'Y-tocopherol and 
a-tocopherol levels and risk of coronary atherosclerosis was found. Based on findings 
from previous studies this result was not expected.'" Although not significant, some 
other studies have also suggested higher rather than lower vitamin E levels in 
serum6•12•32•33 and atherosclerotic lesions" in cases compared to controls. Higher 
vitamin E levels in cases might be explained if the concentration tocopherol in LDL is 
increased as a response to atherosclerotic lesions. Especially for 'Y-tocopherol a diffe-
rence was present when calculating ORs in the separate control groups. The positive 
association was most clear in the population control group, suggesting that the physio-
logy of tocopherol uptake and metabolism in cases is different from that in healthy 
subjects. This has been suggested by Kardinaal et aI., who found different correlations 
between dietary vitamin E intake and adipose tissue markers in MI patients and con-
trols." Another indication that the physiology of vitamin E uptake and metabolism in 
LDL may be different in healthy subjects and cases is seen in correlations calculated 
in sub-samples of our study population. In a sub-sample of population controls 
(n - 67) significant correlations between LDL and plasma levels of 'Y-tocopherol 
(1' - 0.53) and a-tocopherol (1' - 0.42) were found, whereas the con'elations in a sub-
sample of the case group (n - 69) were virtually absent (-0.01 for 'Y-tocopherol and 
0.13 for a-tocopherol). A difference in correlations between plasma and LDL levels in 
CHD patients and controls is also described by Regnstriim et al.24 Therefore, studies 
on plasma or selUm levels may need to be interpreted differently from studies on LDL 
levels. 
We found higher carotenoid levels in controls compared to the cases, but only for 
a-carotene and lutein/zeaxanthin this difference was significant. These two carotenoids 
were inversely related to risk of coronary atherosclerosis in analyses adjusted for age 
and smoking. However, further adjustment for cholesterol attenuated the result. To date 
no study has reported on LDL carotenoid levels and risk of CHD in a non-supplemen-
ted population. Other studies have described an inverse association between dietary,' 
plasma and selUm' and adipose tissue' ~-carotene levels and risk of CHD, but results 
from recently published intervention studies on ~-carotene could not confirm this 
protective effect. 13· 15 In oUt' study no association was found for ~-carotene and risk of 
coronary atherosclerosis. 
In our study an inverse association between vitamin C levels and risk of coronruy 
atherosclerosis was seen only in the never/ex-smokers, but after adjustment for choles-
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terol this association was no longer significant. In previous studies, intake of vitamin C 
intake has been strongly and inversely associated with risk of GlD,' whereas no 
relation was found in two larg~ prospective studies.'" Adequate plasma vitamin C 
levels above a desirable level for protection against CHD (>40-50 Ilmol/L for non-
smokers), could have resulted in lack of association in our study and in the latter 
prospective studies.36 
Our second hypothesis concemed a protective effect of antioxidants against athero-
sclerosis through protection of LDL against oxidation. Vitamin E supplementation in 
intervention studies resulted in a decreased susceptibility of LDL to ex vivo 
oxidation.'·-23 No clear protective effect has been found after p-carotene supplementa-
tion."·22.37 We could not find evidence for an association between levels of LDL 
antioxidants and LDL oxidation. Only marginal differences were found when we 
included resistance time or maximum rate of oxidation into the logistic model to assess 
the risk of coronary atherosclerosis at different levels of LDL antioxidants (results not 
shown). Therefore, we could not confirm an intermediate role for LDL oxidation in the 
association between antioxidants and CHD. Possibly, this may be ascribed to the small 
differences in antioxidant levels between case and control group. Large doses may be 
needed for a sufficiently large contrast in antioxidant levels to be reflected in lower 
oxidation rates. 
In conclusion, no effect of high LDL antioxidant levels and plasma vitamin C on 
risk of coronary atherosclerosis was found. To the contrary, high LDL-tocopherol 
levels showed a positive association with risk of coronary atherosclerosis, which may 
reflect differences in physiology of tocopherol uptake and metabolism in CHD pa-
tients. No indications were found that LDL oxidation plays an intermediate role in the 
relation between antioxidants and risk of coronruy atherosclerosis. 
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4.2 
Plasma Coenzyme QI0 levels are not decreased in coronary 
atherosclerosis patients 
ABSTRACT 
Coenzyme QIO (COQIO) is an important mitochondrial electron transfer component and 
has been postulated to function as a powerful antioxidant protecting LDL from oxida-
tive damage. It could thus reduce the risk of cardiovascular disease. To study the 
relation between plasma COQIO levels and coronary atherosclerosis, we performed a 
case-control study among 71 male cases with angiographically documented severe 
coronary atherosclerosis and 69 healthy male controls free from symptomatic cardio-
vascular disease and without atherosclerotic plaques in the carotid artery. 
Plasma COQIO levels (mean ± SE) were 0.86 ± 0.04 vs. 0.83 ± 0.04 IImoVL for 
cases and controls, respectively. The COQIO / LDL-cholesterol ratio (IImoVmmol) was 
slightly lower in cases than in controls (0.22 ± 0.01 vs. 0.26 ± 0.03). Differences in 
COQIO levels and CoQI(/LDL-cholesterol ratio did not reach significance. The odds 
ratios (95% confidence interval) for the risk of coronary atherosclerosis calculated per 
IImoVL increase of COQIO was 1.12 (0.28-4.43) after adjustment for age, smoking 
habits, total cholesterol and diastolic blood pressure. 
We conclude that an unsupplemented plasma COQIO level is not related to risk of 
coronary atherosclerosis. 
INTRODUCTION 
Antioxidants have been implicated to playa protective role in the atherogenic process. 
They are believed to delay atherogenesis by protecting lipid fractions within the low-
density lipoprotein (LDL) particle against oxidation by free radicals. Oxidative modifi-
cation of LDL has been implicated as an important step in the development of atheros-
clerosis. Oxidative modification accelerates the uptake of LDL by macrophages which 
is the beginning of formation of fatty streak.'·2 
Coenzyme QIO (COQIO) is an important calTier for two-electron transfer within the 
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mitochondrial membrane and has been shown to function as an endogenous lipid-
soluble antioxidant in blood and tissues.' Previous studies have shown that reduced 
COQIO (ubiquinol) exerts a protective effect on LDL oxidation'" and that reduced 
COQIO is depleted before tocopherols during lipid oxidation,'·9.10 consistent with the 
notion that reduced COQIO acts as a scavenger of the tocopheroxyl radical produced 
during lipid oxidation,u·13 Ubiquinol is also believed to function as a chain breaking 
antioxidant in the lipid peroxidation process.'·9.14 
COQIO supplementation has been suggested to have beneficial effects in treatment 
of coronary heart disease (CHD) patientsI,.I6 and to result in decreased thiobarbituric 
acid-reactive substances (TBARS) levelsI' and conjugated diene' production after 
oxidative stress. Some authors also have reported decreased levels of COQIO in cardio-
myopathy patients compared to normal controls,!' and the LDUubiquinone ratio has 
been suggested to be a coronary risk factor. I9 However, little information is available 
on plasma COQIO levels in CHD patients and healthy subjects under unsupplemented 
conditions. 
To study the association between plasma COQIO levels and the risk of coronary 
atherosclerosis, we performed a case-control study among cases with severe coronary 
atherosclerosis and healthy controls. 
METHODS 
Study population 
The study was conducted in several hospitals and clinical centres in Rotterdam and 
Dordrecht, the Netherlands, in the period 1993-1995. The study was approved by an 
ethical committee on human research and all participants gave informed consent. We 
selected a group of patients with coronary atherosclerose and a group of population 
controls without symptomatic cardiovascular disease. All were men between 45 and 80 
years of age. Enrolment procedures allowed for similar distributions of age (in 5-year 
categories) and smoking status (smoking, non-smoking). 
Selection of the cases was based on angiographic reports. To reduce the impact of 
disease on dietary and life-style patterns, we selected only those patients who under-
went their first angiography and who had not experienced a myocardial infarction in 
the year prior to the study. For the same reason, blood was collected within 2 months 
after angiography. Subjects using HMG-CoA reductase inhibitors were excluded 
because of the possible inhibiting effect of this dlUg on ubiquinone production by 
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interfering in the mevalonate pathway" and its possible influence on LDL oxidation. 
In the study period 2830 patients underwent coronary angiography for suspected 
CHD, including 1966 male subjects. Subjects were not eligible if they met one of the 
following exclusion criteria: under 45 or over 80 years of age (n = 144), not the first 
coronary angiography (n = 289), MI in the 12 months prior to the study (n = 180), 
diabetes mellitus (n = 84), liver, kidney 01' thyroid disease (n = 15), alcohol or drug 
abuse (n = 4), use of HMO-CoA reductase inhibitors (n = 82), vegetarian diet (n = 3), 
psychiatric complaints (n = 2). For 88 subjects more than 2 months had elapsed 
between angiography and case selection and 12 patients had died in the meantime, 
leaving a population of 1063 eligible subjects. Of this group 124 refused to participate 
and 50 could not be contacted or were otherwise indisposed. From the remaining 889 
men, 71 cases with at least 85% stenosis in one and at least 50% stenosis in a second 
of the three major coronary vessels were selected for assessment of plasma CoQ". Of 
these subjects, 57% had a narrowing of at least 50% in all three major coronary 
vessels. The percentage of stenosis was scored by the cardiologist performing the 
angiography. 
Population controls were selected from participants in the Rotterdam Study. The 
rationale and design of this population-based prospective cohort study have been 
described previously." We selected subjects without any plaques in the carotid artery 
as assessed by ultrasound. Further, these subjects repot1ed not to have a histoty of 
cardiac treatment, not to have diabetes mellitus, or liver, kidney 01' thyroid disease, not 
to use HMO-CoA reductase inhibitors nor to be vegetarian. As the participants in the 
Rotterdam Study were all 55 years and over at baseline, we additionally recruited men 
between 45 and 55 years of age through an advertisement in a local newspaper. 
Recruitment took place in the area the other population controls originated from. A 
questionnaire was used to obtain information on medical histoty; when candidates 
fulfilled the inclusion criteria they were invited to the research centre. Enrolment in 
the study took place after it had been echographically ascertained that subjects' carotid 
art elY was free of plaques. A total of 69 population controls were included in which 
plasma CoQ" was assessed. 
Data collection 
For the cases information on medical history was obtained from hospital records and 
through a questionnaire within 2 months after angiography. Information on dietary 
pattems, smoking and drinking pattems, medicine use, use of vitamin supplements, 
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occupation and family history of CVD was obtained. Weight, height and blood pres-
sure were measured. A fasting venous blood sample was collected in EDTA Vacutai-
ner tubes and immediately placed on ice and cooled to 4'c' Plasma was prepared 
within I h after blood collection by centrifugation at 1750 x g for 15 min, frozen in 
methanol of -80'C or liquid nitrogen, and stored at -80'C. 
Allalytical11leasllremellts 
Procedures for analysis of total COQIO and tocopherols in plasma were as follows: 100 
pi plasma was extracted after addition of 25 pi I mglml BHT in EtOH, and 900 pi 0.1 
M SDS and 2 ml hexane. 1.5 ml of the hexane layer was taken to dryness under 
nitrogen and redissolved in 200 pi ethanol. 10 pi was used for HPLC analysis (method 
adapted from Lang et al.)." The HPLC analysis was performed on a Waters system 
with Waters 610 pumps, a Beckman Ultrasphere ODS C-18 column, 4.6 mm i.d., 25 
cm, 5 pm particle size, a Waters Wisp 717 autosampler, and Millenium software and 
using a Coulochem 5100A electrochemical detector (Environmental Sciences Assoc., 
Bedford, MA., USA), equipped with a Model 5020 Conditioning cell set at -750 mY, 
and a Model 5011 Analytical cell with 2 electrodes in series, the first set at -750 mY, 
and the second set at +500 mY. The eluent was ethanolJmethanolJisopropanol 
715:245:40 containing 0.1 % WI, lithium perchlorate at 1.2 mIJmin' (slightly modified). 
Measurements were performed in duplicate and quantification was carried out by 
comparing peak areas to the area of standard curves obtained with authentic com-
pounds. 
Cholesterol and triglyceride concentrations were determined enzymatically using 
commercially available reagents (CHOD-PAP kit 236.691 and Triglyceride kit 
701.904, Boehringer-Mannheim, Mannheim, Germany). High-density lipoprotein 
(HDL)-cholesterol was measured after precipitation of very-low-density lipoprotein 
(VLDL), intermediate-density lipoprotein (IDL) and LDL using the precipitation 
method with sodium phosphotungstate-Mg"." LDL-cholesterol concentrations were 
calculated by the formula of Friedewald et a\.24 
Preparatioll alld oxidatioll of LDL 
The procedure for preparation and lipid peroxidation of LDL was adapted from Ester-
bauer et al." with some major modifications as described previously in detail."'" The 
kinetics of LDL oxidation were followed by continuously monitoring the change of 
absorbance at 234 nm."·27 Absorbance curves of LDL preparations obtained from an 
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equal number (3) of subjects from each study group were determined in pru:allel. Each 
LDL preparation was oxidized in three consecutive oxidation runs on the same day. 
Means were calculated on the basis of these three observations. 
Statistical allalysis 
Characteristics of the case group and the control group were compared with Student's 
t-test for unpaired samples. Age-adjusted means were compared by analysis of cova-
riance. Pearson' cOlTelations were calculated between COQIO levels and risk factors for 
CRD. Odds ratios (OR) were calculated to quantify the association between plasma 
COQIO concentrations and coronary atherosclerosis. DRs are calculated per ~moJJL 
increase of COQIO' Confounding factors taken into account were: age, smoking habits, 
body mass index, total, HDL- and LDL-cholesterol, diastolic and systolic blood pres-
sure. Data were analysed with the statistical package BMDP.29 
RESULTS 
Table 1 lists the characteristics of cases and controls. Groups were comparable regard-
ing the prestratification factors age and smoking status. Total cholesterol, LDL-choles-
terol and triglycerides were lower in controls and RDL-cholesterol and diastolic blood 
pressure were higher in controls. 
Table 1. Characteristics of the study population (Meatl ± SD) 
Age (years) 
Smokers (%)' 
Ex-smokers (%)1 
Body mass index (kg/m') 
Total cholesterol (nunoVI) 
Triglycerides (mmoJ/l) 
HDL (mmol/I) 
LDL (mmol/I) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Cases 
(n-71) 
61.9 ± 9.3 
33.8 
9.9 
26.3 ± 2.4 
5.9 ± l.l 
2.1 ± 0.8 
0.8 ± 0.2 
4.2 ± 1.0 
132.9 ± 16.6 
81.4 ± 8.0 
Controls 
(n=69) 
61.4 ± 8.8 
21.7 
18.8 
26.2 ± 3.3 
5.4 ± l.l • 
1.6 ± 0.9 • 
1.0 ± 0.3 • 
3.6 ± 1.0 • 
136.4 ± 18.5 
85.4 ± 9.9 * 
lex-smoker stopped smoking more than one year ago, othenvise current smoker. *significant differ-
ence p<O.05. 
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The frequency of reported prescribed diet use was similar in both groups (17.6% in 
cases, 13.0% in controls). Cases more frequently reported use of antihypertensive 
medication (93.0% vs. 10.1%) and aspirin and coumarin derivatives (93.0% vs. 4.3%), 
while 37% of the cases reported a history of MI. 
The mean levels of plasma antioxidants for the two groups are listed in Table 2. 
No differences in COQIO levels between patients and controls were found. A slightly 
lower CoQu/LDL ratio was seen in the case group. However, a significant age-
adjusted difference was found for a-tocopherol only, with higher tocopherol levels in 
cases. 
Table 2. Concelllrations of plasma antioxidants for patients with corollary atherosclerosis alld 
collfrols (Mean ± SE) 
Coenzyme QIO (pmoVL) 
CoQ\o'LDL cholesterol (pmoVml) 
y-Tocopherol (pmoVL) 
a-Tocopherol (pmoVL) 
~-Carotene (pmoVL) 
'age-adjusted. 
Cases 
(n~71) 
0.86 ± 0.04 
0.22 ± O.oI 
2.44 ± 0.14 
29.8 ± 0.6 
0.22 ± 0.Q2 
Controls 
(11~69) 
0.83 ± 0.04 
0.26 ± 0.03 
2.16±0.11 
25.4 ± 0.7 
0.26 ± 0.Q2 
p-value' 
0.50 
0.21 
0.13 
<0.01 
0.17 
In the control group we calculated con-elation coefficients for the association between 
cardiovascular risk factors and the level of COQIO' Positively con-elated (p<0.05) to 
COQIO levels were: total cholesterol «r = 0.57), LDL-cholesterol (1' = 0.49), diastolic 
blood pressure (r = 0.25), y-tocopherol (r = 0.40) and a-tocopherol (1' = 0.53). No 
correlations were found with age, body mass index, systolic blood pressure, HDL-
cholesterol and triglyceride levels. 
In Table 3 ORs (and 95% confidence interval) for the risk of coronary atheros-
clerosis per JlmoVL increase of plasma COQIO and per unit increase of CoQll/LDL-
cholesterol ratio are presented. No association was found between plasma levels of 
COQIO and risk of coronary atherosclerosis. Because crude and age-adjusted ORs 
differed only marginally, only the age-adjusted OR is presented. To ensure that other 
differences between the cases and controls did not confound the risk estimate, we 
adjusted the OR for the potential confounding factors total cholesterol, diastolic blood 
pressure and smoking habits (Table 3). The OR was 1.12 which means that every 
JlmoVL increase of COQIO results in a non-significant 12% increase in risk of coronary 
atherosclerosis. 
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Table 3. Odds ratios (and 95% el) for risk of corOllmy atherosclerosis per llmaUL increase of CoQJO 
and per wlit increase ill CoQJ(/LDL cholesterol. 
COQIO 
CoQlO/LDL cholesterol 
Age-adjusted 
1.50 (0.48-4.67) 
0.18 (0.01-3.55) 
ladjusted for age, smoking, total cholesterol and diastolic blood pressure. 
Multivariate] 
1.12 (0.28-4.43) 
1.01 (0.09-11.2) 
Additional adjustment for a-tocopherol resulted in an OR of 0.37 (0.08-1.78). The 
interaction between plasma levels of COQIO and a-tocopherol was not significant 
(p = 0.38). Calculation of the ORs over quartiles of COQIO levels in the control group 
yielded essentially similar results. ORs for the successive quartiles were 1.0 (refer-
ence), 0.98 (0.34-2.86), 1.00 (0.33-3.05) and 1.31 (0.43-4.02) after adjustment for total 
cholesterol, smoking habits and diastolic blood pressure. 
Stratified analysis in separate strata of total cholesterol « 5.5 or <: 5.5) or smoking 
status (smokers or never/ex-smokers) did not essentially change the results. 
Associations with oxidation parameters 
A possible mechanism by which COQIO and other plasma antioxidants may playa role 
in the atherogenic process is by inhibition of LDL oxidation. Resistance time, as a 
measure of LDL resistance to oxidation ex vivo, and maximum rate of oxidation did 
not differ between cases and controls (Table 4) and were not conelated to plasma 
COQIO levels. The OR (95% confidence interval) for coronary atherosclerosis per 
I'molll increase of COQIO was 0.99 (0.24-4.06), after further adjustment for resistance 
time and maximum rate of oxidation. 
Table 4. Oxidation characteristics for patiellts with coroJlmy atherosclerosis and controis (mean ± 
SE) 
Resistance time (min) 
Maximum rate of oxidation (nmol dienelmin per 
mg protein) 
Cases 
(n=71) 
87 ± 1 
10.4 ± 0.1 
Controls 
(n=68)' 
90 ± 1 
10.3 ± 0.1 
0.20 
0.54 
lone control with unreliable data for oxidation parameters was left out for the analyses. 2age-adjusted. 
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DISCUSSION 
We investigated the relationship between plasma total COQIO levels and the risk of 
coronary atherosclerosis in unsupplemented individuals in a case-control study. No 
association could be detected. 
A protective effect against CHD has been ascribed to COQIO' possibly due to the 
antioxidant function of the reduced form of COQIO' ubiquinol. In this study we measu-
red the total COQIO concentration, but data from other studies indicate that at least 75-
80% of the total COQIO can be found in reduced form,'·'·17 and therefore differences in 
total COQIO levels also reflect differences in the levels of reduced COQIO' 
It seems unlikely that the finding of no difference between the groups is a result of 
flaws in the study design. As a result of the disease status changes in life-style and 
nutritional patterns could have occurred in the patient group. COQIO is present in a 
wide variety of foods, but is mainly high in organ meats (e.g. heart, liver, kidney), 
beef, vegetable oils (e.g. soy oil), fish (e.g. sardines, mackerel), and peanuts. A change 
in dietmy patterns towards these products is not veIY likely, as organ meats are not 
veIY popular in the Netherlands, and diets prescribed to CHD patients commonly are 
energy- mId/or fat-restricted. In addition, recent studies have shown that the average 
COQIO intake of an average Danish person is 3-5 mg per day, an amount that is not 
likely to affect the plasma level dramatically.17 
Another important difference between our two groups is drug. use. As many as 
93% of our patients used antihypertensive medication, aspirins or coumarin deriva-
tives. From the literature the only drugs which may have an inhibitory effect on 
ubiquinone production are HMG-CoA reductase inhibitors.'o In our study subjects who 
used these drugs were excluded. 
The COQIO level in our study is similar to levels reported by Hanaki et al.'o and 
slightly higher than those reported by Weber et al. 17 Several studies have reported on 
decreased susceptibility to oxidation after supplementation with CoQIO' Weber et al. 
rep0l1ed a significant decrease in TBARS production after a 1 I'mol/l increase of 
plasma QIO level. 17 Kontush et al. reported that incorporation of ubiquinol-IO in LDL, 
which led to an increase in LDL ubiquinol-IO from 0.1 0-0.20 to 0.55-1.48 mol/mol 
LDL, resulted in a decreased conjugated diene production.' Further, a decrease in 
hydroperoxide levels was detected after supplementation of LDL with COQIO. 8 To our 
knowledge no study has reported on significantly reduced susceptibility to oxidation at 
physiological plasma levels of COQIO in unsupplemellted subjects. KOlltush et al. 
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described only a small effect of ubiquinone-IO and a-tocopherol incorporated in LDL 
at physiological levels, whereas at high levels of incOlporation (more than eight-fold 
increase) an antioxidant effect of ubiquinone-IO was seen.' Also in a study by Frei et 
al. no effect of physiological LDL-ubiquinol concentrations on LDL oxidation was 
found. 30 This is in accordance with the lack of association between CoQJO levels and 
LDL oxidizability in our study in unsupplemented subjects. 
In this study we did not detect differences in plasma levels of CoQJO between 
cases with coronary atherosclerosis and controls, nor did we find a decreased risk of 
coronary atherosclerosis at higher CoQJO levels. We conclude that no relation between 
physiological concentrations of plasma CoQJO levels and the risk of coronary atheros-
clerosis was detected. 
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Dietary antioxidants and coronary 
heart disease 

5.1 
Major dietary antioxidants and risk of silent myocardial 
infarction: the Rotterdam Study 
ABSTRACT 
Antioxidants have been implicated to play a protective role in the atherosclerotic 
process. We studied the relation between dietary intakes of p-carotene, vitamin C and 
vitamin E and the presence of silent myocardial infarction (MI) in baseline data from 
the Rotterdam Study (1990-1993), a prospective cohort study among 7983 men and 
women aged 55 years and over. Silent MI subjects were studied. As they are not aware 
of their disease status, dietary changes as a result of the disease are unlikely. Dietary 
intake of major antioxidants was estimated by a semi-quantitative food frequency 
questionnaire (170 items). The assessment comprised a simple self-reported question-
naire which formed the basis for a detailed interview by a trained dietician. Self-reports 
of cardiovascular disease (CVD) were validated by medical records. Silent MI was 
defined as 'ECG evidence of MI without medical information or self-reported history 
of MI'. Subjects with a silent MI (n ~ 89) were compared to subjects without any 
CVD history (n = 2333). 
Adjusted odds ratios (95% confidence interval) for risk of MI per quartile of 
vitamin C were 1.0 (reference), 1.1 (0.7-2.0), 0.6 (0.3-1.1) and 0.8 (0.4-1.4) 
(P.oo' ~ 0.2), for vitamin E 1.0, 1.6 (0.9-2.8), 1.1 (0.6-2.0), 1.0 (0.5-2.0) (p,,,o' = 0.7), 
and 1.0, 1.4 (0.8-2.3), 0.8 (0.4-1.5), 0.5 (0.2-1.0) (p,,,o' = 0.04) for p-carotene. Associa-
tions were more pronounced in women. 
In conclusion, p-carotene intake is inversely associated with risk of MI. No associ-
ation between vitamin C or vitamin E intake and risk of MI was seen. Whether the 
effect of p-carotene is attributable to p-carotene itself or other components in 
p-carotene containing foods needs further to be determined. 
INTRODUCTION 
Antioxidant vitamins have been implicated to play a protective role against coronmy 
III 
Chapter 5.1 
heart disease (CHO). The antioxidant vitamins vitamin E, ~-carotene and vitamin C 
may prevent or slow down the atherogenic process by protecting low-density lipopro-
teins (LOL) from oxidation. Oxidized LOL may playa role in foam cell formation and 
in formation of atherosclerotic lesions. 1 
Large prospective studies have shown a lower risk of CHO at high intakes of 
vitamin C,'·3 and vitamin E.'-' Further, high plasma levels of vitamin E' and ~-carote­
ne' are associated with lower risk of ischaemic heart disease, whereas adipose tissue 
levels showed a reduction in risk of myocardial infarction (MI) in the highest compa-
red to the lowest quintile of ~-carotene but not vitamin E.' Results from trials on 
antioxidant supplementation do not support a benificial effect of ~-carotene.IO-12 For 
vitamin E supplementation no effect on CHD mortality has been observed,IO·13 whereas 
it may have a preventive effect on CHO morbidity, e.g. high doses were found to 
prevent non-fatal MI in angiography patients 13 and the incidence of angina pectoris. 14 
We studied the relationship between antioxidant intake and CHO in a large group 
of subjects who had a silent MI. This group is of particular interest, as they have 
definitely cardiovascular disease, but are not aware of their disease status. Therefore, 
change in dietary patterns as a result of the disease and misclassification of subjects 
due to information bias in reporting dietary intake are unlikely. We compared subjects 
with silent MI to subjects without any history of cardiovascular diseases in the baseline 
data from the Rotterdam Study. 
SUBJECTS AND METHODS 
Study design and subjects 
The Rotterdam Study is a single-centre community-based prospective cohort study 
among 7983 subjects aged 55 years and over, living in Ommoord, an urban district of 
Rotterdam, the Netherlands. The rationale and design have been described previously." 
In short, the Rotterdam Study investigates prevalence, incidence, and determinants of 
cardiovascular, neurological, locomotor, and ophthalmological diseases. Baseline data 
were collected between 1990-1993. The study comprised an extensive home interview 
(participation rate 78%) and two visits at a research centre for a clinical examination 
(participation rate 69%). The study has been approved by the Medical Ethics Commit-
tee of the Erasmus University Rotterdam, and written consent was obtained from all 
participants. Dietary assessment was undertaken to investigate the role of nutrition and 
nutrition-related factors in the development of clu'onic diseases. 
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Dietary assessmellt 
Dietary assessment was performed during the second visit at the research centre. 
Habitual consumption pattems over the past year were determined by a semi-quantita-
tive food frequency questionnaire. The questionnaire was a modified version of a 
validated self-administered semi-quantitative food frequency questionnaire previously 
used in a large-scale prospective cohort study. Measures of the validity and 
repeatability of the original questionnaire for several nutrients have been reported. 16.17 
The questionnaire was adapted to allow an easy and time-efficient dietary assessment 
in an older population. Furthermore, some additional items were included and more 
detailed information on vegetable, flUit and meat consumption could be obtained. The 
modified questionnaire contains 170 food items in 13 food groups and general 
questions about dietary pattems. 
Dietary assessment was undeliaken in two consecutive phases. In the first phase a 
self-administered questionnaire was handed out and explained to each patiicipant 
during a home visit by a trained research assistant. Participants had to mark the foods 
they had consumed at least twice a month and whether consumption was season bound 
(summer or winter). In the second phase a dietary interview was conducted by a 
trained dietician on the basis of the completed dietat')' questionnaire. During the dieta!,), 
interview the dieticians concentrated on obtaining accurate information on quantity and 
frequency of food items noted by patiicipants as consumed at least twice a month. The 
conversion from foods to energy and nutrient intake was established with a computeri-
zed version of the Dutch Food Composition Table,ls completed with tables for vitamin 
E and ~-carotene.19 
No dietat')' data were available for pat·ticipants of the pilot study (n ~ 277), for 
those living in nursing homes (n ~ 479), and for persons with reduced cognitive 
function (n ~ 122) assessed by a neuropsychological test. For logistic reasons no 
dietat·y assessment could be made in an additional 482 persons. On the basis of the 
judgement of investigators 212 subjects were excluded from atlalysis due to unreliabi-
lity of reported dietary intake. 
Examillatioll procedures 
The pat'ticipants came to the research center at varying times during the day. At the 
reseat'ch center they underwent a brief clinical examination; height at!d weight were 
measured and body mass index was calculated (kg/m'). Blood pressure was calculated 
as the average of two consecutive measurements with a random zero sphygmomanome-
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tel'. A 12-lead ECG was recorded with an ESAOTE-ACTA cardiograph with a 
sampling frequency of 500 Hz and digitally stored. ECG data were evaluated by 
research physicians using a protocol for standardized clinical ECG evaluation. All 
BCGs with possible characteristics of MI were checked by an experienced cardiologist 
who determined the final diagnosis. During the interview questions on history of MI 
were asked, including the following questions: 'Did you ever have a heart attack?' and, 
if so, 'At what age?', 'Who made the diagnosis?', and 'Were you admitted to a 
hospital?'. All ECGs of subjects with self-reported MI without BCG evidence were re-
analyzed by the Modular ECG Analysis System (MEANS)20·2l to detect cases of 
electrocardiographic MI which had been missed by the research physician. The final 
diagnosis for these cases was made by another cardiologist with large specialized 
experience in reading ECGs. From subjects with ECG evidence without self-rep0l1ed 
MI, additional clinical information from the GP or cardiologist was obtained to 
confirm that the MI has occured silent. 
Populatioll for allalysis 
In this study dietary data and evaluated BCG data were available for 2743 subjects. 
Excluded were all subjects with self-reported MI with or without matching BCG 
evidence (n = 228) and subjects with missing information on cardiovascular disease 
(n = 93). This left 2333 subjects without any history of MI or ECG evidence for MI 
and 89 subjects with a silent MI (ECG evidence but no self-rep0l1ed MI and no MI 
reported in the medical record) for the analysis. 
Data allalysis 
Baseline characteristics were compared by Student's t-test for unpaired samples and 
Pearson X2 analysis (p<0.05) and by analysis of covariance. Skewed distributions of 
vitamin E, vitamin C, ~-carotene and energy intake were normalized by natural loga-
rithm transformation. Odds ratios were calculated to quantify the association between 
antioxidant intake and the risk of a silent MI. Division into quartiles of antioxidant 
intake was based on antioxidant intake in the baseline popUlation without CVD 
(n = 2333). Quartile distribution for stratified analysis was based on the intake in the 
cOlTesponding strata of the baseline. Multiple logistic regression was used to obtain 
odds ratios adjusted for known risk factors for CVD; i.e. age, gender, smoking habits, 
systolic blood pressure, total cholesterol. Trend analysis were pelformed over the 
medians of the quartiles. 
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RESULTS 
Baseline characteristics of subjects with silent MI and the population without eHD are 
given in Table 1. Subjects with silent MI were significantly older than those without a 
history of eHD. Further, subjects with silent MI had higher systolic and diastolic blood 
pressure and were more likely to be men than in the population without eHD. The use 
of a prescribed diet was more common, but not significantly so, in the population 
without eHD. 
Table 1. Baseline characteristics (mean ± sd) 0/ cases with a silent myocardial in/action and 
controls without cardiovascular disease 
Age (years) 
Body mass index (kg/m2) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Cholesterol (mmoUI) 
HDL (mmoUl) 
Men ('!o) 
Smokers (\'0) 
Ex-Smokers (%) 
Diet (\'0) 
Vitamin supplement users (%) 
Mineral supplements users (%) 
Antidiabetic medication users (%) 
'p<0.05. 
Silent MI cases 
(n~89) 
70.4 ± 7.4 
26.8 ± 4.7 
147.1 ± 22.6 
77.6± 13.3 
6.5 ± 1.1 
1.3 ± 0.4 
5l.7 
33.7 
39.3 
7.9 
9.0 
3.4 
3.4 
Subjects without CHD 
(n=2333) 
67.9 ± 7.6' 
26.4 ± 3.7 
139.3 ± 22.2' 
74.3 ± 11.0' 
6.7 ± 1.2 
1.4 ± 0.4 
36.8' 
25.4 
39.4 
12.8 
9.3 
2.2 
3.8 
In Table 2, age- and gender adjusted mean daily intake of antioxidants is shown. 
Overall, no significant differences between the groups were found. 
Table 2. Age- and gender-adjusted mean daily intake of energy and antioxidaflfs (mean ± SE) 
Energy intake (kJ/d) 
Il-carotene (mg/d) 
Vitamin E (mg/d) 
Vitamin C (mg/d) 
Silent MI cases 
(n=89) 
7885 ± 201 
1.38 ± 0.07 
12.8 ± 0.6 
106.5 ±5.3 
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Subjects without CHD 
(n~2333) 
8264 ± 39 
1.51 ± 0.01 
13.6 ± 0.1 
116.5 ± 1.0 
p-value 
0.07 
0.06 
0.18 
0.06 
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Odds ratios were calculated for quartiJes of antioxidant intake, with the lowest qUa!1iJe 
as reference (Table 3). No association was found between the risk of MI and vitamiu 
C or vitamiu E iutake. Only the highest compared to the lowest quartile of p-carotene 
iutake showed a significantly lower risk of MI, when adjusted for age and gender. 
After adjustment for convential risk factors for CVD the reduced risk in the highest 
iutake group remaiued (Po,,,,, - 0.02). Adjustment for the other antioxidants only 
resulted iu miuor differences. 
Table 3. Odds ratio (95% el) per quartile of antioxidam imake 
Quartile I 2 3 4 p-value 
(reference) for trend 
Vitamin C (mg/d) <83.0 83.0 - 110.3 110.3-141.5 >141.5 
no. of cases 27 28 16 18 
age + gender 1.0 1.1 (0.6-1.8) 0.6 (0.3-1.2) 0.7 (0.4-1.3) p~0.12 
multiple' 1.0 1.2 (0.7-2.0) 0.6 (0.3-1.2) 0.7 (0.4-1.4) p~0.16 
multiple+antiox2 1.0 1.3(0.7-2.2) 0.8 (0.4-1.5) 1.0 (0.5-1.9) p~0.30 
Vitamin E (mg/d) <9.3 9.3-12.8 12.8-16.8 >16.8 
no. of cases 20 30 21 18 
age + gender 1.0 1.5 (0.9-2.7) 1.0 (0.5-1.8) 0.8 (0.4-1.5) p~0.20 
multiple' 1.0 1.5 (0.8-2.7) 1.0 (0.5-1.8) 0.8 (0.4-1.6) p~0.24 
multiple+antiox2 1.0 1.6(0.9-2.9) 1.1 (0.6-2.0) 1.0 (0.5-2.0) p~0.50 
~-Carotene (mg/d) <1.11 1.11-1.43 1.43-1.80 >1.80 
no. of cases 26 34 19 10 
age +gender 1.0 1.3 (0.8-2.3) 0.7 (0.4-1.4) 0.4 (0.2-0.9)3 p~O.OI 
multiple l 1.0 1.4 (0.8-2.3) 0.8 (0.4-1.4) 0.4 (0.2-0.9)3 p~0.02 
muItipJe+antiox2 1.0 1.4 (0.8-2.3) 0.8 (0.4-1.5) 0.5 (0.2-1.0)3 p~0.02 
ladjusted for age, gender, smoking habits (current, former, never), systolic blood pressure, serum total 
cholesterol. 2 adjusted for age, gender, smoking habits and other antioxidants. 3p<O.05. 
Use of vitamiu supplementation was reported iu 9% of all subjects; 4% of the subjects 
with silent MI and 7% iu the subjects without CHD history used vitamin C supplemen-
tation, and use of multivitamins was documented in 5% of the silent MI group and in 
7% of the population without CHD. Use of vitamiu E and ca!'otenoid supplements was 
absent in the silent MI group and 1.5% and 0.9%, respectively, in the non-CHD group. 
ORs (95% Cl) with supplement users excluded were essentially similar as those 
presented in Table 3, i.e. 1.0, 1.2(0.7-2.2), 0.7(0.3-1.3), 0.8(0.4-1.6) for the succesive 
qUa!1iles of vitamiu C, 1.0, 1.4(0.8-2.6), 0.8(0.4-1.6), 0.7 (0.3-1.4) for vitamiu E and 
1.0, 1.3(0.7-2.2),0.7 (0.4-1.4) and 0.4 (0.2-0.8) for p-carotene. 
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Stratified analyses for men and women disclosed clear gender differences (Table 4). 
For men, none of the antioxidants seems to be related to risk of silent MI, whereas in 
women for all three antioxidants an inverse trend could be detected. The highest 
quartile of vitamin e and ~-carotene showed a 90% reduction in risk of MI. For 
vitamin E a reduction of 70% was found. 
Table 4. Odds ratio (95% Cl) per quartile of amioxidant intake, stratified for gel/der 
Quartile 2 3 4 p-value 
(reference) for trend 
Men 
Vitamin C (mg/d) <79.5 79.5-106.8 106.8-137.8 >137.8 
no. of cases 10 14 6 16 
multiple! 1.0 1.5 (0.7-3.6) 0.6 (0.2-1.8) 1.8 (0.8-4.2) p=0.26 
Vitamin E (mg/d) <10.5 10.5-14.2 14.2-18.6 >18.6 
no. of cases II 11 14 10 
multiple' 1.0 1.1 (0.4-2.5) 1.3 (0.6-3.0) 1.0 (0.4-2.5) p=0.88 
~·Carotene(mg/d) <1.15 1.15-1.49 1.49-1.86 >1.86 
no. of cases 9 19 10 8 
multiple' 1.0 2.3 (1.0-5.2) 1.3 (0.5-3.3) 1.1 (0.4-3.0) p=0.7S 
'Vornen 
Vitamin C (mg/d) <85.3 85.3-113.0 113.0-143.1 >143.1 
no. of cases 16 16 9 2 
multiple! 1.0 0.9 (0.5-1.9) 0.5 (0.2-1.2) 0.1 (0.0-0.6) p<O.OI 
Vitamin E (mg/d) <8.7 8.7-11.8 11.8-15.9 >15.9 
no. of cases 13 14 12 4 
multiple! 1.0 1.2 (0.6-2.6) 0.9 (0.4-1.9) 0.3 (0.1-1.0) p=O,03 
p-Cal'otene(mg/d) <1.09 1.09-1.40 ·1.40-1.77 >1.77 
no. of cases 17 IS 9 2 
multiple' 1.0 0.9 (0.4-1.8) 0.6 (0.3-1.3) 0.1 (0.0-0.6) p<O.OI 
ladjusted for age, gender, smoking habits (current, fonner, never). systolic blood pressure, serum total 
cholesterol. 
In order to test if smoking had any influence on the association between antioxidant 
levels and risk of MI, we performed stratified analysis for smoking habits. Because of 
small numbers we calculated ORs in tertiles of antioxidant intake. ORs (95% eI) 
adjusted for age, gender, selUm total cholesterol and systolic blood pressure in smokers 
(30 silent MI subjects, 593 others) were 1.0, 1.2 (0.5-3.0), 1.2 (0.5-3.0) for vitamin e, 
1.0, 0.8 (0.3-2.0), 0.8 (0.3-2.0) for vitamin E and 1.0, 1.9 (0.8-4.5), 0.7(0.2-2.1) for 
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~-carotene, respectively. In the never and ex-smokers group the ORs were 1.0, 0.7 
(0.4-1.2),0.4 (0.2-0.8) (Ptre,d<O.OI) for vitamin C, 1.0, 1.0 (0.5-1.9), 0.8 (0.4-1.5) for 
vitamin E and 1.0, 1.2 (0.6-2.1), 0.5 (0.3-1.1) for ~-carotene. 
DISCUSSION 
In this study we investigated the relation between the risk of silent myocardial infarc-
tion and vitamin C, vitamin E and ~-carotene intake in a cross-sectional study. For 
vitamin C and vitamin E no clear decrease in risk in the higher intake groups could be 
observed. Beta-carotene intake showed a significant inverse trend with risk of silent 
MI. Stratified analysis in men and women showed inverse trends for vitamin C, 
vitamin E and ~-carotene in women only. 
To assess dietary intake of antioxidants we used a semi-quantitave food frequency 
questionaire. Food frequency questionaires are commonly used in epidemiological 
studies to measure diet over a longer period of time." Other dietary methods as recall 
methods and diet record methods can not give a good indication of usual diet and are 
less representative for past intake." By means of a food frequency questionaire ranking 
of subjects into high or low intake categories for specific nutrients is very well 
possible. In our questionaire 170 food items were included. The calculated daily intake 
were compatible with other Dutch data. By means of a two-day dietary record method 
among more than 6000 subjects devided into age and gender categories, slighly lower 
vitamin C and ~-carotene levels were found, whereas vitamin E levels were compa-
rable.23 In the Dutch part of the EURAMIC study among MI patients vitamin E levels 
were higher, albeit ~-carotene levels were lower as assessed by a written food frequen-
cy questionaire.24 
Assessment of dietary intake is prone to bias. Especially in cross-sectional and 
case-control studies the influence of changed dietary and lifestyle patterns and differen-
ces in recalling dietalY intake due to a manifest illness may occur. To overcome this 
bias we selected people with an ECG documented silent MI who were not aware of 
their illness and therefore had not yet changed their lifestyle or diet. This assumption 
seems justifiable, because comparison of the use of prescribed diets between the silent 
MI group and the group with typical MI (self-reported MI and ECG evidence for MI 
(n = 11 0)) in our population showed a significantly higher use of prescribed diets in 
the clinically diagnosed MI group (24% against 8% in the silent MI group). Of course, 
the possibility of changed dietary patterns due to physiological changes as a result of 
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the underlying illness cannot be excluded. Further, the low prevalence of prescribed 
diets, which is even lower than in the group without history of CVD, could be indica-
tive to a certain indifference towards personal health, which also may help explain why 
these subjects have missed or neglected symptoms of MI. 
Studies on antioxidants and risk of CVD comprise studies on dietary intake, 
plasma and serum levels and one study used adipose tissue levels to assess long term 
exposition to antioxidants. Plasma or adipose tissue levels can be used as a biomarker 
for dietary intake and may be more informative to assess the intemal dose, taking into 
account the variation in absorbtion and metabolism. A preventive effect of dietary 
and/or supplementruy vitamin E against CHD has been described in prospective 
studies,'-6 whereas prospective studies on plasma vitamin E did not reveal clear 
associations with CRD.'·25-27 In a case-control study an inverse association between 
plasma levels of vitamin E and risk of angina pectoris was reported." However, MI 
patients and controls did not differ in vitamin E content of adipose tissue.' In our study 
no relationship between vitamin E intake and risk of silent MI was found. Exclusion of 
supplement users did not change this result. The vitamin E intake in our study was 
high compared to levels in the US4., and Finland' and may be sufficiently high to 
achieve desirable plasma levels (230 ]lmoIlL) to prevent hru-mfull effects on CVD 
risk." 
Studies on the relation between MI and ~-carotene in adipose tissue,' between 
plasma levels and angina pectoris" and between serum levels'·"·27.30 and dietruy 
intake"" of ~-carotene and risk of CVD have shown inverse trends. Results from our 
study concur with the results from these case-control and cohort studies, but contradict 
data from recently published intervention studies on ~-carotene describing no effect or 
a slightly increased risk for CVD.IO-I2 It seems that the conclusion that a diet rich in 
~-carotene containing products is protective against CVD still stands, but that this 
effect may not exclusively be ascribed to ~-carotene. Other nutrients in these ~-carote­
ne containing foods or a combination of ~-carotene with another nutrient may explain 
this protective effect. 
An inverse con-elation between dietary vitamin C and risk of CRD has been found 
in NHANES I,' in a prospective study in Finland' and in men, but not in women, in 
the Scottish Herut Health Study." Patients with angina pectoris, however, had no lower 
plasma vitamin C levels than controls after con-ection for smoking" and, in two 
prospective studies, no inverse relation between vitamin C intake and risk of CHD was 
described.4•6 The results of our study are compatible with these last findings. For our 
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study and the latter ones, vitamin C intake could have been sufficiently large to 
minimize the risk of CVD. 
We performed an analysis stratified for gender, which showed a clear inverse 
association between vitamin C and ~-carotene and the risk of a silent MI in women 
only. We should, however, be careful in interpreting these results because the number 
of cases was small (46 men, 43 women). Differences in associations between men and 
women could be due to bias in the measurement of dietary intake. Possibly women are 
more aware about their diet, especially in this age category (55 years and over), in 
which it is likely that women do the cooking and hence will better estimate daily 
intake. However, we reduced this source of bias by means of verification of nutritional 
questionnaires by a dietician. Further, subjects with unreliable data were excluded from 
the analyses. Whereas atherosclerosis is a slow-moving process, dietruy intake in a 
period decades before the dietruy intelview could be of importance. A change in diet 
after retirement could have taken place, which is most likely to occur in men, as many 
women in this age categOlY were housewives. Our results describe an association in 
women only and thus are compatible with findings in the study of Knekt et al.,' 
whereas Kushi et al. did not find any association between antioxidants and CHD in a 
study among women6 and in the Scottish Heart Health Study this association was 
described in men and not in women.31 . 
In conclusion, our findings support a reduced risk of MI with higher ~-carotene 
intake, suggesting that a diet rich in ~-carotene containing foods may protect against 
CHD. Whether this is attributable to ~-carotene itself or to other nutrients in these 
foods needs to be further investigated. 
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Dietary intake of flavonoids is not related to risk of coro-
nary atherosclerosis: a case-control study 
ABSTRACT 
High flavonoid intake has been associated with decreased risk of coronary heart 
disease (CHD), possible through the antioxidative effect of flavonoids, which protects 
low-density lipoprotein from oxidation. We investigated this association in a case-
control study among men, 45-80 years of age. From subjects undergoing their first 
coronary angiography 82 cases with severe coronary atherosclerosis and 84 hospital 
controls with no or minor coronary atherosclerosis were selected. The hospital controls 
were pooled for statistical analysis with 73 population controls free of plaques in the 
carotid artery. Dietary intake of the flavonoids, quercetin, kaempferol and myricetin 
was assessed by means of a self-administered 105 item food frequency questionnaire 
assessing habitual antioxidant intake. 
Total flavonoid intake, or intake of a specific flavonol, did not differ between the 
case group and the control groups. Mean (± SO) daily flavonoid intake was 20.0 ± 1.8 
mgld for cases and 19.8 ± 1.3 mg/d for controls. Intake of flavonoids was positively 
associated with intake of vitamin C (r = 0.33, p<O.Ol) and P-carotene (r = 0.19, 
P = 0.02), whereas no association with vitamin E intake was found. No association was 
found between dietary flavonoid intake and risk of coronary atherosclerosis. The odds 
ratio (and 95% confidence interval) for the successive quartiles of total flavonoid 
intake were 1.0 (reference), 0.88 (0.40-1.93), 0.88 (0.39-1.95) and 1.08 (0.47-2.47) 
after adjustment for age, smoking and plasma cholesterol level. Further adjustment for 
other antioxidants had little impact on the results. 
We conclude that this study does not support a protective effect of a high intake of 
flavonoids on risk of coronary atherosclerosis. 
INTRODUCTION 
High intake of dietruy antioxidants can play a protective role against coronary heart 
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disease (CHD). Large prospective studies have reported preventive effects of vitamin 
C'·' and vitamin E.'-' Further, high plasma levels of vitamin E6 and p-carotene7 are 
associated with lower risk of ischaemic heart disease. Other antioxidants worthy of 
being considered are flavonoids, poly phenolic substances most abundantly present in 
tea, onions, wine and apples. In vitro, flavonoids are scavengers of oxidative agents' 
and can inhibit oxidation of low-density lipoproteins (LDL),"IO an important step in the 
atherogenic process." Further, flavonoids may have an antithrombotic effect through 
inhibition of platelet aggregation. 12 At present, few studies have investigated this 
association in vivo. TIle Zutphen Elderly Study, a Dutch cohort study, reported an 
inverse association between flavonoid intake and risk of CHD mortality." This inverse 
association was confirmed in a cross-sectional study in 16 cohorts14 and in a Finnish 
cohort study, 15 whereas no clear association was found in the prospective Health 
Professionals Study." 
We studied the association between flavonoid intake levels and risk of coronary 
atherosclerosis in a case-control study of men differing in degree of coronary athero-
sclerosis. 
SUBJECTS AND METHODS 
Study population 
The study was conducted in several hospitals and clinical centres in Rotterdam and 
Dordrecht, the Netherlands, in the period 1993-1995. The study was approved by an 
ethical committee on human research and all participants gave their informed consent. 
Detailed information on selection procedures have been described elsewhere. 17 In short, 
cases with severe coronary atherosclerosis and hospital controls with no or minor 
coronary atherosclerosis were selected from patients undergoing their first coronary 
angiography. Cases had at least 85% stenosis in one and at least 50% stenosis in a 
second of the three major coronary vessels. Hospital controls had less than 50% 
stenosis in no more than two of the three major coronary vessels. The percentage of 
stenosis was scored by the cardiologist performing the angiography. Further, a group of 
population controls without symptomatic cardiovascular disease (CVD) was selected 
from participants in the Rotterdam Study, a population-based prospective cohort study" 
and through an advertisement in a local newspaper. Of this latter group, subjects were 
included only after echographical confirmation that the carotid artery was free of 
plaques. Enrolment procedures allowed for similar distributions of age (in 5-year 
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categories) and smoking habits (smoking, non-smoking). 
All subjects were men between 45 and 80 years of age. Exclusion criteria were; 
use of HMO-CoA reductase inhibitors; diabetes mellitus; liver, kidney or thyroid 
disease; alcohol or drug abuse; vegetarian diet; and psychiatric complaints. The study 
population consisted of 92 cases, 95 hospital controls and 85 popUlation controls. 
Data collectioll 
For the hospital groups information on medical history was obtained from the medical 
files and through a questionnaire within 2 months after angiography. Information on 
dietary, smoking and drinking patterns, medicine use, use of vitamin supplements, 
occupation and family history of CVD was obtained. Weight, height and blood 
pressure were measured. 
Food jreqllellcy qllestiOllllaire 
Dietary intake of the flavonoids quercetin, myricetin and kaempferol, vitamin E, 
vitamin C and p-carotene was assessed by means of a self-administered 105 item semi-
quantitative food frequency questionnaire, asking the habitual consumption patterns 
over the past year. The questionnaire was a modified version of the food frequency 
questionnaire used to assess antioxidant intake in the Dutch part of the Euramic 
study.19 To estimate flavonoid intake, extra items were included. Selection of these 
items was based on flavonoid content of specific food items reported by Hertog et 
al.20•21 and the frequency of use of these items in the Dutch population." To the 
original questionnaire items were added on consumption of onions, tea (including a 
question on type of tea and use of tea bags or loose tea leaves) and apples (pared or 
unpared). 
Frequency of consumption was reported in 8 categories: never, rarely, once a 
month, I day every 2-3 weeks, 1 day every week, 2-3 days a week, 4-5 days a week, 
6-7 days a week. The numbers of servings were quantified by the subject in ordinary 
household measures (spoons, cups, slices). Items processed in a meal and, therefore, 
difficult to quantify on an individual level were quantified per meal for the whole 
family. Individual levels were calculated by dividing the total amount per meal over 
the number of family members (children under 13 were counted for 0.5). Completeness 
and reliability of the questionnaire based on reported frequency of consumption, and 
credibility of reported number of servings was checked. Intake of antioxidants and 
linoleic acid was calculated with a computerized version of the Dutch Food Composi-
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tion Table,23 completed with a table for flavonoids.20•21 The questionnaire was not 
specifically designed to calculate linoleic acid. However, since impOltant sources of 
vitamin E and linoleic acid are largely the same foods, the questionnaire was conside-
red good enough to obtain an adequate ranking of subjects according to intake. 
On the basis of judgement by the investigators 15 subjects were excluded from the 
analysis due to unreliability of reported dietary data. A missing on one item was 
handled as follows. Depending on the contribution of an item to a specific antioxidant, 
the subject was excluded for analyses of this antioxidant. For instance, a missing on 
mayonnaise resulted in exclusion for vitamin E, but not for the other antioxidants. 
Depending on the missing item(s) extra subjects were excluded from analysis of flavo-
noids (n = 6; 3 cases, 2 hospital controls and 1 population control), vitamin C (n = 2; 
2 cases), vitamin E (n = 4; 1 case and 3 hospital controls) and ~-caroteue (n = 2; 1 
case and 1 hospital control). 
Statistical analysis 
Characteristics of the case group and the control groups were compared with Student's 
t-test for unpaired samples. Because the two control groups were comparable regarding 
lipid levels, age and smoking status, an increase in statistical power was obtained by 
pooling the two control groups for data analysis. Age-adjusted means were compared 
by analysis of covariance. Log transformations were performed to compare non-
normally distributed variables. Pearson X2 analysis was applied for class variables. 
Correlations were calculated by Pearson correlation coefficients. Odds ratios (ORs) 
were calculated to quantify the association between dietary antioxidant intake and 
coronary atherosclerosis. Quartile distributions for calculation of ORs were based on 
distribution of intake in the control group. Confounding factors taken into account 
were; body mass index (BMI), total, high-density lipoprotein (HDL) and LDL choleste-
rol, diastolic and systolic blood pressure, diet use, medicine use and dietary fibre 
intake. Data analysis was conducted with the statistical package BMDP.33 
RESULTS 
Characteristics of the study population are presented in Table 1. No differences were 
seen for age, smoking status, body mass index (BMI), systolic and diastolic blood 
pressure. Total cholesterol, LDL-cholesterol and triglyceride levels were significantly 
lower and HDL-cholesterol was significantly higher in controls. Cases reported more 
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frequently the use of antihypertensive medication (92% in cases vs. 44% in controls), 
lipid-lowering medication (6% vs. 1%), aspirin + coumarin derivatives (93% vs. 21%) 
and a history of myocardial infarction (39% vs. 5%). Groups did not differ signifi-
cantly in frequency of a special diet. 
Table 1. Characteristics of the study population, mean ± SD 
Age (years) 
Smokers (%)! 
Ex~smokers (%)' 
Body mass index (kg/m') 
Total cholesterol (mmoVI) 
Triglycerides (mmoVI) 
HDL-cholesterol (mmoVI) 
LDL-cholesterol (mmoVl) 
Systolic blood pressure (mmHg) 
Diastolic blood pressure (mmHg) 
Cases (n~85) 
60.8 ± 9.1 
34.1 
50.6 
26.3 ± 2.5 
6.1±1.1 
2.1 ± 0.9 
0.9 ± 0.2 
4.3 ± 1.1 
132.4 ± 16.8 
81.4 ± 8.2 
Controls (n~160) 
60.2 ± 8.3 
29.4 
53.1 
26.2 ± 3.3 
5.5±1.0' 
1.7 ± 0.9 • 
1.0 ± 0.3 • 
3.8 ± 1.0 • 
135.2 ± 16.9 
83.5 ± 8.5 
lex-smokers stopped smoking more than one year ago; othenvise they are categorized as current 
smokers. *p<O.O 1. 
Table 2 lists mean dietary antioxidant levels in both groups. Mean dietary intake of 
flavonoids did not differ between the two groups. Intake levels ranged from 0.7 to 96.2 
mg/d. With respect to the other antioxidants, the absolute intake of vitamin C was 
higher in controls, although the difference did not reach significance. No differences 
were seen foJ' ~-carotene and vitamin E, whereas the vitamin Ellinoleic acid ratio was 
significantly higher in cases. 
Table 2. Antioxidant intake levels, mean ± SEM 
Cases (n~85) Controls (n~160) p-value§ 
Flavonoids (mg)' 20.0 ± 1.8 19.8 ± 1.3 0.88 
Quercetin (mg)! 12.0 ± 1.0 12.2 ± 0.8 0.78 
Kaempferol (mr)! 6.7 ± 0.7 6.4 ± 0.4 0.92 Myricetin (mg) 1.3 ± 0.2 1.2 ± 0.1 0.37 
Vitamin C (mg)2 115.0 ± 4.9 135.5 ± 6.0 0.12 
Beta-carotene (mg)3 1.2 ± 0.1 1.3 ± 0.1 0.42 
Vitamin E (mg)4 16.4 ± 0.8 16.3 ± 0.7 0.88 
Vitamin Fllinoleic acid4 0.93 ± 0.02 1.03 ± 0.02 <0.01 
Iflavonoids= quercetin + keampferol + myricetin (82 cases, 157 controls). 283 cases. 384 cases, 159 
controls. 4 84 cases, 157 controls. §ageMadjusted difference on logMtransformed data. 
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Dietruy intake of flavonoids was not associated with dietruy vitamin E intake 
(1' = -0.06). The cOITelation coefficients of flavonoid intake with vitamin C, ~-cru'otene 
and fibre intake were 0.33 (p < 0.01), 0.19 (p = 0.02) and 0.20 (p = 0.01), respective-
ly. 
Table 3. Odds ratios (95% confidence interval) for risk of coronary atherosclerosis per quartile of 
flavonoid intake 
II JII IV 
(reference) 
Total flavonoids (mg)' 0.7-8.8 8.8-16.5 16.5-27.7 ~27.7 
number of cases 22 20 20 20 
age-adjusted 1.0 0.91 (0.43-1.93) 0.87 (0.41-1.86) 0.88 (0.41-1.91) 
multivariate2 1.0 0.88 (0.40-1.93) 0.88 (0.39-1.95) 1.08 (0.47-2.47) 
Quercetin (mg) 0.3-5.2 5.2-9.9 9.9-16.5 ~16.5 
number of cases 17 26 19 20 
age-adjusted 1.0 1.48 (0.70·3.17) 1.11 (0.50-2.47) 1.15 (0.52-2.58) 
multivariate 1.0 1.63 (0.73-3.63) 1.18 (0.51-2.71) 1.43 (0.61-3.38) 
Kaempferol (mg) 0.1-2.3 2.3-4.5 4.5-9.1 ~9.1 
number of cases 17 18 28 19 
age-adjusted 1.0 1.05 (0.47-2.35) 1.55 (0.73-3.31) 1.13 (0.50-2.56) 
multivariate 1.0 1.03 (0.45-2.40) 1.71 (0.77-3.80) 1.45 (0.60-3.50) 
Myricetin (mg) 0-0.2 0.2-0.8 0.8-1.6 ~1.6 
number of cases 16 19 31 16 
age-adjusted 1.0 1.18 (0.53-2.66) 1.62 (0.76-3.45) 1.04 (0.44-2.44) 
multivariate 1.0 1.05 (0.45-2.46) 1.77 (0.80-3.89) 1.28 (0.52-3.16) 
[flavonoids= quercetin + keampferol + myricetin, 2adjusted for age, smoking status, plasma total 
cholesterol. 
Table 3 presents ORs (and 95% confidence interval) for the risk of coronruy athero-
sclerosis per qurutile of flavonoid intake. No effect of total flavonoids or one of the 
specific flavonoids was detected. Further adjustment for the prestratification vru'iables 
age and smoking status and total cholesterol had only a minor influences on the ORs 
(Table 3). No interaction was observed with smoking status or antioxidant levels. ORs 
calculated after additional adjustment for vitamin E, vitamin C and p-carotene were 1.0 
(reference), 0.84 (0.37-1.93), 0.96 (0.41-2.27) and 1.11 (0.45-2.72) for the successive 
qurutiles of total flavonoid intake. 
In the results presented in Tables 1-3, hospital and population controls were pooled 
for statistical analyses. We also calculated the ORs for the control groups separately. 
Qurutiles were defined on the basis of the distribution in the respective control groups. 
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The ORs for comparison of the highest to the lowest quartile of total flavonoid intake 
were 1.68 (0.64-4.44) and 0.97 (0.36-2.58) for comparison with hospital controls and 
population controls, respectively. 
DISCUSSION 
The results of this case-control study did not confirm the hypothesis that a high intake 
of flavonoids reduces the risk of coronary atherosclerosis. 
Flavonoid intake as assessed in our study was lower than the levels in the Zutphen 
Elderly Study (mean ± SO of 26.6 ± 13.2)13 and the Netherlands Cohort Study, a 
prospective study on cancer." In our study quercetin made up 61 % of the flavonoids. 
This percentage is comparable with that reported by Hertog et al. (63%). We calculated 
dietary intake of the three major flavonoids: the flavonols quercetin, kaempferol and 
myricetin. Another group of flavonoids, the flavones apigenin and luteolin, were not 
taken into account. This may have resulted in an underestimation, but, the most impor-
tant sources of apigenin, celery," parsley and thyme,'6 are no major contributors to 
flavonoid intake in the Netherlands." Further, differences in assessment of dietary 
intake may have resulted in differences in intake levels. 
Assessment of dietary intake, especially in a case-control study, is prone to bias. 
To overcome this problem we used two control groups, a group of hospital controls 
and a group of population controls. Because hospital controls underwent coronary 
angiography because of suspected CHO, cases and hospital controls will have been 
equally prone to bias caused by differences in recalling dietary intake. Calculation of 
the OR for coronary atherosclerosis for the separate control groups yielded similar 
results as those for the pooled control group, which leads to the conclusion that recall 
bias has not influenced the results. 
The use of a biomarker for flavonoid intake would decrease the chance of potential 
bias. At present not much is known about the absorption of flavonoids in human 
beings. Hollman et al. recently reported an uptake of 52% of quercetin in onions.'6 In 
cooperation with Hollman, flavonoid compounds were measured in fasting plasma 
samples collected in our study. Fasting flavonoid levels appeared to be very low and 
barely exceeded the detection level. Because plasma flavonoid levels can give only a 
short -term impression of intake, it is not an useful tool for assessing usual intake. 
To date only four studies have reported on the association between dietary 
flavonoid intake and risk of CHO. In the Zutphen Elderly Study an inverse association 
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between intake of flavonoids and risk of coronary death was found after a follow-up of 
5 years. The association between flavonoid intake and incidence of myocardial 
infarction (MI) failed to reach significance." An ecological study in 16 cohorts of the 
Seven Country Study confirmed the inverse association between flavonoid intake and 
CHD mortality. The mean intake levels in the cohorts varied from 2.6 mgld to 68.2 
mgld. 14 Results from ecological studies, however, should be interpreted with caution 
because cross-cultural differences may confound the association. In a Finnish cohort 
study among 2748 men and 2385 women, a significant inverse association was seen 
for coromuy mortality in women, whereas in men the association did not reach 
significance. After fUliher adjustment for other antioxidants and fatty acids associations 
were no longer significant in women. The mean flavonoid intake reported in this 
Finnish COh01i was 3.4 mgld, substantially lower than values seen in the Netherlands. ls 
Results from the US Health Professionals Study showed no association between 
flavonoid intake and non-fatal MI after a 6 year fOllow-up. The average intake in this 
study was 20.1 mgld. 16 
Rimm et al. suggested in their discussion that a high flavonoid intake seems to be 
associated with a decreased risk of coronary mortality only. This may point to a 
specific effect of flavonoids on thrombosis.16 Data from our study support this 
suggestion, as no association was found with prevalent coronary atherosclerosis. 
In conclusion, this study among cases with severe coronary atherosclerosis and 
controls with no or minor atherosclerosis did not reveal an association with flavonoid 
intake. 
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Epilogue 
Almost four years have passed since I struted this study on the relationship between 
the susceptibility of low-density lipoprotein (LDL) to oxidation and risk of 
atherosclerosis. The hypothesis that oxidation of LDL plays a role in the atherogenic 
process in men was mainly based on ill vitro studies. Few studies had shown that LDL 
oxidati<!n occurs ill vivo,'-3 and no studies were available to relate LDL oxidation to 
cardiovascular risk. This motivated the studies presented in this thesis. In summary, 
our work does not provide strong evidence for the susceptibility of LDL to oxidation 
to be associated with atherosclerosis, which may indicate that LDL oxidation plays no 
or a less impOltant role in atherosclerosis. The association between LDL oxidation and 
risk of coronary atherosclerosis was weak and not statistically significant. However, 
resistance time to oxidation appears to be positively associated with risk of peripheral 
atherosclerosis. 
That we could not disclose an association between susceptibility of LDL to oxida-
tion and risk of coronary atherosclerosis in our studies is unlikely to be due to the 
design of the study. The sample size was larger than those in other recently reported 
studies which did suggest an increased susceptibility of LDL to oxidation,"" and the 
contrast in atherosclerotic coronary artery disease between our groups should be suffi-
ciently high to reveal an association. Possibly, the measurement of susceptibility of 
LDL to oxidation by monitoring diene production ex vivo after incubating isolated 
LDL under strong pro-oxidant conditions, i.e. using eu'+ ions, does not reflect the ill 
vivo situation. III vivo the oxidative process is not only influenced by composition and 
structure of the LDL particle itself, but is part of a larger mechanism in which plasma 
antioxidants and cell constituents also play a role. Therefore, as a measure of LDL 
oxidation ill vivo, autoantibody titres against oxidized forms of LDL were measured in 
a smaller case-control study. This study, again, did not reveal an association between 
autoantibody titres and severity of coronary atherosclerosis. Although the contrast 
between cases and controls was smaller than in the case-control study on susceptibility 
of LDL to oxidation, these results indicate that autoantibody titres do not strongly 
reflect the atherosclerotic process and are not suppOltive of a marked role for LDL 
oxidation in the atherogenic process. As we studied atherosclerosis exclusively, a 
possible role of oxidation of LDL in other processes related to the development of 
coronary heart disease, such as the process of thrombosis or an influence on the sus-
ceptibility to .ischemia can not be excluded. 
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A rather indirect way of measuring the possible role of LDL oxidation in the 
atherosclerotic process is by measuring antioxidant status. High levels of antioxidants 
may, through inhibition of LDL oxidation, decrease the risk of coronary 
atherosclerosis. The results form our study on LDL antioxidants did not support this 
hypothesis. Unexpectedly, higher LDL tocopherol levels were found in cases which 
may indicate that tocopherol metabolism changes as a result of the disease status. 
Therefore, metabolic and genetic differences among individuals, and perhaps between 
subjects susceptible and those not or less susceptible to cardiovascular disease; should 
be further elucidated. 
The study on LDL and plasma antioxidants made clear that only small differences 
in antioxidant levels and LDL fatty acid composition occurred between our cases and 
controls, which may have had an effect on the small differences in the oxidation 
parameters. However, we did not find a correlation between antioxidant levels and 
oxidation parameters, whereas fatty acid composition tinned out to' be an important 
determinant of the maximum rate of oxidation. Thus far, most data on the influence of 
antioxidants and fatty acid composition on susceptibility of LDL to oxidation are based 
on intervention studies.'" Concerning antioxidants, supplementation with a-tocopherol 
has been shown to decrease susceptibility of LDL to oxidation.' This effect is ah'eady 
reached at a low dose (25 IU/d),' however, this dose is still twice as high as the daily 
recommended intake for a-tocopherol. These studies and results from our study indi-
cate that in an unsupplemented population the variation in antioxidant levels is not 
sufficiently high to be reflected in differences in susceptibility of LDL to oxidation ex 
vivo. A threshold level for tocopherol has been suggested above which tocopherol can 
actually decrease susceptibility of LDL to oxidation.' Below this treshold other factors, 
such as fatty acid composition, may determine susceptibility of LDL to oxidation. 
Whether this will also have an effect on oxidation ill vivo is unknown yet. 
In observational studies, a beneficial effect has been described at high levels of 
antioxidant intake, often through supplementation. This association is most convincing 
for vitamin E 10.11.,,,,,,, 1 In our study on coronary atherosclerosis and susceptibility of 
LDL to oxidation no differences in dietary antioxidant intake between cases and 
controls were found. In our analysis in data from the Rotterdam Study we found a 
reduced risk of silent myocardial infarction at high intake levels of ~-carotene. Recall 
bias is absent or limited in both studies. In the Rotterdam Study patients were not 
aware of their disease status, and in the LDL oxidation study no differences were 
found irrespective of whether cases were compared to hospital controls or to popula-
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tion controls. 
The results from our studies and from other observational studies give no clear 
indication which antioxidant may be a marker or cause of disease under 
unsupplemented conditions. With a few exceptions, findings in randomized trials on 
vitamin E, ~-carotene and vitamin C did not support the view that supplementation 
with a specific antioxidant or a combination of antioxidants decreases the risk of 
CHD,IO,ll,chapter 1 
The discrepancy between results from observational studies on diet and CHD risk 
and those of intervention studies could imply that the protective effects of antioxidants 
may not be ascribed to the antioxidant alone, but rather to other compounds or a 
combination of compounds in foods rich in antioxidants. This seems especially tme for 
~-carotene. Therefore, in future studies emphasis should be placed on foods instead of 
nutrients, to find out which foods may help to protect against CHD. Another cause of 
the discrepancy might be that a high consumption of fmit and vegetables is a marker 
for differences in life-style. A more 'healthy' behaviour in subjects with a high intake 
of fmits and vegetables may have resulted in an inverse association between a high 
intake of antioxidants and risk of CHD. 
The results from our studies do not indicate that high doses of specific nutrients 
are necessary to reduce the risk of atherosclerosis. Antioxidant supplementation may 
have an effect on LDL oxidation, but the importance of LDL oxidation in risk of 
atherosclerosis is not convincing. Other factors seem to playa more prominent role in 
determining which subject has an increased risk of developing atherosclerosis. 
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Summary 
In the studies presented in this thesis we tested the hypothesis that oxidation of low-
density lipoproteins (LDL) increases the risk of atherosclerosis and that antioxidants 
protect against coronary heart disease (CHD), possibly through inhibition of LDL 
oxidation. 
CHD is the major cause of death in most industrialized countries. To reduce 
mortality and morbidity from CHD, more insight into the process of atherosclerosis is 
necessary. During the atherogenic process cholesterol and other lipids accumulate in 
the arterial wall, which may cause partial or complete obstruction of the lumen of the 
blood vessel. A high level of cholesterol, especially LDL-cholesterol, is a major risk 
factor for atherosclerosis. A current hypothesis is that the LDL particle becomes even 
more atherogenic after it has been chemically altered by free radicals and is recognized 
by the 'scavenger receptor' on the macrophages. This results in accelerated uptake of 
cholesterol into macrophages in the vessel wall, which is the beginning of the fatty 
streak. Protection of LDL, in particular protection of polyunsaturated fatty acids in 
LDL, against oxidation may be achieved by antioxidant defence. Several antioxidant 
enzymes, including the selenium-containing glutathione peroxidase, superoxide 
dismutase and catalase, and dietary antioxidants (vitamin E, vitamin C, p-carotene and 
possibly flavonoids) may have this protective effect. Epidemiological studies have not 
demonstrated unequivocally that a high intake of antioxidants decreases the risk of 
CHD. Studies on dietary intake and serum levels of antioxidants do point to a preven-
tive effect, whereas results from intervention studies are less conclusive (Chapter I). 
Several studies have reported seasonal fluctuation in antioxidant levels. Fluctu-
ations in antioxidants may be reflected in differences in susceptibility to oxidation of 
LDL. We measured resistance time, i.e. the time until onset of LDL oxidation, and 
maximum rate of oxidation by monitoring ex vivo diene production after copper-
induced LDL oxidation. In a small experiment blood from 10 healthy free-living 
subjects was collected at 4 different time points over one year. No seasonal fluctuation 
in resistance time or maximum rate of oxidation was detected. Small differences were 
seen in determinants of LDL oxidation, including LDL particle size and vitamin E, 
lutein and p-carotene levels. No differences were seen in fatty acid composition, 
although this turned out to be the main determinant of oxidation susceptibility (Chapter 
2). 
To examine whether the susceptibility of LDL to oxidation plays a role in the 
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atherogenic process (Chapter 3), we performed a case-control study among men 45-80 
years of age. Three groups of subjects participated: a group of cases with 
angiographically diagnosed severe coronary atherosclerosis (n ~ 92), a group of hospi-
tal controls with no or minor coronary atherosclerosis according to coronary 
angiography (n ~ 95) and a group of population controls free of symptomatic 
cardiovascular disease and with the carotid artery free of plaques (n ~ 86). For the 
analyses we pooled the two control groups. To test the hypothesis that susceptibility of 
LDL to oxidation is elevated in patients with severe coronary atherosclerosis, we 
measured resistance time and maximum rate of oxidation. Resistance time was inverse-
ly associated with risk of coronary atherosclerosis. However, the association was of 
borderline significance. No association was found with maximum rate of oxidation. 
Though resistance to oxidation may be a factor in atherogenesis, the ex vivo measure 
of LDL oxidation is no strong predictor of severity of coronary atherosclerosis (section 
3.1). 
In these participants also the ankle-arm blood pressure index was measured. The 
ratio of systolic blood pressure in the ankle divided by systolic blood pressure in the 
arm can be used as a' measure of peripheral atherosclerosis. The lowest of the ankle-
arm indices in both legs was used to categorize subjects into groups with and without 
peripheral atherosclerosis. The study population consisted of 39 men with (ankle-arm 
index < 1.00) and 210 men without (ankle arm index 2 1.00) peripheral 
atherosclerosis. A strong inverse association between resistance time and risk of 
peripheral atherosclerosis was present, suggesting that patients with peripheral 
atherosclerosis are more susceptible to LDL oxidation than subjects without peripheral 
atherosclerosis (section 3.2). 
Oxidatively modified LDL has immunogenic properties and has the ability to 
induce the formation of autoantibodies. We measured autoantibody titres as an ill vivo 
measure of LDL oxidation in a sub-study among men and women 26-68 years of age. 
A group of cases with angiographically detected severe coronary atherosclerosis 
(n ~ 47), a group of hospital controls with no or minor atherosclerosis (n~47) and a 
group of healthy population controls (n ~ 49) were selected. No association was found 
between autoantibody titre and atherosclerosis. From our results and results from other 
studies we conclude that autoantibodies are not related to chronic atheriosclerotic 
arterial disease although they may play a part at a certain stage of the disease process 
(section 3.3). 
High plasma or LDL antioxidant levels have been hypothesized to decrease the 
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susceptibility of LDL to oxidation, thereby potentially decreasing the risk of CHD. In 
the case-control study on LDL oxidation and coronary atherosclerosis, antioxidant 
levels within the LDL particle and plasma vitamin C levels were measured to assess 
the association between antioxidant levels and risk of coronary atherosclerosis. In 
general, no relation of LDL antioxidant levels with risk of coronary atherosclerosis 
was detected. Marginally decreased risks were seen for high LDL a-carotene and LDL 
lutein/zeaxanthin levels. Unexpectedly, a positive association between LDL tocopherol 
levels and risk of coronary atherosclerosis was found. The associations between anti-
oxidants and coronary atherosclerosis could not be ascribed to inhibition of LDL 
oxidation (section 4.1). 
In a sub-sample of participants in this case-control study, consisting of 70 cases 
and 70 population controls, we assessed plasma levels of the antioxidant Coenzyme 
QIO' III vitro a marked antioxidative potential is ascribed to Coenzyme QIO' No differ-
ences were seen in Coenzyme QIO levels between the two groups, making us conclude 
that the protective effect of Coenzyme QIO is not reached at levels present under 
normal, un supplemented conditions (section 4.2). 
To study the association between antioxidant intake and risk of CHD we studied 
baseline dietary data from the Rotterdam Study, a prospective cohort study among men 
and women aged 55 and over. A group of 89 subjects who had undergone a silent 
myocardial infarction (MI), defined as 'ECG evidence of MI without medical informa-
tion or self-reported history of MI', were selected. These subjects with CHD are not 
aware of their disease status and therefore changes in dietary or life-style patterns can 
be excluded. Comparison of this group with the baseline population without 
cardiovascular disease (n = 2333) revealed an inverse association between intake of [3-
carotene and risk of silent MI. The associations were most pronounced in women 
(section 5.1). 
In addition to LDL antioxidant levels, we estimated dietary intake of antioxidants 
in the case-control study on LDL oxidation by means of a self-administered food 
frequency questionnaire in which the habitual antioxidant intake in the previous year 
was asked. In this study we paid special attention to the intake of flavonoids, which 
are polyphenolic substances commonly present in fruit and vegetables. No difference 
in dietary intake of flavonoids or other antioxidants was seen between the cases with 
severe coronary atherosclerosis and the pooled control groups (section 5.2). 
In the studies described in this thesis we were not able to find support for our 
main hypothesis that susceptibility of LDL to oxidation plays an important role in the 
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atherogenic process. Possibly, the method of measuring LDL oxidation ex vivo is not 
an adequate parameter. However, LDL oxidation measurement ill vivo by means of 
autoantibodies gave the same result. With respect to antioxidants, no clear protective 
effect of antioxidants in LDL or plasma was detected, whereas dietary antioxidants 
gave inconclusive results with respect to the question which antioxidant may be 
important. Further, it is not clear whether the antioxidant intake levels itself, or rather 
an overall healthy life-style, is responsible for the observed associations. Therefore, the 
results of our study and from other observational and intervention studies, do not 
support a general advice in favour of supplementation with antioxidants. A dietary 
pattern with ample food rich in antioxidants (e.g. fruit and vegetables) is still to be 
recommended. 
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In de studies beschreven in dit proefschrift hebben we de hypothese onderzocht of 
oxidatie van lage-dichtheidslipoproterne (transportdeeltjes voor cholesterol in het bloed) 
het risico op hart- en vaatziekte verhoogt. Antioxidanten zoals vitamine E, vitamine C 
en ~-caroteen kunnen deze chemische omzetting mogelijk voorkomen of ve11ragen. 
Hart- en vaatziekte (HVZ) is de belangrijkste doodsoorzaak in de meeste gerndus-
trialiseerde landen. Om het risico op ziekte en sterfte als gevolg van HVZ te verlagen 
is het belangrijk inzicht te krijgen in het proces van atherosclerose ('aderverkalking'). 
Tijdens het atherosclerotisch proces stapelen cholesterol en andere vetachtige 
substanties zich op in de wand van de bloedvaten. Hierdoor kan het bloedvat gedeel-
telijk of helemaal geblokkeerd worden, waardoor de bloeddoorstroming wordt 
gehinderd. Hoge cholesterol niveaus in het bloed, vooral hoge hoeveelheden van het 
'slechte cholesterol', het lage-dichtheidslipoproterne (LDL), vormen een belangrijke 
risico-factor voor atherosclerose. De huidige idee is dat het LDL-deeltje nog een groter 
risico voor HVZ vormt op het moment dat het deeltje geoxideerd is. Deze oxidatie 
vindt plaats onder invloed van 'vrije radicalen', reactieve deeltjes die in het Iichaam 
voorkomen. In de vaatwand wordt cholesterol uit het LDL-deeltje afgegeven aan 
macrofagen. Voor afgifte van cholesterol aan de macrofagen moet een koppeling 
plaatsvinden tussen het LDL-deeltje en de macrofaag. Daartoe bevinden zich op het 
ontvangende deeltje receptoren. Dit zijn stl1lcturen die herkend worden door het LDL 
en waar het LDL op past zoals een sleutel op een slot. Na oxidatie wordt het LDL 
herkend door een andere receptor op de macrofagen. Door de koppeling aan deze 
zogenaamde 'scavenger receptor' wordt de afgifte van cholesterol aan de macrofaag 
versneld, resulterend in een versnelde stapeling van cholesterol-geladen macrofagen 
(schuimcellen) in de vaatwand. Deze opstapeling van schuimcellen is het begin van het 
atherosclerotisch proces en het begin van de plaques. Antioxidanten knnnen het LDL, 
of meer in het bijzonder kunnen de meervoudig-onverzadigde vetzuurketens in het 
LDL, beschermen tegen oxidatie. In ons Iichaam komen van nature antioxidant-
enzymen voor, zoals superoxide dismutase, het selenium-bevattende glutathion 
peroxidase en catalase. Andere antioxidanten komen via de voeding binnen. Dit zijn de 
antioxidant-vitamines vitamine E (tocoferol), vitamine C en ~-caroteen (pro-vitamine 
A), maar mogelijk kunnen ook andere carotenoiden of andere stoffen zoals flavonorden 
antioxidatief werken. Epidemiologische studies hebben nog niet eenduidig aangetoond 
dat een hoge inneming van antioxidanten tot een verlaging van het risico op HVZ 
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leidt. Studies naar inneming en bloedniveaus van antioxidanten wijzen wei in de 
richting van een beschermend effect, echter resultaten van interventiestudies waarin 
mensen voor langere tijd supplementen gebruiken laten een minder duidelijk effect 
zien (Hoofdstuk I). 
De mate van oxidatie van LDL kan op verschillende manieren worden bepaald. 
Wij hebben gevoeligheid van LDL voor oxidatie gemeten met behulp van een ex vivo 
(buiten het lichaam) bepaling. Aan een buisje gelsoleerd LDL wordt koper (Cu2+) 
toegevoegd. Dit en2+ is een sterke pro-oxidant en zorgt er voor dat LDL gaat oxideren. 
Afhankelijk van de antioxidantbescherming van het LDL zal de tijd die verstrijkt 
tussen toevoegen van Cu2+ en de daadwerkelijke aanvang van de oxidatie verschillen. 
Deze periode wordt de resistentie-tijd genoemd. Ook de snelheid waarmee de oxidatie 
verloopt kan verschillen. De maximale snelheid van oxidatie wordt ook gebruikt als 
maat voor oxidatie-gevoeligheid. 
In hoofdstuk 2 is een studie gepresenteerd waarin gekeken is of oxidatie-
gevoeligheid van LDL varieert gedurende het jaar. Vit verschillende studies is 
gebleken dat er een seizoensvariatie in antioxidant-niveaus bestaat. Ben fluctuatie van 
antioxidant-niveaus zou als gevolg kunnen hebben dat de oxidatie-gevoeligheid van het 
LDL ook belnvloed wordt door het moment van bloedafname. In een klein experiment 
bij 10 gezonde vrijwilligers is de oxidatie-gevoeligheid van het LDL gemeten in 4 
periodes over een jaar. Er bleek geen seizoensvariatie in resistentie-tijd of maximale 
oxidatie-snelheid te zijn. Wei werden kleine verschillen gevonden in determinanten die 
de oxidatie-gevoeligheid bepalen. De deeltjesgrootte fluctueerde, evenals vitamine E, 
lutelne en p-caroteen' niveaus. De vetzuursamenstelling van het LDL liet geen 
seizoensvariatie zien. Dit bleek wei een belangrijke factor die de snelheid van oxidatie 
belnvloedt. 
Om na te gaan of de oxidatie-gevoeligheid van LDL een rol speelt in het proces 
van atherosclerose (hoofdstuk 3), hebben wij een patient-controle onderzoek uitgevoerd 
bij mannen tussen de 45-80 jaar. Drie groepen deeinemers zijn geselecteerd. Ben groep 
patienten met emstige coronaire atherosclerose (aderverkalking rond het hart) (n - 92) 
en een groep ziekenhuiscontroles met geen of minimale coronaire atherosclerose 
(n - 95) zijn geselecteerd op basis van catheterisatieverslagen. Verder is een groep 
populatiecontroles geselecteerd (n - 86) uit deeinemers aan het ERGO-onderzoek, een 
prospectief vervolgonderzoek uitgevoerd in Rotterdam bij mannen en vrouwen van 55 
jaar en ouder, en via een advertentie in een locale krant. Van deze deelnemers was 
bekend dat ze geen atherosclerose in de halsslagader en geen symptomatische HVZ 
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hadden. Voor de statistische analyses zijn de twee controlegroepen samengevoegd. Om 
te testen of de oxidatie-gevoeligheid van patienten hoger is dan die van controles is de 
resistentie-tijd en de maximale oxidatiesnelheid tussen patienten en controles 
vergeleken. De resistentie-tijd was invers geassocieerd (hoe hoger de resistentie-tijd 
hoe lager de kans op coronair atherosclerose). Dit verband was echter net niet signifi-
cant. Geen associatie werd gevonden met de maximale oxidatiesnelheid. Alhoewel uit 
deze resultaten blijkt dat de resistentie-tijd mogelijk wei een verband houdt met het 
risico op HVZ, is het verband in ieder geval niet duidelijk. Dit zou erop kunnen wijzen 
dat de oxidatie-gevoeligheidsmeting door middel van een ex vivo maat geen goede 
weerslag geeft van de processen die zich ill vivo afspelen (paragraaf 3.1). 
Bij de deeinemers van deze studie is ook de enkel-arm bloeddruk index bepaald. 
De ratio van de systole bloeddruk in de enkel gedeeld door de systole bloeddruk van 
de arm kan gebruikt worden als een maat voor perifere atherosclerose (aderverkalking 
in de benen). De deeinemers zijn heringedeeld op basis van de laagste ratio gemeten 
aan de linker- of rechterzijde van het lichaam. Negenendertig maunen met perifeer 
atherosclerose (een enkel-arm index lager dau 1.00) zijn vergeleken met 210 maunen 
zonder perifeer atherosclerose (enkel-arm index groter of gelijk aan 1.00). Ben sterk 
inverse associatie werd gevonden tussen de resistentie-tijd en het risico op perifere 
atherosc1erose, hetgeen een aauwijzing geeft dat mensen met perifere atherosclerose 
meer gevoelig zijn voor oxidatie (paragraaf 3.2). 
Oxidatief verauderde LDL-deeltjes hebben een immunogene werking, wat betekent 
dat ze de productie vau antilichamen kunnen induceren. De concentratie antilichamen 
in het bloed kau als een ill vivo maat vau LDL-oxidatie worden onderzocht. Wij 
hebben de concentratie van auto-autilichamen gevormd tegen MDA-gemodificeerd 
LDL gemeten in een patient-controle onderzoek onder maunen en vrouwen tussen de 
26 en 68 jaar. Met behulp vau catheterisatieverslagen zijn 47 patienten met emstige 
coronair atherosclerose en 47 ziekenhuiscontroles met matige atherosclerose 
geselecteerd. VerdeI' zijn 47 gezonde populatiecontroles geselecteerd. In bloed vau 
deze deeinemers is de auto-antilichaam titer bepaald. Wij vonden geen associatie met 
de concentratie auto-autilichamen en het risico op atherosclerose. Uit de resultaten vau 
onze studie en vau studies vau anderen hebben we geconc1udeerd dat de autilichaam-
concentratie niet direct gerelateerd is aau chronische atherosclerose, maar dat het meer 
een maat zou kunnen zijn voor een bepaalde fase in het atherosc1erotisch proces 
(paragraaf 3.3). 
Hoge autioxidantniveaus in plasma of in het LDL-deeltje zouden de gevoeligheid 
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van LDL voor oxidatie kunnen verminderen en op deze manier het risico op HVZ 
kleiner maken. In ons patient-controle onderzoek naar LDL-oxidatie en coronair athe-
rosclerose zijn de antioxidantniveaus in het LDL-deeltje en de plasma vitamine C 
niveaus gemeten om de associatie tussen antioxidanten en het risico op coronair 
atherosclerose te meten. Uit dit onderzoek werden geen duidelijke verbanden 
gevonden. Ben matige verlaging van het risico op coronair atherosclerose trad op bij 
hogere concentraties a-caroteen en lutelne/zeaxanthine concentraties in het LDL. Tegen 
de verwachting in vonden wij een positief verband tussen de hoeveeIheid LDL-tocofe-
rol en het risico op atherosclerose. Het verband tussen de antioxidanten en coronair 
atherosclerose kon niet toegeschreven worden aan het remmende effect van antioxi-
danten op de oxidatie van LDL (paragraaf 4.1). 
In 70 patienten en 70 populatie-controles die deelnamen aan het patient-controle 
onderzoek zijn plasmaniveaus van het antioxidant Coenzyme QIO bepaald. III vitro 
studies hebben een sterk antioxidatieve werking aan dit coenzyme toegescbreven. In 
onze stu die hebben we echter geen verschil gevonden in Coenzyme QIO niveaus tussen 
de twee groepen. Het lijkt erop dat het mogelijk antioxidatieve beschermende effect 
nog niet wordt bereikt bij van nature voorkomende, niet gesupplementeerde, 
concentraties in het bloed (paragraaf 4.2). 
In hoofdstuk 5 zijn twee studies bescbreven waarin we de associatie tussen antioxi-
dantinneming en het risico op HVZ hebben bestudeerd. In data verzameld aan het 
begin van het ERGO onderzoek is gekeken naar de associatie tussen antioxidant-
inneming en het risico op een stil myocard infarct. Bij 89 deelnemers werd de dia-
gnose 'stil myocard infarct' gesteld. Deze deelnemers hadden op het ECG (electro 
cardiogram) duidelijke aanwijzingen van een doorgemaakt infarct, terwijl dit noch bij 
de deelnemer noch bij zijn!haar ru1s bekend was. Omdat deze deelnemers zich niet 
bewust waren van het doorgemaakt infarct, is een verandering van voeding of leefpa-
troon als gevolg van de ziekte uit te sluiten. We hebben de antioxidant-inneming van 
deze groep vergeleken met de inneming van de mensen in de beginpopulatie die geen 
HVZ hadden (n ~ 2333). Vergelijking van deze twee groepen gaf aan dat een hogere 
inneming van ~-caroteen, of van voedingsmiddelen rijk aan ~-caroteen het risico op 
een stil myocard infarct verlaagde. Deze associatie was het duidelijkst bij vrouwen 
(paragraaf 5.1). 
In het patient-controle onderzoek naru· LDL-oxidatie en coronair atherosclerose 
hebben we naast het meten van antioxidantniveaus in plasma en LDL ook de voe-
dingsinneming van antioxidanten gemeten. Door middel van een voedselfrequentie-
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vragenlijst, thuis ingevuld door de deelnemers, is de gebruikeJijke voeding in het jaar 
voorafgaande aan de studie bepaald. In deze studie hebben we speciaal gekeken naar 
de imleming van flavonolden. Dit zijn polyfenolische deeltjes aanwezig in groente en 
fruit (belangrijke bronnen: appels, ui, rode wijn en thee). We vonden geen verschil in 
inneming van flavonolden of van een van de andere antioxidanten tussen de patienten 
en controles (paragraaf 5.2). 
In de hier beschreven studies hebben wij geen sterke aanwijzingen kunnen vinden 
tel' ondersteuning van onze belangrijkste hypothese, dat de gevoeligheid van LDL voor 
oxidatie een belangrijke rol zou spelen in het proces van atherosclerose. 
MogeJijkerwijs is de methode voar het meten van LDL-oxidatie ex vivo niet geschikt 
als parameter voor het meten van een ill vivo proces. De meting van auta-antilichamen 
als ill vivo maat gaf echter dezelfde resultaten te zien. Met betrekking tot de 
antioxidanten zijn er geen duidelijk beschermende effecten van antioxidanten in LDL 
of plasma gevonden. Wat de inneming van antioxidanten via de voeding betreft, is het 
niet duidelijk welk antioxidant nou speciaal van belang is. VerdeI' is het mogelijk dat 
bij een gevonden associatie tussen antioxidantinneming en het risico op HVZ niet de 
antioxidantinneming zelf, maar het totaal gezondere leefpatroon van een persoon met 
hoge antioxidantinneming een rol speeit in de gevonden associaties. Vande resultaten 
van onze studie en van andere observationele en interventiestudies kan nog steeds niet 
geconcludeerd worden dat supplementatie met antioxidanten gunstig zal zijn voor het 
risico op HVZ. Een voedingspatroon met voedsel rijk aan antioxidanten (zoals groente 
en fruit) strekt tot de aanbeveJing. 
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danken voor je opbouwende kritiek en inspirerende opmerkingen. Je doelgericht 
denken heeft zeker een bijdrage geleverd aan de snelle afronding van dit proefschrift 
en ook je overs tap naar Utrecht bleek ideaal voor het maken van afspraken. 
Mijn co-promotores Geert van Poppel en Hans Princen zijn een goede stimuleren-
. de factor geweest achter dit onderzoek. Hans, als co-promotor moet je het af en toe 
weI zwaar hebben gehad met deze epidemioloog, toch een beetje een ander onder-
zoeksveld met andere benadering van feiten. lk vond de samenwerking erg plezierig en 
heb veel van je geleerd. Of ik echter ooit die nauwgezetheid zal bereiken die jij 
verwacht, ik betwijfel het. 
Geert, ik hoop dat de uitwerking van jouw onderzoeksvoorstel is geworden zoals je je 
had voorgesteld. De eerste jaren kon je dit nog in de gaten houden, maar na je over-
stap naar de afdeling Fysiologie moest je de dagelijkse begeleiding toch uit handen 
geven. Bedankt voor het bijbrengen van de eerste praktische vaardigheden van de 
uitvoering van een patient-controle onderzoek en de functionele, maar ook gezellige, 
besprekingen die we hadden. 
Alwine, aan jou was de taak om mij door het, voor mij toch een beetje statische 
proces van data-analyse en artikelen schrijven te loodsen. Dank voor je motiverende 
begeleiding en het stlUctureren van mijn soms chaotische gedachten. lk ben blij dat jij 
me de lie juni terzijde zal staan. 
De uitvoering van het patient -controle onderzoek zou niet mogelijk zijn geweest 
zonder aIle deelnemers die bereid waren naar de onderzoekscentra te komen en vra-
genlijsten in te vullen. Bedankt u allen. 
En dan natuurlijk mijn onderzoekonderzoeksassistentes Annelies Legters en Ria 
van Vliet. Annelies, met een gelUst hart kon ik de patientenwerving aan jou overlaten. 
Jammer dat je door omstandigheden niet bij de gehele patientenselectie betrokken kon 
zijn. Ik wiI Ria van Vliet dan ook bedanken voor het ovememen van deze taak. In 
totaal hebben jullie toch bijna 3000 catheterisatieverslagen bekeken en de hoeveelheid 
bloedmonsters die in totaal zijn verwerkt ... , ik ben de tel kwijtgeraakt. Ook de assis-
ten tie van Petra Verhoef voor het belwerk en de meetdagen was onontbeerlijk. 
Natuurlijk is een bedankje voor aIle cardiologen van de participerende ziekenhui-
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zen op zijn plaats. Met name bedank ik Dick Kruijssen voor zijn hulp bij de opzet en 
uitvoering van dit onderzoek. VerdeI' ben ik veel dank verschuldigd aan aile arts-ass is-
tentes en de secretaresses in het Zuiderziekenhuis, Ruwaard van Putten, St. Clara 
Ziekenhuis, Usselland ziekenhuis, Ikazia, Franciscus Gasthuis, voor hun hulpvaardig-
heid bij het nazoeken van de medische gegevens. 
De cardiologen van het Refaja ziekenhuis in Dordrecht waren redders in de nood 
toen de patientenselectie trager liep dan de plarmillg toeliet. Dr. Stoel en Dr. Fels, 
bedankt voor het vertrouwen dat jullie in mij stelden. Dhr. Sirpenstein van de cathete-
risatiekamer en Dhr. Pronk van het laboratorium ben ik erkentelijk voor de mogelijk-
heid om van de aanwezige faciliteiten gebruik te maken. 
Voor de selectie van de populatiecontroles mochten we gebruik maken van gege-
vens uit het ERGO onderzoek. Ik wil Michiel Bots en Harmeke den Breeijen bedanken 
voor de hulp bij de selectie van deelnemers. VerdeI' dank ik de medewerkers van het 
onderzoekscentrum Ommoord, in het bijzonder Inge Haumersen voor de ultrasound 
metingen van de halsslagaders van de jongere deelnemers. 
Naast werving en selectie van proefpersonen moest ook bloed geanalyseerd wor-
den. Wim van Duyvenvoorde en Rien Buytellhek, hartelijk dank voor aile oxidatiebe-
palingen en overige bepalingen die bij TNO-PG zijn uitgevoerd. Het was leuk om met 
jullie samen te werken. Bij TNO-Voeding was ik blij met de hulp van Jan van 
Schoonhoven, Frank van Schaik en de mensen op hun afdeling voor de uitvoering van 
de vitamine bepalingen. Beny Wezendonk wil ik bedanken voor de bepaling van de 
vetzuursamenstelling van het LDL. Finally, I want to thank Christine Weber for 
performing the analysis for the plasma Coenzyme Q 10 data. 
Gedurende het onderzoek zijn ruim 300 voedselfrequentie Iijsten op mijn bureau 
terecht gekomen. Invoer hiervan kost veel tijd. De hulp die ik kreeg van Willy van 
Dijk en Dorette Verhoeven was dan ook zeer welkom en de hulp van Henny Brants bij 
de controle van de uiteindelijke dataset was onontbeerlijk. 
VerdeI' bedank ik Hanny Leezer voor de hulp bij de selectie van de deelnemers, 
het oplossen van tal van WP-probleempjes en het verwijderen van de laatste schoon-
heidsfoutjes in de lay-out en Dirk van del' Heij voor de controle van de Engelse 
teksten. 
En dan de immer enthousiaste secretaresse van Rick, Linda Verbeek. Linda, 
hartelijk dank voor je interesse in mijn wei en wee en al de afspraken die je toch in 
Rick zijn agenda wist te plaatsen. 
Ik wil iedereen die op wat voor manier dan ook interesse heef! getoond in mijn 
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onderzoek of in mijn persoonlijk welzijn van harte bedanken. Aile collega's, stagiaires 
en tijdelijk werknemers van TNO bedankt voor 4 gezellige jaren. Ik bedank aile 
(ex-)AIO's met wie met veel plezier het wei en wee van het AIO-leven werd bespro-
ken. In het bijzonder bedank ik Ellen van de Heuvel en mijn dierbare kamergenoten 
Ellen Kampman, Dorette Verhoeven en Adriaan Kole. Eenieder van jullie heef! op zijn 
benrt me terzijde gestaan in verschillende fases van het onderzoek. Dorette, het is 
jammer dat jij je tijd bij TNO niet volgemaakt hebt, ik ben daarom ook zeer verheugd 
dat je toch eenmaal voor de commissie moet verschijnen, al is het dan om mij te 
steunen. 
Het hebben van twee werkplekken houdt ook in dat je twee groepen coUega's 
hebt. Aile collega's van de afdeling Epidemiologie en Biostatistiek van de Erasmus 
Universiteit wil ik bedanken voor hun collegialiteit. Ondanks het feit dat ik maar af en 
toe eens kwam binnenlopen, gaven jullie me het gevoel erbij te horen. Heel in het 
bijzonder bedank ik Jacqueline Witteman voor de besprekingen die we hadden naar 
aanleiding van de analyses bij de stil infarct patienten en Martine de Bruijne voor de 
analyses van de ECGs. Verder bedank ik de principal investigators van het ERGO 
onderzoek, zonder wie deze analyses nooit tot stand gekomen zouden zijn. 
Vrienden en kennissen die er altijd waren om wat afwisseling in het werkende 
leven te brengen, en natuurlijk mijn (ex-)huisgenoten van 'huize Homerus' die er voor 
zorgden dat er op tijd aan ontspanning werd gedacht. En als laatste natuurlijk mijn 
familie, pa, rna, Marc, Jack en Carla, 'da judder bedankt zin, dil weet je, hee'. Bedankt 
voor alles. 
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